EPICORE Embase Updates: EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

Total documents retrieved: 93

Results Generated From:
Embase <1980 to 2023 Week 13>
Embase Weekly Updates (updates since 2023-03-24)

<1>
Accession Number
2021978721
Title
Early Transcatheter or Surgical Aortic Valve Replacement Versus
Conservative Management in Asymptomatic Patients With Severe Aortic
Stenosis: A Systematic Review and Meta-analysis.
Source
Current Problems in Cardiology. 48(3) (no pagination), 2023. Article
Number: 101477. Date of Publication: March 2023.
Author
Yasmin F.; Shaikh A.; Asghar M.S.; Moeed A.; Najeeb H.; Waqar E.; Ram
M.D.; Nankani A.; Ochani R.K.; Aamir M.; Ullah W.; Waqar F.; Johnson D.M.
Institution
(Yasmin, Moeed, Najeeb, Waqar, Ram, Nankani, Ochani) Department of
Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
(Shaikh) Department of Medicine, Aga Khan University Hospital, Karachi,
Pakistan
(Asghar) Division of Nephrology and Hypertension, Mayo Clinic, Rochester,
MN
(Aamir) Lehigh Valley Heart Specialists, Lehigh Valley Health Network,
Allentown, PA, United States
(Ullah, Johnson) Division of Cardiology, Sidney Kimmel Medical College,
Thomas Jefferson University Hospitals, Philadelphia, PA
(Waqar) Division of Cardiovascular Health and Disease, University of
Cincinnati College of Medicine, Cincinnati, OH
Publisher
Elsevier Inc.
Abstract
The merits of conservative management vs early intervention in patients
with asymptomatic severe aortic stenosis remains unknown. Digital
databases (MEDLINE, Google Scholar, and Embase) were searched for all
relevant studies from inception through September 2022. Studies comparing
conservative management with early intervention were compared using a
random-effects model to calculate risk ratios (RRs) with 95% confidence
interval (CI). A total of 12 studies comprising 3624 asymptomatic aortic
stenosis patients (1747 receiving surgery, and 1877 receiving conservative
treatment) were included in the analysis. The average follow-up time was
4.45 (IQR 3.5-5) years. Early intervention was associated with a
significantly reduced risk of cardiac (RR 0.42, 95% CI 0.25-0.72; P =
0.001; I2 = 54%), non-cardiac (RR 0.46, 95% CI 0.32-0.68; P <
0.0001; I2 = 0%), all-cause mortality (RR 0.40, 95% CI
0.32-0.51; P < 0.00001; I2 = 58%), heart failure
hospitalization (RR 0.21, 95% CI 0.13-0.36; P < 0.00001; I2 =
0%), sudden cardiac death (RR 0.29, 95% CI 0.12-0.66; P = 0.004,
I2 = 24%), and MACE (RR 0.46, 95% CI; 0.28-0.75; P = 0.002;
I2 = 68%), compared with conservative management. There was no
significant difference in the 30-day mortality (RR 0.63, 95% CI 0.19-2.04;
P = 0.44; I2 = 28%), myocardial infarction (RR 0.44, 95% CI
0.19-1.06; P = 0.07, I2=0%), and 90-day mortality (RR 0.68, 95%
CI 0.20-2.37; P = 0.55; I2 = 61%) between the 2 groups. This
meta-analysis shows statistically significant reductions in the risk for
all-cause mortality, cardiac specific mortality, non-cardiac mortality,
heart failure hospitalization, MACE, and sudden cardiac death among
asymptomatic aortic stenosis patients who underwent early intervention as
opposed to conservative management. Copyright © 2022 Elsevier
Inc.

<2>
Accession Number
2022551314
Title
The Role of Insulin-Like Growth Factor 1 in Delirium: A Systematic Review
and Meta-Analysis.
Source
Dementia and Geriatric Cognitive Disorders. 51(6) (pp 449-459), 2023. Date
of Publication: 01 Feb 2023.
Author
Adamis D.; Eikelenboom P.
Institution
(Adamis) Sligo Mental Health Services, Sligo, Ireland
(Eikelenboom) GGZinGeest, Amsterdam, Netherlands
(Eikelenboom) Department of Neurology, Academic Medical Center, Amsterdam,
Netherlands
Publisher
S. Karger AG
Abstract
Background: The relationship between delirium and low levels of
insulin-like growth factor 1 (IGF-1) is contradictory and uncertain. We
hypothesised that low levels of IGF-1 are a predisposing factor for
delirium in medical and abdominal surgical cohorts, in contrast to other
surgical cohorts. Aim(s): Systematic review and meta-analysis
investigating the association between peripheral levels of IGF-1 and
delirium in medical and surgical patients to explore if there are distinct
patterns of associations by using subgroup meta-analysis. Method(s):
PubMed, Scopus, CINAHL, Cochrane, and Embase databases were searched.
Inclusion criteria were prospective studies in medical and surgical
populations and available data. The following were collected: the setting
(surgical/medical), the type (orthopaedic surgery, abdominal,
cardiovascular, or medical), the number of participants, mean age, the
number of delirious patients, scale/criteria for delirium, IGF-1 levels,
and MMSE. Result(s): Thirteen studies were included and analysed. Low
levels of IGF-1 are significantly associated with delirium in abdominal
surgical samples and medical samples but not in the other surgical
samples. Age, cognition, and the setting (medical vs. surgical) do not
have any significant effect on the differences in IGF-1 levels between
those with and without delirium. Discussion(s): Delirium in acute
medical and abdominal surgery is triggered by low IGF-1 which may reflect
chronic conditions like frailty/cachexia/sarcopenia, while in other
surgeries perhaps from an inflammatory process. Conclusion(s): Low
peripheral levels of IGF-1 are a predisposing factor for delirium only in
acute medical and abdominal surgery. More studies are needed to confirm
and to explore further this finding. Copyright © 2023 S. Karger
AG. All rights reserved.

<3>
Accession Number
2020227833
Title
Health-related quality of life impacts upon 5-year survival after coronary
artery bypass surgery.
Source
Journal of Cardiac Surgery. 37(12) (pp 4899-4905), 2022. Date of
Publication: December 2022.
Author
Bishawi M.; Hattler B.; Almassi G.H.; Quin J.A.; Grover F.L.; Collins
J.F.; Ebrahimi R.; Wolbrom D.H.; Shroyer A.L.
Institution
(Bishawi) Department of Surgery, Duke University, Durham, NC, United
States
(Hattler) Rocky Mountain Regional Veterans Affairs Medical Center, Aurora,
CO, United States
(Hattler) Division of Cardiology, University of Colorado School of
Medicine, Aurora, CO, United States
(Almassi) Department of Surgery, Clement J. Zablocki Veterans Affairs (VA)
Medical Center, Milwaukee, WI, United States
(Almassi) Department of Surgery, Division of Cardiothoracic Surgery,
Medical College of Wisconsin, Milwaukee, WI, United States
(Quin) Department of Surgery, Division of Cardiac Surgery, VA Boston
Healthcare System, Boston, MA, United States
(Grover) Department of Surgery, Division of Cardiothoracic Surgery,
University of Colorado School of Medicine, Denver, CO, United States
(Collins) Cooperative Studies Program Coordinating Center, Veterans
Affairs Medical Center, Perry Point, MD, United States
(Ebrahimi) Department of Cardiology, Veterans Affairs Greater Los Angeles
Healthcare System, Los Angeles, CA, United States
(Ebrahimi) Department of Medicine, University of California Los Angeles,
Los Angeles, CA, United States
(Wolbrom, Shroyer) Northport Veterans Affairs Medical Center, Research and
Development Office, Northport, NY, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Poor preoperative health-related quality of life (HRQoL) has
been associated with reduced short-term survival after coronary artery
bypass graft (CABG) surgery; however, its impact on long-term mortality is
unknown. This study's objective was to determine if baseline HRQoL status
predicts 5-year post-CABG mortality. Method(s): This prespecified,
randomized on/off bypass follow-up study (ROOBY-FS) subanalysis compared
baseline patient characteristics and HRQoL scores, obtained from the
Seattle Angina Questionnaire (SAQ) and Veterans RAND Short Form-36
(VR-36), between 5-year post-CABG survivors and nonsurvivors. Standardized
subscores were calculated for each questionnaire. Multivariable logistic
regression assessed whether HRQoL survey subcomponents independently
predicted 5-year mortality (p <=.05). Result(s): Of the 2203 ROOBY-FS
enrollees, 2104 (95.5%) completed baseline surveys. Significant
differences between 5-year post-CABG deaths (n = 286) and survivors (n =
1818) included age, history of chronic obstructive pulmonary disease,
stroke, peripheral vascular disease, renal dysfunction, diabetes, lower
left ventricular ejection fraction, atrial fibrillation, depression,
non-White race/ethnicity, lower education status, and off-pump CABG.
Adjusting for these factors, baseline VR-36 physical component summary
score (p =.01), VR-36 mental component summary score (p <.001), and SAQ
physical limitation score (p =.003) were all associated with 5-year
all-cause mortality. Conclusion(s): Pre-CABG HRQoL scores may provide
clinically relevant prognostic information beyond traditional risk models
and prove useful for patient-provider shared decision-making and enhancing
pre-CABG informed consent. Copyright Published 2022. This article is a
U.S. Government work and is in the public domain in the USA.

<4>
Accession Number
2019987069
Title
Furosemide does not reduce the incidence of postoperative acute kidney
injury in adult patients undergoing cardiac surgery: A PRISMA-compliant
systematic review and meta-analysis.
Source
Journal of Cardiac Surgery. 37(12) (pp 4850-4860), 2022. Date of
Publication: December 2022.
Author
Xie C.-M.; Yao Y.-T.; Yang K.; Shen M.-Q.; He L.-X.; Dai Z.
Institution
(Xie, Yang, Shen, He, Dai) Department of Anesthesiology, Fuwai Yunnan
Cardiovascular Hospital, Affiliated Cardiovascular Hospital of Kunming
Medical University, Kunming, China
(Yao) Department of Anesthesiology, Fuwai Hospital, National Center for
Cardiovascular Diseases, Peking Union Medical College and Chinese Academy
of Medical Sciences, Beijing, China
Publisher
John Wiley and Sons Inc
Abstract
Objective: Acute kidney injury (AKI) is a common complication of cardiac
surgical patients, the occurrence of which is multifactorial. Furosemide
is the most common loop diuretic and widely used in cardiac surgery to
reduce fluid overload, increase tubular flow and urine output. It remains
unknown whether furosemide affects the incidence or prognosis of cardiac
surgery-induced acute kidney injury (CS-AKI). Therefore, the current study
was performed to address this question. Method(s): PubMed, Embase,
Scopus, Cochrane Library, and Web of Science databases were searched for
relevant studies. Primary outcomes of interest included postoperative
CS-AKI incidence, need for renal replacement therapy (RRT) rate. Secondary
outcomes of interest included postoperative serum creatinine (Scr) and
blood urea nitrogen (BUN) levels, postoperative mechanical ventilation
duration (MVD), length of stay (LOS) in intensive care unit (ICU) and in
hospital, and mortality. The odds ratio (OR) and/or the weighted mean
difference (WMD) with 95% confidence interval (CI) were used to pool the
data. Result(s): Database search yielded six studies including 566
adult patients, and 283 patients were allocated into Group Furosemide and
283 into Group Control (Placebo). Heterogeneity between studies was deemed
acceptable, and the publication bias was low. Meta-analysis suggested that
furosemide administration in adult cardiac surgical patients had no effect
on CS-AKI incidence (n = 4 trials; OR = 0.92; 95% CI: 0.37-2.30; p =.86;
I2 = 57%) and need for RRT rate (n = 2 trials; OR = 4.13; 95%
CI: 0.44-38.51; p =.21; I2 = 0%). Diversely, furosemide
administration in adult cardiac surgical patients significantly decreased
postoperative BUN level (n = 3 trials; WMD = 0.71; 95% CI: 0.10-1.33; p
=.02; I2 = 0%), postoperative MVD (n = 2 trials; WMD = -3.13;
95% CI: -3.78 to -2.49; p <.00001; I2 = 0%) and postoperative
LOS in ICU (n = 3 trials; WMD = -0.47; 95% CI: -0.76 to -0.18; p =.001;
I2 = 0%). However, it had no significant impact on
postoperative Scr level, postoperative LOS in hospital, and postoperative
mortality. Conclusion(s): This meta-analysis suggested that
furosemide administration in adult cardiac surgical patients had no
significant effect on CS-AKI incidence, need for RRT rate, postoperative
Scr level, LOS in hospital and mortality, but could reduce postoperative
BUN level, MVD, and LOS in ICU. As only a limited number of studies were
included, these results should be interpreted carefully and cautiously.
Future high-quality randomized controlled trials are needed to define the
role of furosemide in CS-AKI prevention and management. Copyright
© 2022 Wiley Periodicals LLC.

<5>
Accession Number
640315252
Title
Alcohol septal ablation versus surgical septal myectomy of obstructive
hypertrophic cardiomyopathy: systematic review and meta-analysis.
Source
European journal of cardio-thoracic surgery : official journal of the
European Association for Cardio-thoracic Surgery. 63(3) (no pagination),
2023. Date of Publication: 01 Mar 2023.
Author
Yokoyama Y.; Shimoda T.; Shimada Y.J.; Shimamura J.; Akita K.; Yasuda R.;
Takayama H.; Kuno T.
Institution
(Yokoyama) Department of Surgery, St. Luke's University Health Network,
Bethlehem, PA, United States
(Shimoda) School of Medicine, University of Tsukuba, Ibaraki, Japan
(Shimada, Akita, Yasuda) Division of Cardiology, Department of Medicine,
Columbia University Irving Medical Center, New York, NY, USA
(Shimamura) Department of Surgery, Division of Cardiothoracic Surgery,
Emory University, Atlanta, GA, United States
(Takayama) Department of Surgery, Columbia University Irving Medical
Center, New York, NY, USA
(Kuno) Department of Cardiology, Montefiore Medical Center, Albert
Einstein College of Medicine, Bronx, NY, United States
Publisher
NLM (Medline)
Abstract
OBJECTIVES: To elucidate the optimal septal reduction therapy for
obstructive hypertrophic cardiomyopathy, we conducted a meta-analysis
comparing alcohol septal ablation (ASA) and septal myectomy.
 METHOD(S): MEDLINE, EMBASE and Cochrane CENTRAL were searched to
identify studies investigating the outcomes of ASA and septal myectomy in
patients with obstructive hypertrophic cardiomyopathy in January 2023. The
primary outcome of interest was all-cause mortality in studies with
>=1year of follow-up. The secondary outcomes of interest comprised left
ventricular outflow tract (LVOT) pressure gradient reduction and
reoperations of LVOT. A subgroup analysis of all-cause mortality including
studies with follow-up >=5years was performed. RESULT(S): 27
observational studies were included (15 968 patients). Analysis
demonstrated similar all-cause mortality [hazard ratio (HR) (95%
confidence interval) (CI) 1.24 (0.88-1.76); P=0.21; I2=56%]. In contrast,
ASA was associated with less reduction of LVOT pressure gradient and a
reoperation rate [weighted mean difference (95% CI) 11.04mmHg
(5.60-16.48); P<0.01; I2=64%, HR (95% CI) 9.14 (6.55-12.75); P<0.001;
I2=0%, respectively]. The subgroup analysis with follow-up >=5years
revealed higher long-term mortality with ASA [HR (95% CI) 1.50
(1.04-2.15); P=0.03; I2=52%]. CONCLUSION(S): Although both septal
reduction therapies were associated with similar all-cause mortality, ASA
was associated with a higher rate of reoperation and less reduction of
LVOT pressure gradient. Furthermore, all-cause mortality with follow-up
>=5years showed favourable outcomes with septal myectomy, although the
result is only hypothesis-generating given a subgroup
analysis. Copyright © The Author(s) 2023. Published by Oxford
University Press on behalf of the European Association for Cardio-Thoracic
Surgery. All rights reserved.

<6>
Accession Number
2022207793
Title
A prospective randomized controlled study to assess the effectiveness of
super FIXSORB WAVE for sternal stabilization after sternotomy.
Source
General Thoracic and Cardiovascular Surgery. (no pagination), 2023. Date
of Publication: 2023.
Author
Oishi K.; Arai H.; Kuroki H.; Fujioka T.; Tomita M.; Tasaki D.; Oi K.;
Nagaoka E.; Fujiwara T.; Takeshita M.; Yoshizaki T.; Someya T.; Mizuno T.
Institution
(Oishi, Arai, Oi, Nagaoka, Fujiwara, Takeshita, Mizuno) Department of
Cardiovascular Surgery, Graduate School of Medical and Dental Science,
Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-Ku, Tokyo
113-8519, Japan
(Kuroki, Someya) Department of Thoracic Surgery, Ome Municipal General
Hospital, Tokyo, Japan
(Fujioka) Department of Diagnostic Radiology, Tokyo Medical and Dental
University, Tokyo, Japan
(Tomita) School of Data Science, Yokohama City University, Kanagawa, Japan
(Tasaki, Yoshizaki) Department of Cardiovascular Surgery, Musashino Red
Cross Hospital, Tokyo, Japan
Publisher
Springer
Abstract
Background: We developed a new sternal fixation device, Super FIXSORB
WAVE, a corrugated plate made of u-HA/PLLA, to improve sternal
stability after sternotomy. This present study aimed to evaluate the new
device clinically. Method(s): This prospective, single-blinded,
multicenter trial randomized 69 patients to either wire cerclage only
(group C, n = 30) or wire cerclage plus Super FIXSORB WAVE
(group W, n = 39). The primary endpoint was a degree of sternal
displacement at six months. Displacement of the sternal halves in the
anteroposterior and lateral directions was measured using computed
tomography horizontal section images at the third costal and fourth
intercostal levels. The secondary endpoints were sternal pain and
quality-of-life over 6 months. Result(s): Group W showed
significantly reduced sternal anteroposterior displacement at both the
third costal (0 [0-1.9] mm vs. 1.1 [0-2.1] mm; P = 0.014) and fourth
intercostal (0 [0-1.0] mm) vs. 1.0 [0-1.8] mm; P = 0.015) levels than
group C. In group W, lateral displacement was suppressed without a
significant increase from 2 weeks to 6 months, while it increased in group
C. There was no significant difference in postoperative sternal pain and
quality-of-life between the two groups. No adverse events, such as
infection, inflammation, or foreign body reaction, were observed with this
device. Conclusion(s): Using Super FIXSORB WAVE, sternal
displacement was significantly suppressed in both the anteroposterior and
lateral directions. The use of this device results in safe and easy
sternal reinforcement without any adverse events, and sternal healing can
be accelerated. Clinical trial registry number: This study was registered
in the Japan Registry of Clinical Trials (February 21, 2019;
jRCTs032180146). Copyright © 2023, The Author(s), under exclusive
licence to The Japanese Association for Thoracic Surgery.

<7>
Accession Number
2022076783
Title
Extracorporeal Membrane Oxygenation for Graft Dysfunction Early After
Heart Transplantation: A Systematic Review and Meta-analysis.
Source
Journal of Cardiac Failure. 29(3) (pp 290-303), 2023. Date of Publication:
March 2023.
Author
Aleksova N.; BUCHAN T.A.; FOROUTAN F.; ZHU A.; CONTE S.E.A.N.; MACDONALD
P.; NOLY P.-E.; CARRIER M.; MARASCO S.F.; TAKEDA K.O.J.I.; POZZI M.;
BAUDRY G.; ATIK F.A.; LEHMANN S.V.E.N.; JAWAD K.; HICKEY G.W.; DEFONTAINE
A.; BARON O.; LOFORTE A.; CAVALLI G.G.; ABSI D.O.; KAWABORI M.;
MASTROIANNI M.A.; SIMONENKO M.; SPONGA S.; MOAYEDI Y.; ORCHANIAN-CHEFF
A.N.I.; ROSS H.J.; RAO V.; GUYATT G.; BILLIA F.; ALBA A.C.
Institution
(Aleksova, BUCHAN, FOROUTAN, MOAYEDI, ROSS, RAO, BILLIA, ALBA) Peter Munk
Cardiac Centre, Toronto General Hospital, Toronto, ON, Canada
(ZHU) Faculty of Medicine, University of Toronto, Toronto, ON, Canada
(CONTE, MACDONALD) Heart Transplant Unit, St Vincent's Hospital, Sydney,
NSW, Australia
(NOLY, CARRIER) Department of Cardiac Surgery, Montreal Heart Institute,
University of Montreal, Montreal, Canada
(MARASCO) Department of Cardiothoracic Surgery, The Alfred Hospital,
Melbourne, Australia
(TAKEDA) Department of Surgery, Division of Cardiac, Thoracic & Vascular
Surgery, Columbia University, New York, New York, United States
(POZZI, BAUDRY) Service de Chirurgie Cardiaque et Cardiologie, Hospices
Civils de Lyon, Hopital Louis Pradel, Lyon, France
(ATIK) Instituto de Cardiologia e Transplantes do Distrito Federal (ICDF),
Brasilia, Brazil
(LEHMANN, JAWAD) Clinic of Cardiac Surgery, Heart Center, University of
Leipzig, Leipzig, Germany
(HICKEY) UPMC Heart and Vascular Institute, University of Pittsburgh,
Pittsburgh, PA, United States
(DEFONTAINE, BARON) Centre Hospitalier Universitaire de Nantes, Nantes,
France
(LOFORTE, CAVALLI) Division of Cardiac Surgery, S. Orsola University
Hospital, IRCCS Bologna, Bologna, Italy
(ABSI) Cardiovascular and Intrathoracic Transplant Department, Favaloro
Foundation University Hospital, Buenos Aires, Argentina
(KAWABORI, MASTROIANNI) Department of Cardiovascular Surgery, Tufts
Medical Center, Boston, Massachusetts, United States
(SIMONENKO) Almazov National Medical Research Centre, St. Petersburg,
Russian Federation
(SPONGA) Cardiothoracic Department, University Hospital of Udine, Udine,
Italy
(ORCHANIAN-CHEFF) Library and Information Services, University Health
Network, Toronto, ON, Canada
(GUYATT) Department of Health Research Methods, Evidence and Impact,
McMaster University, Hamilton, ON, Canada
Publisher
Elsevier B.V.
Abstract
Introduction: Venoarterial extracorporeal membrane oxygenation (VA-ECMO)
is a prevailing option for the management of severe early graft
dysfunction. This systematic review and individual patient data (IPD)
meta-analysis aims to evaluate (1) mortality, (2) rates of major
complications, (3) prognostic factors, and (4) the effect of different
VA-ECMO strategies on outcomes in adult heart transplant (HT) recipients
supported with VA-ECMO. Methods and Results: We conducted a
systematic search and included studies of adults (>=18 years) who received
VA-ECMO during their index hospitalization after HT and reported on
mortality at any timepoint. We pooled data using random effects models. To
identify prognostic factors, we analysed IPD using mixed effects logistic
regression. We assessed the certainty in the evidence using the GRADE
framework. We included 49 observational studies of 1477 patients who
received VA-ECMO after HT, of which 15 studies provided IPD for 448
patients. There were no differences in mortality estimates between IPD and
non-IPD studies. The short-term (30-day/in-hospital) mortality estimate
was 33% (moderate certainty, 95% confidence interval [CI] 28%-39%) and
1-year mortality estimate 50% (moderate certainty, 95% CI 43%-57%).
Recipient age (odds ratio 1.02, 95% CI 1.01-1.04) and prior sternotomy (OR
1.57, 95% CI 0.99-2.49) are associated with increased short-term
mortality. There is low certainty evidence that early intraoperative
cannulation and peripheral cannulation reduce the risk of short-term
death. Conclusion(s): One-third of patients who receive VA-ECMO for
early graft dysfunction do not survive 30 days or to hospital discharge,
and one-half do not survive to 1 year after HT. Improving outcomes will
require ongoing research focused on optimizing VA-ECMO strategies and care
in the first year after HT. Copyright © 2022 The Author(s)

<8>
Accession Number
640871019
Title
Effects of pecto-intercostal fascial block combined with rectus sheath
block for postoperative pain management after cardiac surgery: a
randomized controlled trial.
Source
BMC anesthesiology. 23(1) (pp 90), 2023. Date of Publication: 23 Mar 2023.
Author
Wang L.; Jiang L.; Jiang B.; Xin L.; He M.; Yang W.; Zhao Z.; Feng Y.
Institution
(Wang, Jiang, Jiang, Xin, He, Feng) Department of Anesthesiology, Peking
University People's Hospital, 11 Xizhimen South Street, Beijing 100044,
China
(Yang, Zhao) Department of Cardiac Surgery, Peking University People's
Hospital, Beijing, China
Publisher
NLM (Medline)
Abstract
BACKGROUND: Pecto-intercostal fascial block (PIFB) provides analgesia for
cardiac median sternotomy, but many patients complain of severe drainage
pain that cannot be covered by PIFB. Rectus sheath block (RSB) has been
attempted to solve this problem, but whether PIFB combined with RSB can
achieve better analgesia is uncertain. METHOD(S): This was a
single-center randomized controlled trial at Peking University People's
Hospital from September 22, 2022 to December 21, 2022. Patients undergoing
elective cardiac surgery with a median sternotomy were randomized at a 1:1
ratio to receive either bilateral PIFB and RSB (PIFB+RSB group) or PIFB
(PIFB group). The primary outcome was intravenous opioid consumption
within 24 h after surgery. Secondary outcomes included opioid consumption
within 48 h, postoperative pain scores, time to extubation, and length of
stay in the hospital. Interleukin (IL)-6, IL-10, and tumor necrosis factor
(TNF)-alpha before and the first 24 h after surgery were measured.
 RESULT(S): A total of 54 patients were analyzed (27 in each group).
Intravenous opioid consumption within 24 h after surgery was 2.33+/-1.77
mg in the PIFB+RSB group vs 3.81+/-2.24 mg in the PIFB group (p=0.010).
Opioid consumption within 48 h after surgery was also reduced in the
PIFB+RSB group (4.71+/-2.71 mg vs 7.25+/-3.76 mg, p=0.006). There was no
significant difference in pain scores, time to extubation, length of stay
in hospital, or the levels of IL-6, IL-10 and TNF-alpha between the two
groups. CONCLUSION(S): The combination of PIFB and RSB reduced
postoperative intravenous opioid consumption until 48 h after cardiac
surgery. TRIAL REGISTRATION: This trial is registered at the Chinese
Clinical Trial Registry ( www.chictr.org.cn , ChiCTR2200062017) on
19/07/2022. Copyright © 2023. The Author(s).

<9>
Accession Number
2022150138
Title
Clinical characteristics, management, and outcomes of pulmonary valve
myxoma: systematic review of published case reports.
Source
World Journal of Surgical Oncology. 21(1) (no pagination), 2023. Article
Number: 99. Date of Publication: December 2023.
Author
Saputra P.B.T.; Jannah A.R.; Rofananda I.F.; Al-Farabi M.J.; Wungu C.D.K.;
Susilo H.; Alsagaff M.Y.; Gusnanto A.; Oktaviono Y.H.
Institution
(Saputra, Al-Farabi, Alsagaff, Oktaviono) Department of Cardiology and
Vascular Medicine, Faculty of Medicine, Universitas Airlangga-Dr. Soetomo
General Academic Hospital, Surabaya, Indonesia
(Jannah, Rofananda) Faculty of Medicine, Universitas Airlangga, Surabaya,
Indonesia
(Wungu) Department of Physiology and Medical Biochemistry, Faculty of
Medicine, Universitas Airlangga, Surabaya, Indonesia
(Wungu) Institute of Tropical Disease, Universitas Airlangga, Surabaya,
Indonesia
(Susilo, Alsagaff) Department of Cardiology and Vascular Medicine,
Universitas Airlangga Hospital, Surabaya, Indonesia
(Gusnanto) School of Mathematics, University of Leeds, Leeds, United
Kingdom
Publisher
BioMed Central Ltd
Abstract
Background: Cardiac myxoma is the most common type of primary cardiac
tumor, with the majority located in the atrial wall. The tumor is attached
to valvular structures in a few cases, of which the pulmonary valve is the
least affected. Pulmonary valve myxoma may have different clinical
manifestations from the more common cardiac myxomas because of its vital
position. A misdiagnosis of these types of cardiac myxoma may be
detrimental to the care and well-being of patients. Therefore, this
systematic review aims to define the clinical characteristics of pulmonary
valve myxoma and how this differs from a more common cardiac myxoma.
 Method(s): Employed literature was obtained from PubMed,
ScienceDirect, Scopus, Springer, and ProQuest without a publication year
limit on August 23, 2022. The keyword was "pulmonary valve myxoma."
Inclusion criteria were as follows: (1) case report or series, (2)
available individual patient data, and (3) myxoma that is attached to
pulmonary valve structures with no evidence of metastasis. Non-English
language or nonhuman subject studies were excluded. Johanna Briggs
Institute checklists were used for the risk of bias assessment. Data are
presented descriptively. Result(s): This review included 9 case
reports from 2237 articles. All cases show a low risk of bias. Pulmonary
valve myxoma is dominated by males (5:4), and the patient's median age is
57 years with a bimodal distribution in pediatric and geriatric
populations. The clinical manifestation of pulmonary valve myxoma is often
unspecified or asymptomatic. However, systolic murmur in the pulmonary
valve area is heard in 67% of cases. Echocardiography remains the
diagnostic modality of choice in the majority of cases. Tumor attached to
the pulmonary cusps or annulus and extended to adjacent tissues in all
cases. Therefore, valve replacement or adjacent tissue reconstructions are
required in 77% of cases. The recurrence and mortality are considerably
high, with 33% and 22% cases, respectively. Conclusion(s): Pulmonary
valve myxoma is more common in males with a bimodal age distribution, and
its outcomes seem worse than usual cardiac myxomas. Increasing awareness
of its clinical symptoms, early diagnosis, and complete myxoma resection
before the presence of congestive heart failure symptoms are important in
achieving excellent outcomes. A firm embolization blockade is needed to
prevent myxoma recurrence. Copyright © 2023, The Author(s).

<10>
Accession Number
2023540034
Title
Comparison of efficacy of erector spinae plane block, thoracic
paravertebral block, and erector spinae plane block and thoracic
paravertebral block combination for acute pain after video-assisted
thoracoscopic surgery: a randomized controlled study.
Source
Minerva Anestesiologica. 89(3) (pp 138-148), 2023. Date of Publication:
March 2023.
Author
Zengin M.; Alagoz A.; Sazak H.; Ulger G.; Baldemir R.; Senturk M.
Institution
(Zengin, Alagoz, Sazak, Ulger, Baldemir) Department of Anesthesiology and
Reanimation, Ankara Ataturk Chest Diseases and Thoracic Surgery Training
and Research Hospital, University of Health Sciences, Ankara, Turkey
(Senturk) Department of Anesthesiology and Reanimation, Faculty of
Medicine, Istanbul University, Istanbul, Turkey
Publisher
Edizioni Minerva Medica
Abstract
BACKGROUND: The aim of this study was to compare the efficacy of
ultrasound-guided erector spinae plane block (ESPB), thoracic
paravertebral block (TPVB), and ESPB and TPVB combination on acute pain
after video-assisted thoracoscopic surgery (VATS). METHOD(S):
Seventy-five patients were evaluated (three groups: ESPB, TPVB, or
combined ESPB-TPVB [comb-group], each 25 patients). All interventions were
performed with the same volume of bupivacaine (20 mL). Primary outcome was
VAS (Visual Analog Scale) during the first 24 hours. Secondary outcomes
were postoperative morphine consumption and rescue analgesic requirements.
 RESULT(S): VAS during rest and coughing of TPVB was significantly
higher compared to other groups (in all measurements compared to
comb-group; and in all but 24 hours measurement to ESPB) ESPB and
comb-group had similar VAS in all measurements (e.g., median VAS in ESPB,
TPVB and comb-group at 8th hour: 3-4-2 [P=0.014] during
coughing and 2-3-1 in rest [P<0.001], respectively). Morphine consumption
was statistically significantly higher in TPVB than comb-group (ESPB:
15.28 mg; TPVB: 19.30 mg; ESPB+TPVB: 10.00 mg) (P=0.003). Rescue analgesic
requirement was statistically significantly higher in the TPVB group than
comb-group (P=0.009). CONCLUSION(S): ESPB alone and the combination
of ESPB and TPVB provided superior primary outcomes compared to TPVB
alone. Morphine and rescue analgesic consumptions were higher in TPVB than
comb-group. ESPB and comb-group were statistically similar in terms of
primary and secondary outcomes. This study is one of the first studies
using the combination of ESBP and TPVB for pain after VATS, and shows the
efficacy of this approach. Copyright © 2022 EDIZIONI MINERVA
MEDICA.

<11>
Accession Number
640873827
Title
Natural history of moderate aortic stenosis and predictors for mortality:
Systematic review and Meta-analysis.
Source
Journal of cardiology. (no pagination), 2023. Date of Publication: 22 Mar
2023.
Author
Yokoyama Y.; Fukuhara S.; Takagi H.; Kuno T.
Institution
(Yokoyama) Department of Surgery, St. Luke's University Health Network,
PA, United States
(Fukuhara) Department of Cardiothoracic Surgery, University of Michigan,
Ann Arbor, MI, United States
(Takagi) Department of Cardiovascular Surgery, Medical Center, Shizuoka,
Japan
(Kuno) Division of Cardiology, Montefiore Medical Center, Albert Einstein
College of Medicine, NY, United States
Publisher
NLM (Medline)
Abstract
Although the current guidelines advocate imaging surveillance for moderate
aortic stenosis (AS), recent studies suggest a worse prognosis associated
with moderate AS than previously reported. Considering the recent paradigm
shift in AS management, the risk/benefit profile of aortic valve
replacement (AVR) for moderate AS needs to be re-evaluated. Herein, we
conducted meta-analyses of natural history and risk predictors in patients
with moderate AS. PubMed and EMBASE were searched through May 2022 to
identify studies that investigated the natural history of patients with
moderate AS. Meta-analyses with random effects model were conducted. Our
analysis included 20 observational studies which enrolled a total of
11,114 patients with moderate AS. The rate of all-cause death was 11.0
[95% confidence interval (CI), 7.6-14.4] per 100 patients per year.
Surgical or transcatheter AVR occurred at a rate of 8.5 (95% CI, 6.2-10.8;
I2, 98.9%) per 100 patients per year. Occurrence of AVR during follow-up
[hazard ratio (HR) (95% CI) =0.56 (0.42-0.75), p<0.001] and early AVR for
moderate AS [HR (95% CI)=0.47 (0.25-0.90), p=0.02] were associated with
significantly lower all-cause mortality, while left ventricular ejection
fraction <50% [HR (95% CI) =1.84 (1.33-2.57), p=0.0003] and symptomatic
status [HR (95% CI)=1.52 (1.32-1.75), p<0.0001] were associated with
increased all-cause mortality. Sex difference was not related to all-cause
mortality. Our meta-analysis suggested that moderate AS was associated
with high mortality, especially in low left ventricular systolic function
or symptomatic patients. In addition, significant portion of the patients
underwent AVR during follow-up. Copyright © 2023. Published by
Elsevier Ltd.

<12>
Accession Number
2022155546
Title
The effect of nicorandil on cardiac function and clinical outcomes in
ST-segment elevation myocardial infarction patients undergoing primary
percutaneous coronary intervention: a randomised trial.
Source
Acta Cardiologica. (no pagination), 2023. Date of Publication: 2023.
Author
Choe J.C.; Oh J.-H.; Lee H.C.; Lee J.W.; Park T.S.; Park J.H.; Kim L.E.;
Kim M.S.; Ahn J.; Park J.S.; Lee H.W.; Choi J.H.; Cha K.S.
Institution
(Choe, Oh, Lee, Park, Park, Kim, Ahn, Park, Lee, Choi, Cha) Department of
Internal Medicine, Division of Cardiology, Medical Research Institute,
Pusan National University Hospital, Busan, South Korea
(Lee) Department of Radiology, Pusan National University Hospital, Busan,
South Korea
(Kim) Department of Thoracic and Cardiovascular Surgery, Pusan National
University Hospital, Busan, South Korea
Publisher
Taylor and Francis Ltd.
Abstract
Background: We investigated the effect of nicorandil on infarct size,
cardiac function assessed by cardiac magnetic resonance imaging (CMR) and
outcomes in ST-segment elevation myocardial infarction (STEMI) patients
undergoing primary percutaneous coronary intervention (PCI).
 Method(s): In a prospective, randomised, controlled trial, 83
patients with STEMI receiving primary PCI were randomised into the
nicorandil (n = 40) or placebo (n = 43) groups. Nicorandil was
administered in the emergency room before primary PCI as an intravenous
bolus of 4 mg followed by a continuous infusion of 6 mg/h for 24 h and as
2-mg intracoronary injections prior to balloon dilatation and coronary
stenting. Nicorandil was continued orally at 10-20 mg/d for 6 months.
Infarct size and cardiac function were measured by CMR at 5 d and 6 months
after primary PCI. Furthermore, major adverse cardiac events (MACEs)
including all-cause death, nonfatal myocardial infarction (MI), any
revascularisation, stroke, and definite/probable stent thrombosis (ST)
were compared. Result(s): There were no significant differences in
baseline clinical characteristics between the groups. Infarct size at
baseline and 6 months as well as infarct size changes during 6 months as
measured by CMR were similar between the groups. Similarly, other CMR
parameters were comparable at baseline and 6 months between the groups.
MACEs occurred in four patients (4.8%) during 6 months. No significant
difference in the risk of MACEs was observed between the groups.
 Conclusion(s): Treatment with nicorandil for 6 months after primary
PCI was not associated with any improvement in infarct size,
CMR-determined cardiac function, and outcomes in STEMI
patients. Copyright © 2023 Belgian Society of Cardiology.

<13>
Accession Number
2023400145
Title
Topical and Intravenous Tranexamic Acid in Acyanotic Children Undergoing
Congenital Heart Surgery: A Randomized Clinical Trial.
Source
Journal of Surgical Research. 288 (pp 64-70), 2023. Date of Publication:
August 2023.
Author
Bigdelian H.; Montazeri M.; Sedighi M.; Mansouri M.; Amanollahi A.
Institution
(Bigdelian, Montazeri) Department of Cardiovascular Surgery, School of
Medicine, Isfahan University of Medical Sciences, Isfahan, Iran, Islamic
Republic of
(Sedighi) Trauma and Injury Research Center, Iran University of Medical
Sciences, Tehran, Iran, Islamic Republic of
(Mansouri) Cardiovascular Anesthesia Research Center, Cardiovascular
Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran,
Islamic Republic of
(Amanollahi) Department of Epidemiology, School of Public Health and
Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran,
Islamic Republic of
Publisher
Academic Press Inc.
Abstract
Introduction: Postoperative bleeding is a common complication in
congenital heart surgery. We aimed to evaluate effects of topical and
intravenous tranexamic acid (TXA) administration on postoperative
hemoglobin and bleeding in children with acyanotic congenital heart
disease (CHD). Method(s): In this randomized clinical trial, 50
acyanotic CHD children were allocated into two groups of topical (n = 25)
and infusion (n = 25). Children in the infusion group were given
intravenous TXA 50 mg/kg-1 after sternotomy. Children in
topical group were given 50 mg/kg-1 TXA added to 20 mL of
saline intrapericardially before sternal closure. Primary endpoint of
study was comparison of postoperative hemoglobin and bleeding between
topical and infusion groups. A linear mixed model (LMM) was used to
estimate longitudinal changes in postoperative endpoints. Result(s):
We did not observe significant differences in children's characteristics
between two groups. Also, intraoperative and postoperative outcomes did
not differ between two groups but children with intravenous TXA
experienced significantly longer intubation time than topical children (P
= 0.047). LMM analysis revealed that postoperative bleeding in topical
group was lower compared to infusion group (P = 0.036). Also, age of
children had a significant effect on mean changes of hemoglobin during
postoperative care (beta = -0.27, P = 0.030). No children died and none
had serious postoperative complications such as seizures and reoperation.
 Conclusion(s): We found that topical TXA is not superior to
intravenous administration in management of blood loss. Also, no
additional effect was found about topical TXA in further reducing
transfusion rates and postoperative complications in acyanotic CHD
children undergoing cardiac surgery. Copyright © 2023 Elsevier
Inc.

<14>
Accession Number
2023110367
Title
Meta-Analysis of Cerebral Embolic Protection During Transcatheter Aortic
Valve Replacement.
Source
American Journal of Cardiology. 192 (pp 255-257), 2023. Date of
Publication: 01 Apr 2023.
Author
Al-Abdouh A.; Mhanna M.; Jabri A.; Ahmed T.; Altibi A.M.; Ghanem F.;
Alhuneafat L.; Albadawi A.; Barbarawi M.; Dewaswala N.; Bhopalwala H.;
Kundu A.; Elgendy I.Y.
Institution
(Al-Abdouh, Ahmed, Bhopalwala) Department of Medicine, University of
Kentucky, Lexington, Kentucky
(Mhanna) Department of Cardiovascular Medicine, University of Iowa, Iowa
City, IA, United States
(Jabri) Department of Cardiology, Case Western University (Metrohealth),
Cleveland, Ohio, United States
(Altibi) Division of Cardiology, Oregon Health and Science University,
Portland, Oregon, United States
(Ghanem) Department of Internal Medicine, East Tennessee State University,
Johnson City, TN, United States
(Alhuneafat) Department of Internal Medicine, Allegheny Health Network,
Pittsburgh, PA, United States
(Albadawi) Division of Cardiology UT Southwestern Dallas, TX, United
States
(Barbarawi, Kundu) Department of Cardiology, University of Connecticut,
Framingham, CT, United States
(Dewaswala, Elgendy) Division of Cardiovascular Medicine, Gill Heart
Institute, University of Kentucky, Lexington, Kentucky
Publisher
Elsevier Inc.

<15>
Accession Number
2022041099
Title
Safety and efficacy of direct oral anticoagulants in bioprosthetic valves:
A systematic review and meta-analysis.
Source
Frontiers in Cardiovascular Medicine. 10 (no pagination), 2023. Article
Number: 1099591. Date of Publication: 2023.
Author
Bakr L.; Elsayed A.; Saleh O.; Abdalraouf M.; Ng G.A.; Ibrahim M.
Institution
(Bakr) The Royal College of Surgeons of England, London, United Kingdom
(Elsayed) Liverpool University Hospitals NHS Foundation Trust, Liverpool,
United Kingdom
(Elsayed) NHS, Health Education England - North West (HEENW), Manchester,
United Kingdom
(Saleh) Suez Canal University Hospital, Ismailia, Egypt
(Abdalraouf) Sheikh Zayed Specialized Hospital, Giza, Egypt
(Ng, Ibrahim) Glenfield Hospital, University Hospitals of Leicester NHS
Trust (UHL), Leicester, United Kingdom
(Ng) Department of Cardiovascular Sciences, University of Leicester,
National Institute for Health Research Leicester Biomedical Research
Center, Leicester, United Kingdom
(Ibrahim) Department of Cardiology, Ain Shams University, Cairo, Egypt
Publisher
Frontiers Media S.A.
Abstract
Background: Direct oral anticoagulants are efficient alternatives to
vitamin K antagonists. There is little evidence regarding their use in
patients who underwent bioprosthetic valve replacement whether surgically
or through a transcatheter approach and have another indication of
anticoagulation. Trials have compared different members of the DOACs
family to VKAs and showed that they were at least non-inferior to VKAs
with regard to safety and efficacy. However, this is still controversial.
Our meta-analysis aims at providing a clearer view of their future use in
this subgroup of patients. Method(s): PubMed and Cochrane were
searched for randomised clinical trials and observational studies.
Bleeding, stroke, and all-cause mortality were the outcomes of interest.
 Result(s): Ten papers with a total of 4,088 patients were included.
Our meta-analysis revealed no significant differences between the
incidence of bleeding between DOACs and warfarin (16% vs. 17%, OR = 0.94,
95% CI [0.56-1.57], p = 0.81, I2 = 81%). No statistical
difference was found in stroke between both groups (2.5% vs. 3.3%, OR =
0.75, 95% CI [0.41-1.38], p = 0.36, I2 = 35%). All-cause
mortality was not statistically significant between both groups (9.2% vs.
13.7%, OR = 0.85, 95% CI [0.68-1.07], p = 0.16, I2 = 56%).
Interestingly, subgroup analysis of randomised controlled trials and
prospective studies favoured DOACs with lower risks of both bleeding and
stroke. Conclusion(s): Direct oral anticoagulants appear to be at
least as safe and effective as VKAs in patients with bioprosthetic valves
and another indication of anticoagulation. There could be potential
benefit from the use of DOACs; however, further evidence is required.
Systematic Review Registration:
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021222146,
identifier CRD42021222146. Copyright © 2023 Bakr, Elsayed, Saleh,
Abdalraouf, Ng and Ibrahim.

<16>
Accession Number
2022031163
Title
Perioperative lidocaine and dexmedetomidine intravenous infusion reduce
the serum levels of NETs and biomarkers of tumor metastasis in lung cancer
patients: A prospective, single-center, double-blinded, randomized
clinical trial.
Source
Frontiers in Oncology. 13 (no pagination), 2023. Article Number: 1101449.
Date of Publication: 2023.
Author
Ren B.; Cheng M.; Liu C.; Zheng H.; Zhang J.; Chen W.; Song J.; Zhuang J.;
Liu T.; Wang R.; Wang Z.
Institution
(Ren, Liu, Zheng, Zhang, Chen, Song, Liu, Wang, Wang) Department of
Anesthesiology, The Affiliated Hospital of Xuzhou Medical University,
Xuzhou, China
(Ren, Liu, Zheng, Zhang, Chen, Song, Liu, Wang, Wang) Jiangsu Province Key
Laboratory of Anesthesiology, Xuzhou Medical University, Xuzhou, China
(Cheng) Department of Anesthesiology, Xinhua Hospital Affiliated to
Shanghai Jiao Tong University School of Medicine, Shanghai, China
(Zhuang) Department of Anesthesiology, The First People's Hospital of
Changde City, Changde, China
Publisher
Frontiers Media S.A.
Abstract
Background: Neutrophil extracellular traps (NETs) can enhance the
metastasis of non-small cell lung cancer (NSCLC). As biomarkers of tumor
metastasis, metalloproteinases (MMPs) and vascular endothelial growth
factor (VEGF) together with NETs are essential to
endothelial-to-mesenchymal transition (EMT). We hypothesized that
intravenous infusion of lidocaine and dexmedetomidine could reduce the
production of NETs and biomarkers of tumor metastasis after video-assisted
thoracic surgery (VATS) in NSCLC patients. Method(s): The trial
included 132 NSCLC patients undergoing VATS. The patients were equally
randomized to a placebo group (Group C), a lidocaine group (Group L,
intravenous lidocaine 8 mg/kg/h for 15 minutes before anesthesia, 2
mg/kg/h during surgery, and 1 mg/kg/h until 24 hours after surgery), a
dexmedetomidine group (Group D, intravenous dexmedetomidine 2 mug/kg/h for
15 minutes before anesthesia, 0.5 mug/kg/h during surgery, and 0.25
mug/kg/h until 24 hours after surgery), and a dexmedetomidine plus
lidocaine group (Group LD, combination use of lidocaine and
dexmedetomidine). The primary outcome was the production of
myeloperoxidase (MPO) and citrullinated histone-3 (H3Cit), biomarkers of
NETs, on postoperative day (POD) 1. MMP-3, MMP-9, and VEGF-alpha, as
biomarkers of tumor metastasis, were also evaluated on POD 1.
 Result(s): The baseline patient characteristics and perioperative
data did not differ between the study groups. MPO was significantly
decreased in Groups L, D, and LD (-197.08 +/- 34.01, -137.37 +/- 32.41,
and -189.45 +/- 33.73 U/ml, P<0.001, respectively) compared with Group C
(-106.51 +/- 25.44 U/ml). H3Cit was also lessened in Groups L, D, and LD
(-49.51 +/- 9.11, -34.80 +/- 10.37, and -51.82 +/- 8.98 ng/ml, P<0.001,
respectively) compared with Group C (-24.73 +/- 7.65 ng/ml). Lidocaine and
dexmedetomidine also reduced MMP-3 (-69.08 +/- 13.22, -52.84 +/- 13.78,
-85.34 +/- 12.59 vs. -40.55 +/- 10.71 ng/ml in Group L, D, LD vs. Group C,
P<0.001, respectively), MMP-9 (-8.46 +/- 1.68, -6.07 +/- 1.82, -9.67 +/-
1.43 vs. -4.28 +/- 1.29 ng/ml in Group L, D, LD vs. Group C, P<0.001,
respectively), and VEGF-alpha (-95.55 +/- 22.53, -71.65 +/- 18.77, -104.89
+/- 15.49 vs. -51.73 +/- 16.27 pg/ml in Group L, D, LD vs. Group C,
P<0.001, respectively) on POD 1. Conclusion(s): In NSCLC patients,
continuous perioperative intravenous infusion of lidocaine and
dexmedetomidine significantly reduced the production of NETs and tumor
metastasis biomarkers on POD 1. Meanwhile, it also decreased inflammation,
protected cellular immune function, reduced pain and opioid consumption,
and improved the quality of postoperative recovery. Clinical trial
registration: chictr.org.cn, identifier: 187049. Copyright © 2023
Ren, Cheng, Liu, Zheng, Zhang, Chen, Song, Zhuang, Liu, Wang and Wang.

<17>
Accession Number
2023334704
Title
Multivariable prediction models for atrial fibrillation after cardiac
surgery: A systematic review protocol.
Source
BMJ Open. 13(3) (no pagination), 2023. Article Number: e067260. Date of
Publication: 13 Mar 2023.
Author
Fields K.G.; Ma J.; Petrinic T.; Alhassan H.; Eze A.; Reddy A.; Hedayat
M.; Providencia R.; Lip G.Y.H.; Bedford J.P.; Clifton D.A.; Redfern O.C.;
O'Brien B.; Watkinson P.J.; Collins G.S.; Muehlschlegel J.D.
Institution
(Fields, Hedayat, Muehlschlegel) Department of Anesthesiology,
Perioperative and Pain Medicine, Harvard Medical School, Boston, MA,
United States
(Ma, Collins) Centre for Statistics in Medicine, Nuffield Department of
Orthopedics, Rheumatology and Musculoskeletal Sciences, University of
Oxford, Oxford, United Kingdom
(Petrinic) Bodleian Health Care Libraries, University of Oxford, Oxford,
United Kingdom
(Alhassan) Department of Medicine, University of Pittsburgh Medical
Center, Pittsburgh, PA, United States
(Eze) Department of Surgery, Duke University Medical Center, Durham, NC,
United States
(Reddy) University of Texas Medical Branch, School of Medicine, Galveston,
TX, United States
(Providencia) Institute of Health Informatics Research, University College
London, London, United Kingdom
(Providencia) Department of Cardiac Electrophysiology, Barts Heart Centre,
St. Bartholomew's Hospital, Barts Health NHS Trust, London, United Kingdom
(Lip) Liverpool Centre for Cardiovascular Science, University of
Liverpool, Liverpool John Moores University, Liverpool Heart and Chest
Hospital, Liverpool, United Kingdom
(Lip) Department of Clinical Medicine, Aalborg University, Aalborg,
Denmark
(Bedford, Redfern, Watkinson) Kadoorie Centre for Critical Care Research
and Education, Nuffield Department of Clinical Neurosciences, University
of Oxford, Oxford, United Kingdom
(Clifton) Department of Engineering Science, University of Oxford, Oxford,
United Kingdom
(O'Brien) Department of Cardiac Anesthesiology and Intensive Care
Medicine, Deutsches Herzzentrum Berlin, Charite Universitatsmedizin
Berlin, Berlin, Germany
(O'Brien) Department of Perioperative Medicine, St. Bartholomew's Hospital
and Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom
(O'Brien) Outcomes Research Consortium, Cleveland, OH, United States
(Watkinson) Oxford University Hospitals NHS Trust, Oxford, United Kingdom
(Watkinson) NIHR Biomedical Research Centre, Oxford University Hospitals
NHS Foundation Trust, Oxford, United Kingdom
Publisher
BMJ Publishing Group
Abstract
Introduction Dozens of multivariable prediction models for atrial
fibrillation after cardiac surgery (AFACS) have been published, but none
have been incorporated into regular clinical practice. One of the reasons
for this lack of adoption is poor model performance due to methodological
weaknesses in model development. In addition, there has been little
external validation of these existing models to evaluate their
reproducibility and transportability. The aim of this systematic review is
to critically appraise the methodology and risk of bias of papers
presenting the development and/or validation of models for AFACS. Methods
We will identify studies that present the development and/or validation of
a multivariable prediction model for AFACS through searches of PubMed,
Embase and Web of Science from inception to 31 December 2021. Pairs of
reviewers will independently extract model performance measures, assess
methodological quality and assess risk of bias of included studies using
extraction forms adapted from a combination of the Critical Appraisal and
Data Extraction for Systematic Reviews of Prediction Modelling Studies
checklist and the Prediction Model Risk of Bias Assessment Tool. Extracted
information will be reported by narrative synthesis and descriptive
statistics. Ethics and dissemination This systemic review will only
include published aggregate data, so no protected health information will
be used. Study findings will be disseminated through peer-reviewed
publications and scientific conference presentations. Further, this review
will identify weaknesses in past AFACS prediction model development and
validation methodology so that subsequent studies can improve upon prior
practices and produce a clinically useful risk estimation tool. PROSPERO
registration number CRD42019127329. Copyright © Author(s) (or
their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial
re-use. See rights and permissions. Published by BMJ.

<18>
Accession Number
2022947687
Title
Prognostic Value of RV Abnormalities on CMR in Patients With Known or
Suspected Cardiac Sarcoidosis.
Source
JACC: Cardiovascular Imaging. 16(3) (pp 361-372), 2023. Date of
Publication: March 2023.
Author
Wang J.; Zhang J.; Hosadurg N.; Iwanaga Y.; Liu W.; Wan K.; Patel A.R.;
Wicks E.C.; Gkoutos G.V.; Han Y.; Chen Y.
Institution
(Wang, Chen) Cardiology Division, Department of Medicine, West China
Hospital, Sichuan University, Sichuan, Chengdu, China
(Wang, Gkoutos) College of Medical and Dental Sciences, Institute of
Cancer and Genomic Sciences, University of Birmingham, Birmingham, United
Kingdom
(Zhang, Chen, Liu) West China School of Public Health, Sichuan University,
Sichuan, Chengdu, China
(Hosadurg, Patel) Division of Cardiovascular Medicine, The University of
Virginia Health System, Charlottesville, VA, United States
(Iwanaga) Department of Medical and Health Information Management,
National Cerebral and Cardiovascular Center, Suita, Japan
(Wan) Department of Geriatrics, West China Hospital, Sichuan University,
Sichuan, Chengdu, China
(Wicks) Oxford University Hospitals, John Radcliffe Hospital, Headley Way,
Oxford, Headington, United Kingdom
(Gkoutos) Institute of Translational Medicine, University Hospitals
Birmingham NHS Foundation Trust, Birmingham, United Kingdom
(Gkoutos) Health Data Research UK, Midlands Site, United Kingdom
(Han) Cardiovascular Division, Wexner Medical Center, The Ohio State
University, Columbus, OH, United States
(Chen) Center of Rare Diseases, West China Hospital, Sichuan University,
Sichuan, Chengdu, China
Publisher
Elsevier Inc.
Abstract
Background: Left ventricular abnormalities in cardiac sarcoidosis (CS) are
associated with adverse cardiovascular events, whereas the prognostic
value of right ventricular (RV) involvement found on cardiac magnetic
resonance is unclear. Objective(s): This study aimed to
systematically assess the prognostic value of right ventricular ejection
fraction (RVEF) and RV late gadolinium enhancement (LGE) in known or
suspected CS. Method(s): This study was prospectively registered in
PROSPERO (CRD42022302579). PubMed, Embase, and Web of Science were
searched to identify studies that evaluated the association between RVEF
or RV LGE on clinical outcomes in CS. A composite endpoint of all-cause
death, cardiovascular events, or sudden cardiac death (SCD) was used. A
meta-analysis was performed to determine the pooled risk ratio (RR) for
these adverse events. The calculated sensitivity, specificity, and area
under the curve with 95% CIs were weighted and summarized. Result(s):
Eight studies including a total of 899 patients with a mean follow-up
duration of 3.2 +/- 0.7 years were included. The pooled RR of RV systolic
dysfunction was 3.1 (95% CI: 1.7-5.5; P < 0.01) for composite events and
3.0 (95% CI: 1.3-7.0; P < 0.01) for SCD events. In addition, CS patients
with RV LGE had a significant risk for composite events (RR: 4.8 [95% CI:
2.4-9.6]; P < 0.01) and a higher risk for SCD (RR: 9.5 [95% CI: 4.4-20.5];
P < 0.01) than patients without RV LGE. Furthermore, the pooled area under
the curve, sensitivity, and specificity of RV LGE for identifying patients
with CS who were at highest SCD risk were 0.8 (95% CI: 0.8-0.9), 69% (95%
CI: 50%-84%), and 90% (95% CI: 70%-97%), respectively. Conclusion(s):
In patients with known or suspected CS, RVEF and RV LGE were both
associated with adverse events. Furthermore, RV LGE shows good
discrimination in identifying CS patients at high risk of
SCD. Copyright © 2023 American College of Cardiology Foundation

<19>
Accession Number
2022332615
Title
Rationale and design for the myocardial ischemia and transfusion (MINT)
randomized clinical trial.
Source
American Heart Journal. 257 (pp 120-129), 2023. Date of Publication: March
2023.
Author
Carson J.L.; Brooks M.M.; Chaitman B.R.; Alexander J.H.; Goodman S.G.;
Bertolet M.; Abbott J.D.; Cooper H.A.; Rao S.V.; Triulzi D.J.; Fergusson
D.A.; Kostis W.J.; Noveck H.; Simon T.; Steg P.G.; DeFilippis A.P.;
Goldsweig A.M.; Lopes R.D.; White H.; Alsweiler C.; Morton E.; Hebert
P.C.; Ghafghazi S.; Wood F.; Menegus M.; Uretsky B.; Vallurupalli S.;
Maniatis G.; Gruberg L.; Roswell R.; Rossi J.; Abtahian F.; Tessalee M.;
Barsness G.; Aronow H.; Ramanathan K.; Schmidhofer M.; Keating F.; Carson
M.; Kontos M.; Qureshi M.; Clegg S.; Laskey W.; Polonsky T.; Gupta R.;
Sheikh M.A.; Uhl L.; Mullen P.; Bracey A.; Matthai W.; Stowell C.;
Dudzinski D.; Marhefka G.; Weinstock P.; Lawson W.; Keller N.; Yuriditsky
E.; Thomas M.; Jacobs A.; Hochberg C.; Siddiqi O.; Schulman-Marcus J.;
Torosoff M.; Gitter M.; Dai X.; Traverse J.; McCamant E.; Scott J.;
Swaminathan R.; Rao S.; Salisbury A.; Landers D.; Raveendran G.; Ebrahimi
R.; Bach R.; Delehanty J.; Shah R.C.; Brener S.; Doroshow J.; Caixeta A.;
Precoma D.; Dall'Orto F.T.C.; De Andrade P.B.; Dracoulakis M.; Maia L.N.;
Ritt L.E.F.; Quadros A.; Filho D.C.S.; De Martino F.; Huynh T.; Schnell
G.; Senaratne M.; Tandon V.; Neary J.; Laflamme D.; Dery J.-P.; Bainey K.;
Haichin R.; Dehghani P.; Quraishi A.U.R.; Potter B.J.; Carrier F.M.;
Goldfarb M.; Fordyce C.; Sia Y.T.; Daneault B.; Madan M.; McPherson T.;
Ducas J.; Minhas K.; Brass N.; Bagai A.; Robinson S.; Dzavik V.; Khan R.;
Michaud N.; Steg G.; Ducrocq G.; Puymirat E.; Lemesle G.; Ferrari E.;
Lattuca B.; Silvain J.; Vanzetto G.; Cetran L.; Lhermusier T.; Cottin Y.;
Rosamel Y.; Angoulvant D.; Dillinger J.G.; Thuaire C.; Popovic B.; Durand
E.; Bouleti C.; Roubille F.; Delorme L.; Crozier I.; Benatar J.; Nandra
S.; Ternouth I.; Fisher N.; Brieger D.; Hillis G.
Institution
(Carson, Kostis, Noveck) Rutgers Robert Wood Johnson Medical School, New
Brunswick, NJ
(Brooks, Bertolet) University of Pittsburgh School of Public Health,
Pittsburgh, Panama
(Chaitman) St Louis University School of Medicine, St Louis, Macao
(Alexander, Lopes) Duke Clinical Research Institute, Durham, New Caledonia
(Goodman) St. Michael's Hospital, University of Toronto, Toronto, Canada
(Goodman) Canadian VIGOUR Centre, University of Alberta, Edmonton, AB,
Canada
(Abbott) Warren Alpert Medical School. Brown University, Providence, RI
(Cooper) Westchester Medical Center, Valhalla, NY
(Rao) Durham VA Medical Center, Durham, New Caledonia
(Rao) NYU Langone Health, New York, NY
(Triulzi) University of Pittsburgh School of Medicine, Pittsburgh, Panama
(Fergusson) Ottawa Hospital Research Institute Ottawa, ON, Canada
(Simon) Hopital Saint Antoine, Paris, France
(Steg) Universite Paris-Cite, Paris, France
(DeFilippis) Vanderbilt University, Nashville, Tunisia
(Goldsweig) University of Nebraska Medical Center, Omaha, Niger
(Lopes) Brazilian Clinical Research Institute, Sao Paulo, Brazil
(White, Alsweiler) Green Lane Clinical Coordinating Centre Ltd, Auckland,
New Zealand
(Morton) Finders University, Adelaide, Australia
(Hebert) Centre de Recherche du Centre Hosp. Universitaire de Montreal,
Montreal, Quebec, Canada
(Carson) Rutgers Robert Wood Johnson Medical School (A01), United States
(Ghafghazi) Louisville - University of Louisville (A02), Jewish Hospital
(A14), Norton Hospital (A65), United States
(Cooper) Westchester Medical Center (A03), United States
(Wood) WakeMed Health & Hospitals (A04), United States
(Menegus) Montefiore - Weiler Hospital (A06), Moses Hospital (A23), United
States
(Uretsky) University of Arkansas Medical Sciences - Central Arkansas
Veterans (A07), United States
(Vallurupalli) University of Arkansas Medical Sciences -University of
Arkansas Medical (A49), United States
(Maniatis) Northwell Hospital System - Staten Island University (A09),
United States
(Gruberg) Northwell Hospital System - Southside Hospital (A53), United
States
(Roswell) Northwell Hospital System - Lenox Hill Hospital (A62), United
States
(Rossi) UNC Hospitals (A10), United States
(Abtahian) Rochester General Hospital (A11), United States
(Tessalee) AdventHealth - Adventist Hinsdale Hospital (A12), Adventist La
Grange Hospital (A21), Adventist Bolingbrook (A22), United States
(Barsness) Mayo Clinic (A13), United States
(Abbott) Lifespan - Rhode Island Hospital (A15), United States
(Aronow) Lifespan - The Miriam Hospital (A16), United States
(Ramanathan) Memphis VA Medical Center (A18), United States
(Schmidhofer) UPMC Presbyterian (A20), United States
(Keating) University of Vermont Medical (A27), United States
(Carson) Jersey Shore University Medical (A29), United States
(Kontos) Virginia Commonwealth (A31), United States
(Qureshi) St. Joseph Mercy Hospital (A32), United States
(Clegg, Laskey) University of New Mexico (A33), United States
(Polonsky) University of Chicago (A34), United States
(Gupta, Sheikh) University of Toledo (A36), United States
(Uhl) Beth Israel Deaconess (A37), United States
(Mullen) Memorial Hospital at Gulfport (A38), United States
(Bracey) Baylor St Luke's (A39), United States
(Matthai) PENN Presbyterian (A40), United States
(Stowell, Dudzinski) Massachusetts General Hospital (A44), United States
(Marhefka) Thomas Jefferson University (A45), United States
(Weinstock) Cooper University Hospital (A47), United States
(Lawson) Stony Brook University (A48), United States
(Keller, Yuriditsky) NYU Langone Medical Center (A51), United States
(Thomas) University of Michigan (A54), United States
(Jacobs, Hochberg, Siddiqi) Boston Medical Center (A56), United States
(Schulman-Marcus, Torosoff) Albany Medical College (A57), United States
(Gitter) Medical College of Wisconsin (A59), United States
(Dai) NYP Queens (A60), United States
(Traverse) Minneapolis Heart Institute (Foundation) (A61), United States
(McCamant, Scott) Lancaster General (A63), United States
(Swaminathan, Rao) Durham VA Medical Center (A64), United States
(Goldsweig) University of Nebraska Medical Center (A67), United States
(DeFilippis) Vanderbilt (A69), United States
(Salisbury) Saint Luke's Mid America Heart (A05), United States Sites -
Inactive
(Landers) Hackensack University Medical (A17), United States Sites -
Inactive
(Raveendran) University of Minnesota (A25), United States Sites - Inactive
(Ebrahimi) UCLA / Veterans Affairs Greater LA (A30), United States Sites -
Inactive
(Bach) Washington University St Louis (A35), United States Sites -
Inactive
(Delehanty) University of Rochester (A43), United States Sites - Inactive
(Shah) Rush University Medical Center (A46), United States Sites -
Inactive
(Brener) NYP Brooklyn Methodist (A50), United States Sites - Inactive
(Doroshow) Lankenau Medical Center (A66), United States Sites - Inactive
(Caixeta) Hospital Sao Paulo (B01), Brazilian Sites
(Precoma) Sociedade Hospitalar Angelina Caron (B02), Brazilian Sites
(Dall'Orto) Hospital Maternidade e Pronto Socorro Santa Lucia (B04),
Brazilian Sites
(De Andrade) Santa Casa de Marilia (B05), Brazilian Sites
(Dracoulakis) Hospital da Bahia (B06), Brazilian Sites
(Maia) Hospital de Base de Rio Preto (B07), Brazilian Sites
(Ritt) Hospital Cardio Pulmonar (B10), Brazilian Sites
(Quadros) Instituto de Cardiologia do RS (B13), Brazilian Sites
(Filho) Pronto Socorro Cardiologico de Prof. Luiz Tavares (B14), Brazilian
Sites
(De Martino) Hospital de Clinicas UFTM (B16), Brazilian Sites
(Huynh) Montreal General Hospital (C01), Canadian Sites
(Schnell) Foothills Medical Centre (C02), Canadian Sites
(Senaratne) Grey Nuns Community Hospital (C03), Canadian Sites
(Tandon) Hamilton Health Sciences/St. Joseph's Healthcare Hamilton -
Hamilton General Hospital (C04), Canadian Sites
(Tandon) Hamilton Health Sciences/St. Joseph's Healthcare Hamilton -
Juravinski Hospital (C29), Canadian Sites
(Neary) Hamilton Health Sciences/St. Joseph's Healthcare Hamilton - St.
Joseph's Healthcare Hamilton (C30), Canadian Sites
(Laflamme) Hopital Charles Lemoyne (C05), Canadian Sites
(Dery) Quebec Heart and Lung Institute (C06), Canadian Sites
(Bainey) University Of Alberta Hospital (C07), Canadian Sites
(Haichin) Royal Victoria Hospital (C08), Canadian Sites
(Dehghani) Regina General Hospital (C09), Canadian Sites
(Quraishi) QE II Health Sciences Center (C10), Canadian Sites
(Potter, Carrier) Centre Hosp. Universitaire de Montreal (C12), Canadian
Sites
(Goldfarb) Jewish General Hospital (C14), Canadian Sites
(Fordyce) Vancouver General Hospital (C15), Canadian Sites
(Sia) Centre integre universitaire de sante et de services sociaux de la
Mauricie-et-du-Centre-du-Quebec (C17), Canadian Sites
(Daneault) Centre Hospitalier Sherbrooke (C21), Canadian Sites
(Madan) Sunnybrook Health Sciences Centre (C22), Canadian Sites
(McPherson) London Health Sciences Centre - Victoria Hospital - LHSC
(C11), University Hospital (C23), Canadian Sites
(Ducas) St. Boniface General Hospital (C24), Canadian Sites
(Minhas) St. Boniface General Hospital (C24), Canadian Sites
(Brass) Royal Alexandra Hospital (C25), Canadian Sites
(Bagai) St. Michael's Hospital (C27), Canadian Sites
(Robinson) Victoria Heart Institute (C28), Canadian Sites
(Dzavik) UHN (C31), Canadian Sites
(Khan) Royal Columbian Hospital (C13), Canadian Sites - Inactive
(Michaud) Hotel Dieu de Levis (C19), Canadian Sites - Inactive
(Steg, Ducrocq) Hopital BICHAT - APHP (E01), European Union Sites
(Puymirat) HEGP - APHP (E02), European Union Sites
(Lemesle) CHRU Lille (E03), European Union Sites
(Ferrari) CHU Nice - Hopital Pasteur (E04), European Union Sites
(Lattuca) CHU Caremeau - Nimes (E05), European Union Sites
(Silvain) Hopital Pitie Salpetriere - APHP (E06), European Union Sites
(Vanzetto) Hopital Michalon - Grenoble (E07), European Union Sites
(Cetran) Hopital Haut Leveque - Pessac (E08), European Union Sites
(Lhermusier) CHU Rangueil - Toulouse (E09), European Union Sites
(Cottin) CHU le Bocage - Dijon (E10), European Union Sites
(Rosamel) Centre Hospitalier sud francilien (E11), European Union Sites
(Angoulvant) CHRU Tours - Hopital Trousseau (E12), European Union Sites
(Dillinger) Hopital Lariboisiere - APHP (E13), European Union Sites
(Thuaire) CH Louis Pasteur, Chartres (E14), European Union Sites
(Popovic) CHU Nancy (E15), European Union Sites
(Durand) CHU de Rouen (E16), European Union Sites
(Bouleti) CHU Poitiers (E18), European Union Sites
(Roubille) CHU Arnaud de Villeneuve - Montpellier (E19), European Union
Sites
(Delorme) Clinique du pont de chaume - Montauban (E20), European Union
Sites
(Crozier) Christchurch Hospital (N01), New Zealand Sites
(Benatar) Auckland Hospital (N02), New Zealand Sites
(Nandra) Whangarei Hospital (N04), New Zealand Sites
(Ternouth) Taranaki Hospital (N05), New Zealand Sites
(Fisher) Nelson Hospital (N06), New Zealand Sites
(Brieger) Concord Repatriation General Hospital (V03), Australian Sites
(Hillis) Royal Perth Hospital (V04), Australian Sites
Publisher
Elsevier Inc.
Abstract
Background: Accumulating evidence from clinical trials suggests that a
lower (restrictive) hemoglobin threshold (<8% g/dL) for red blood cell
(RBC) transfusion, compared with a higher (liberal) threshold (>=10 g/dL)
is safe. However, in anemic patients with acute myocardial infarction
(MI), maintaining a higher hemoglobin level may increase oxygen delivery
to vulnerable myocardium resulting in improved clinical outcomes.
Conversely, RBC transfusion may result in increased blood viscosity,
vascular inflammation, and reduction in available nitric oxide resulting
in worse clinical outcomes. We hypothesize that a liberal transfusion
strategy would improve clinical outcomes as compared to a more restrictive
strategy. Method(s): We will enroll 3500 patients with acute MI (type
1, 2, 4b or 4c) as defined by the Third Universal Definition of MI and a
hemoglobin <10 g/dL at 144 centers in the United States, Canada, France,
Brazil, New Zealand, and Australia. We randomly assign trial participants
to a liberal or restrictive transfusion strategy. Participants assigned to
the liberal strategy receive transfusion of RBCs sufficient to raise their
hemoglobin to at least 10 g/dL. Participants assigned to the restrictive
strategy are permitted to receive transfusion of RBCs if the hemoglobin
falls below 8 g/dL or for persistent angina despite medical therapy. We
will contact each participant at 30 days to assess clinical outcomes and
at 180 days to ascertain vital status. The primary end point is a
composite of all-cause death or recurrent MI through 30 days following
randomization. Secondary end points include all-cause mortality at 30
days, recurrent adjudicated MI, and the composite outcome of all-cause
mortality, nonfatal recurrent MI, ischemia driven unscheduled coronary
revascularization (percutaneous coronary intervention or coronary artery
bypass grafting), or readmission to the hospital for ischemic cardiac
diagnosis within 30 days. The trial will assess multiple tertiary end
points. Conclusion(s): The MINT trial will inform RBC transfusion
practice in patients with acute MI. Copyright © 2022 Elsevier
Inc.

<20>
Accession Number
2021954225
Title
Proton Pump Inhibitor Use Associated With an Increased Risk of Gastric
Cancer.
Source
American Family Physician. 106(1) (pp 99C), 2022. Date of Publication:
July 2022.
Author
Ebell M.H.
Institution
(Ebell) University of Georgia, Athens, GA, United States
Publisher
American Academy of Family Physicians

<21>
Accession Number
2020487451
Title
JCS 2022 Guideline on Management and Re-Interventional Therapy in Patients
With Congenital Heart Disease Long-Term After Initial Repair.
Source
Circulation Journal. 86(10) (pp 1591-1690), 2022. Date of Publication:
October 2022.
Author
Kawata M.; Ohuchi H.; Akagi T.; Ichikawa H.; Inai K.; Kasahara S.; Motoki
H.; Sakamoto K.; Senzaki H.; Sugiyama H.; Suzuki T.; Syoda M.; Tsutsui H.;
Uemura H.; Yao A.; Ishizu T.; Izumi C.; Kato A.; Miyazaki A.; Mizuno Y.;
Ochiai R.; Sagawa K.; Sakamoto I.; Shiina Y.; Tatebe S.; Tateno S.; Toh
N.; Ichida F.; Kimura T.; Matsuda H.; Niwa K.
Institution
(Kawata) Division of Pediatric and Congenital Cardiovascular Surgery,
Jichi Children's Medical Center Tochigi, Japan
(Ohuchi) Department of Pediatric Cardiology and Adult Congenital Heart
Disease, National Cerebral and Cardiovascular Center, Japan
(Akagi, Toh) Department of Cardiovascular Medicine, Okayama University,
Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Japan
(Ichikawa) Department of Pediatric Cardiovascular Surgery, National
Cerebral and Cardiovascular Center, Japan
(Inai) Department of Pediatric Cardiology and Adult Congenital Cardiology,
Tokyo Women's Medical University, Japan
(Kasahara) Department of Cardiovascular Surgery, Okayama University,
Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Japan
(Motoki) Department of Cardiovascular Medicine, Shinshu University School
of Medicine, Japan
(Sakamoto) Department of Cardiovascular Surgery, Shizuoka Children's
Hospital, Japan
(Senzaki) Department of Pediatrics, International University of Health and
Welfare, Japan
(Sugiyama) Department of Pediatric Cardiology, Seirei Hamamatsu General
Hospital, Japan
(Suzuki) Department of Pediatric Cardiac Surgery, Saitama Medical
University, Japan
(Syoda) Department of Cardiology, Tokyo Women's Medical University, Japan
(Tsutsui, Sakamoto) Department of Cardiovascular Medicine, Kyushu
University, Graduate School of Medical Sciences, Japan
(Uemura) Congenital Heart Disease Center, Nara Medical University, Japan
(Yao) Division for Health Service Promotion, University of Tokyo, Japan
(Ishizu) Cardiovascular Division, Faculty of Medicine, University of
Tsukuba, Japan
(Izumi) Department of Cardiovascular Medicine, National Cerebral and
Cardiovascular Center, Japan
(Kato) Department of Pediatric Cardiology, National Cerebral and
Cardiovascular Center, Japan
(Miyazaki) Division of Congenital Heart Disease, Department of Transition
Medicine, Shizuoka General Hospital, Japan
(Mizuno) Faculty of Nursing, Tokyo University of Information Sciences,
Japan
(Ochiai) Department of Adult Nursing, Yokohama City University, Japan
(Sagawa) Department of Pediatric Cardiology, Fukuoka Children's Hospital,
Japan
(Shiina) Cardiovascular Center, St. Luke's International Hospital, Japan
(Tatebe) Department of Cardiovascular Medicine, Tohoku University,
Graduate School of Medicine, Japan
(Tateno) Department of Pediatrics, Chiba Kaihin Municipal Hospital, Japan
(Ichida) Sanno Hospital, Department of Pediatrics, International
University of Health and Welfare, Japan
(Kimura) Department of Cardiovascular Medicine, Kyoto University, Graduate
School of Medicine, Japan
(Matsuda) Shion Hospital, Japan
(Niwa) Department of Cardiology, St. Luke's International Hospital, Japan
Publisher
Japanese Circulation Society

<22>
Accession Number
2015866194
Title
Ebstein's Anomaly: From Fetus to Adult-Literature Review and Pathway for
Patient Care.
Source
Pediatric Cardiology. 43(7) (pp 1409-1428), 2022. Date of Publication:
October 2022.
Author
Ramcharan T.K.W.; Goff D.A.; Greenleaf C.E.; Shebani S.O.; Salazar J.D.;
Corno A.F.
Institution
(Ramcharan) Department of Cardiology, Birmingham Women's and Children's
NHS Foundation Trust, Birmingham, United Kingdom
(Goff, Greenleaf, Salazar, Corno) McGovern Medical School, Children's
Heart Institute, University of Texas Health, Houston, TX, United States
(Shebani) East Midlands Congenital Heart Centre, Glenfield Hospital,
University Hospitals of Leicester, Leicester, United Kingdom
Publisher
Springer
Abstract
Ebstein's anomaly, first described in 1866 by Dr William Ebstein, accounts
for 0.3-0.5% of congenital heart defects and represents 40% of congenital
tricuspid valve abnormalities. Ebstein's anomaly affects the development
of the tricuspid valve with widely varying morphology and, therefore,
clinical presentation. Associated congenital cardiac lesions tend to be
found more often in younger patients and may even be the reason for
presentation. Presentation can vary from the most extreme form in fetal
life, to asymptomatic diagnosis late in adult life. The most symptomatic
patients need intensive care support in the neonatal period. This article
summarizes and analyzes the literature on Ebstein's anomaly and provides a
framework for the investigation, management, and follow-up of these
patients, whether they present via fetal detection or late in adult life.
For each age group, the clinical presentation, required diagnostic
investigations, natural history, and management are described. The
surgical options available for patients with Ebstein's anomaly are
detailed and analyzed, starting from the initial mono-leaflet repairs to
the most recent cone repair and its modifications. The review also
assesses the effects of pregnancy on the Ebstein's circulation, and vice
versa, the effects of Ebstein's on pregnancy outcomes. Finally, two
attached appendices are provided for a structured echocardiogram protocol
and key information useful for comprehensive Multi-Disciplinary Team
discussion. Copyright © 2022, The Author(s), under exclusive
licence to Springer Science+Business Media, LLC, part of Springer Nature.

<23>
Accession Number
2020843302
Title
Increasing preoperative cognitive reserve to prevent postoperative
delirium and postoperative cognitive decline in cardiac surgical patients
(INCORE): Study protocol for a randomized clinical trial on cognitive
training.
Source
Frontiers in Neurology. 13 (no pagination), 2022. Article Number: 1040733.
Date of Publication: 12 Dec 2022.
Author
Butz M.; Meyer R.; Gerriets T.; Sammer G.; Doerr J.M.; El-Shazly J.;
Doeppner T.R.; Choi Y.-H.; Schoenburg M.; Juenemann M.
Institution
(Butz, Meyer, Gerriets, Sammer, Doerr, Schoenburg, Juenemann) Heart and
Brain Research Group, Kerckhoff Heart and Thorax Center, Bad Nauheim,
Germany
(Butz, Gerriets, Doerr, Doeppner, Juenemann) Department of Neurology,
University Hospital Giessen and Marburg, Giessen, Germany
(Sammer) Cognitive Neuroscience at the Centre of Psychiatry, University
Giessen, Giessen, Germany
(Sammer) Department of Psychology, Justus-Liebig University, Giessen,
Germany
(El-Shazly) Department of Psychocardiology, Kerckhoff Heart and Thorax
Center, Bad Nauheim, Germany
(Choi, Schoenburg) Department of Cardiac Surgery, Kerckhoff Heart and
Thorax Center, Bad Nauheim, Germany
Publisher
Frontiers Media S.A.
Abstract
Introduction: Postoperative delirium (POD) and postoperative cognitive
decline (POCD) can be observed after cardiosurgical interventions. Taken
together, these postoperative neurocognitive disorders (PNCDs) contribute
to increased morbidity and mortality. Preoperative risk factors of PNCD,
such as decreased neuropsychometric performance or decreased cognitive
daily activities, can be interpreted as reduced cognitive reserve. This
study aims to build up cognitive reserves to protect against the
development of PNCD through preoperative, home-based, cognitive training.
 Method(s): The planned research project is a monocentric, two-arm
randomized controlled intervention study involving 100 patients undergoing
elective cardiac surgery with extracorporeal circulation. Patients will be
assigned to a training group or control group. The intervention involves a
standardized, paper-and-pencil-based cognitive training that will be
performed by the patients at home for ~40 min per day over a preoperative
period of 2-3 weeks. The control group will receive neither cognitive
training nor a placebo intervention. A detailed assessment of
psychological functions will be performed ~2-3 weeks before the start of
training, at the end of the training, during hospitalization, at discharge
from the acute clinic, and 3 months after surgery. The primary objective
of this study is to investigate the interventional effect of preoperative
cognitive training on the incidence of POD during the stay in the acute
clinic, the incidence of POCD at the time of discharge from the acute
clinic, and 3 months after surgery. Secondary objectives are to determine
the training effect on objective cognitive functions before the surgery
and subjective cognitive functions, as well as health-related quality of
life 3 months after surgery. Discussion(s): Should it become evident
that the use of our cognitive training can both reduce the incidence of
POCD and POD and improve health-related quality of life, this intervention
may be integrated into a standardized prehabilitation
program. Copyright © 2022 Butz, Meyer, Gerriets, Sammer, Doerr,
El-Shazly, Doeppner, Choi, Schoenburg and Juenemann.

<24>
Accession Number
2016948571
Title
Triiodothyronine Supplementation in Infants Undergoing Cardiopulmonary
Bypass: A Randomized Controlled Trial.
Source
Seminars in Thoracic and Cardiovascular Surgery. 35(1) (pp 105-112), 2023.
Date of Publication: Spring 2023.
Author
Portman M.A.; Slee A.E.; Roth S.J.; Radman M.; Olson A.K.; Mainwaring
R.D.; Kamerkar A.; Nuri M.; Hastings L.
Institution
(Portman, Radman, Olson) Seattle Children's Research Institute and
Department of Pediatrics, University of Washington, Seattle, WA, United
States
(Slee) New Arch Consulting, Seattle, WA, United States
(Roth) Department of Cardiology and Critical Care, Lucile Packard
Children's Hospital, Palo Alto, California, United States
(Mainwaring) Department of Cardiothoracic Surgery, Lucile Packard
Children's Hospital, Palo Alto, California, United States
(Kamerkar) Department of Critical Care, Los Angeles Children's Hospital,
Los Angeles, California, United States
(Nuri) Division of Cardiothoracic Surgery at Children's Hospital of
Philadelphia, Philadelphia, Pennsylvania
(Hastings) Levine Children's Hospital, Scope Anesthesia, Charlotte, North
Carolina
Publisher
W.B. Saunders
Abstract
Cardiopulmonary bypass (CPB) profoundly suppresses circulating thyroid
hormone levels in infants. We performed a multicenter randomized placebo
controlled trial to determine if triiodothyronine (T3) supplementation
improves reduces time to extubation (TTE) in infants after CPB. Infants (n
= 220) undergoing cardiac surgery with CPB and stratified into 2 age
cohorts: <=30 days and >30 days to <152 days were randomization to receive
either intravenous triiodothyronine or placebo bolus followed by study
drug infusion until extubated or at 48 hours, whichever preceded. T3 did
not significantly alter the primary endpoint, TTE (hazard ratio for chance
of extubation (1.08, 95% CI: 0.82-1.43, P = 0.575) in the entire
randomized population with censoring at 21 days. T3 showed no significant
effect on TTE (HR 0.82, 95% CI:0.55-1.23, P = 0.341) in the younger
subgroup or in the older (HR 1.38, 95% CI:0.95-2.2, P = 0.095). T3 also
did not significantly impact TTE during the first 48 hours while T3 levels
were maintained (HR 1.371, 95% CI:0.942-1.95, P = 0.099) No significant
differences occurred for arrhythmias or other sentinel adverse events in
the entire cohort or in the subgroups. This trial showed no significant
benefit on TTE in the entire cohort. T3 supplementation appears safe as it
did not cause an increase in adverse events. The study implementation and
analysis were complicated by marked variability in surgical risk, although
risk categories were balanced between treatment groups. Copyright
© 2022 Elsevier Inc.

<25>
Accession Number
2023516900
Title
Meta-Analysis of Long-Term (>1 Year) Cardiac Outcomes of Peripartum
Cardiomyopathy.
Source
American Journal of Cardiology. 194 (pp 71-77), 2023. Date of Publication:
01 May 2023.
Author
Koerber D.; Khan S.; Kirubarajan A.; Spivak A.; Wine R.; Matelski J.;
Sobel M.; Harris K.
Institution
(Koerber) Faculty of Medicine, University of Alberta, Edmonton, ON, Canada
(Koerber, Khan, Kirubarajan, Spivak, Wine, Sobel, Harris) Faculty of
Medicine, Canada
(Kirubarajan) Faculty of Medicine, McMaster University, Hamilton, ON,
Canada
(Matelski) Biostatistics Research Unit, University Health Network,
Toronto, ON, Canada
(Sobel) Department of Obstetrics & Gynecology, Mount Sinai Hospital,
Canada
(Harris) Division of Maternal Fetal Medicine, Department of Obstetrics &
Gynecology, St. Michael's Hospital, University of Toronto, Toronto, ON,
Canada
Publisher
Elsevier Inc.
Abstract
Peripartum cardiomyopathy is the development of heart failure toward the
end of pregnancy or in the months after delivery in the absence of other
attributable causes, with left ventricular systolic dysfunction and a left
ventricular ejection fraction (LVEF) generally <45%. Given that patients
are relatively young at the time of diagnosis, this study was performed to
summarize current evidence surrounding the long-term cardiac outcomes.
MEDLINE, Embase, Cochrane CENTRAL, and CINAHL were searched for original
studies that reported long-term (>1 year) patient outcomes. Of the 3,144
total records identified, 62 studies involving 4,282 patients met the
selection criteria. The mean LVEF was 28% at diagnosis and 47% at the time
of the last follow-up. Approximately half of the patients achieved
myocardial recovery (47%), most commonly defined as an LVEF >50% (n = 21).
The prevalence of implantable cardioverter-defibrillator use, left
ventricular assist device implantation, and heart transplantation was 12%,
7%, and 11%, respectively. The overall all-cause mortality was 9%, and
despite having more cardiovascular risk factors, patients residing in
high-income countries had superior outcomes, including reduced rates of
mortality. Copyright © 2023 Elsevier Inc.

<26>
Accession Number
2023452641
Title
Factors associated with major electrolyte disorders among post cardiac
surgery patients at Tikur Anbessa Specialized Hospital and Cardiac Center
Ethiopia in Addis Ababa, Ethiopia, 2021.
Source
International Journal of Africa Nursing Sciences. 18 (no pagination),
2023. Article Number: 100556. Date of Publication: January 2023.
Author
Gebregzabher S.; Gebretensaye T.G.; Alemu T.
Institution
(Gebregzabher) Yekatit 12 Teaching Hospital Medical College, Addis Ababa,
Ethiopia
(Gebretensaye, Alemu) Addis Ababa University College of Health Sciences,
School of Nursing and Midwifery, Department of Nursing, Ethiopia
Publisher
Elsevier Ltd
Abstract
Most patients undergoing cardiac surgery are at a greater risk of
electrolyte disorders, which are important causes for ventricular and
supra-ventricular arrhythmias as well as various other complications.
Early identification of the common electrolyte disorder through serial
monitoring is crucial during post-cardiac surgery periods. The aim was to
assess the factors associated with major electrolyte disorders following
cardiac surgery. A facility-based retrospective survey was conducted among
192 randomly selected patient records from a total of 352 cardiac surgical
patients who underwent cardiac surgery between January 1st, 2016 to
December 31st, 2020. The survey was conducted from February 01 to April
28, 2021. A structured data collection checklist tested for its
reliability and content validity was adopted from similar studies to
gather data. Data was entered and analyzed using statistical software,
SPSS version 26.0. Descriptive statistics were used to describe
participants' characteristics and logistic regression was employed to
examine the association between independent and outcome variables. The
level of significance was determined at p-value < 0.05 and 95% CI.
Participant's age ranged between 25 and 29 with a mean of 29.44 +/- 12.02
SD years. Overall, 141 (73.4%) participants were found to have one or more
major postoperative electrolyte disorders. Close to one third, 58 (30.2%)
were Hyponatremic, 59 (30.7%), Hypokalemic and 58 (30.2%), Hypocalcemic.
Furthermore, cardiac lesions such as Mitral stenosis and Tricuspid
regurgitation were significantly associated with electrolyte disorders
[AOR = 0.5; 95% CI: 0.256-0.994] p-0.24, and [AOR = 4.5; 95% CI:1.49-13.9]
p- 0.003 respectively. Mitral valve replacement was also significantly
related with electrolyte disorders [AOR = 2.05 95% CI: 0.99-4.23] p-0.042.
Patients undergoing cardiac surgery are at high risk of electrolyte
disorders. Type of cardiac surgical procedure and type of cardiac lesions
are significant predictors of electrolyte disorder. Careful monitoring and
prompt correction of electrolytes will contribute to the prevention of
postoperative electrolyte disorders in patients. Copyright © 2023
The Author(s)

<27>
Accession Number
2022201310
Title
Sinus node dysfunction and related permanent pacemaker implantation after
major cardiac surgeries, systematic review, and meta-analysis.
Source
Frontiers in Cardiovascular Medicine. 10 (no pagination), 2023. Article
Number: 1091312. Date of Publication: 2023.
Author
Hosseini Dolama R.; Eghbal A.H.; Rezaee M.; Farahani A.V.; Jalali A.;
Hosseini K.
Institution
(Hosseini Dolama, Eghbal) Students' Scientific Research Center (SSRC),
Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Hosseini Dolama, Rezaee, Farahani, Jalali, Hosseini) Tehran Heart Center,
Cardiovascular Diseases Research Institute, Tehran University of Medical
Sciences, Tehran, Iran, Islamic Republic of
(Rezaee) Department of Pharmacology, School of Medicine, Shahid Beheshti
University of Medical Sciences, Tehran, Iran, Islamic Republic of
(Farahani, Hosseini) Cardiac Primary Prevention Research Center,
Cardiovascular Diseases Research Institute, Tehran University of Medical
Sciences, Tehran, Iran, Islamic Republic of
Publisher
Frontiers Media S.A.
Abstract
Background: There is no concise evidence or clinical guidelines regarding
the incidence of sinus node dysfunction (SND) and permanent pacemaker
(PPM) implantation following cardiac surgeries and their management
approaches. Objective(s): We aim to systematically review current
evidence on the prevalence of SND, PPM implantation concerning it, and its
risk factors in patients undergoing cardiac surgery. Method(s): Four
electronic databases (Cochrane Library, Medline, SCOPUS, and Web of
Science) were systematically searched for articles regarding SND after
cardiovascular surgeries and reviewed by two independent researchers, and
a third review in case of discrepancies. Using the random-effects model, a
proportion meta-analysis was performed on data regarding PPM implantation.
Subgroup analysis was performed for different interventions, and the
possible effect of different covariates was evaluated using
meta-regression. Result(s): From the initial 2012 unique records, 87
were included in the study, and results were extracted. Pooled data from
38,519 patients indicated that the overall prevalence of PPM implantation
due to SND after cardiac surgery was 2.87% (95% CI [2.09; 3.76]). The
incidence of PPM implantation in the first post-surgical month was 2.707%
(95% CI [1.657; 3.952]). Among the four main intervention groups,
including valve, maze, valve-maze, and combined surgeries, maze surgery
was associated with the highest prevalence (4.93%; CI [3.24; 6.92]). The
pooled prevalence of SND among studies was 13.71% (95% CI [8.13; 20.33]).
No significant relationship was observed between PPM implantation and age,
gender, cardiopulmonary bypass time, or aortic cross-clamp time.
 Conclusion(s): Based on the present report, patients undergoing the
maze and maze-valve procedures are at higher risk of post-op SND, whereas
lone valve surgery had the lowest prevalence of PPM implantation.
Systematic Review Registration: PROSPERO (CRD42022341896). Copyright
© 2023 Hosseini Dolama, Eghbal, Rezaee, Farahani, Jalali and
Hosseini.

<28>
Accession Number
2022693536
Title
Anatomic, stage-based repair of secondary mitral valve disease.
Source
Journal of Thoracic and Cardiovascular Surgery. (no pagination), 2023.
Date of Publication: 2023.
Author
Drake D.H.; Zhang P.; Zimmerman K.G.; Morrow C.D.; Sidebotham D.A.
Institution
(Drake) Department of Cardiac Surgery, University of Michigan Medical
School, Ann Arbor, Mich, United States
(Drake) Department of Surgery, Munson Medical Center, Traverse City, Mich,
United States
(Zhang) Department of Surgery, University of Michigan Medical School, Ann
Arbor, Mich, United States
(Zimmerman) Department of Cardiology, Henry Ford Health System, Detroit,
Mich, United States
(Morrow) Health Systems, Management & Policy, Colorado School of Public
Health, Aurora, Colo
(Sidebotham) Department of Cardiothoracic Anaesthesia and Cardiothoracic
Intensive Care, Auckland City Hospital, Auckland, New Zealand
Publisher
Elsevier Inc.
Abstract
Objective: Intervention for repair of secondary mitral valve disease is
frequently associated with recurrent regurgitation. We sought to determine
if there was sufficient evidence to support inclusion of anatomic indices
of leaflet dysfunction in the management of secondary mitral valve
disease. Method(s): We performed a systematic review and
meta-analysis of published reports comparing anatomic indices of leaflet
dysfunction with the complexity of valve repair and the outcome from
intervention. Patients were stratified by the severity of leaflet
dysfunction. A secondary analysis was performed comparing outcomes when
procedural complexity was optimally matched to severity of leaflet
dysfunction and when intervention was not matched to dysfunction.
 Result(s): We identified 6864 publications, of which 65 met inclusion
criteria. An association between the severity of leaflet dysfunction and
the procedural complexity was highly predictive of satisfactory freedom
from recurrent regurgitation. Patients were categorized into 4 groups
based on stratification of leaflet dysfunction. Satisfactory results were
achieved in 93.7% of patients in whom repair complexity was appropriately
matched to severity of leaflet dysfunction and in 68.8% in whom repair was
not matched to dysfunction (odds ratio, 0.148; 95% confidence interval,
0.119-0.184; P <.0001). Conclusion(s): For patients with secondary
mitral valve disease, satisfactory outcome from valve repair improves when
procedural complexity is matched to anatomic indices of leaflet
dysfunction. Anatomic indices of leaflet dysfunction should be considered
when planning interventions for secondary mitral regurgitation. Routine
inclusion of anatomic indices in trial design and reporting should
facilitate comparison of results and strengthen guidelines. There are
sufficient data to support anatomic staging of secondary mitral valve
disease. Copyright © 2023 The American Association for Thoracic
Surgery

<29>
Accession Number
640844949
Title
Exeporfinium chloride (XF-73) nasal gel dosed over 24 hours prior to
surgery significantly reduced Staphylococcus aureus nasal carriage in
cardiac surgery patients: Safety and efficacy results from a randomized
placebo-controlled phase 2 study.
Source
Infection control and hospital epidemiology. (pp 1-3), 2023. Date of
Publication: 23 Mar 2023.
Author
Mangino J.E.; Firstenberg M.S.; Milewski R.K.C.; Rhys-Williams W.; Lees
J.P.; Dane A.; Love W.G.; Gonzalez Moreno J.
Institution
(Mangino) Division of Infection Diseases, Department of Internal Medicine,
Ohio State University, Columbus, OH, United States
(Firstenberg) COUnited States
(Milewski) Department of Surgery, Yale School of Medicine, New Haven, CT,
United States
(Rhys-Williams, Lees, Love, Gonzalez Moreno) BrightonUnited Kingdom
(Dane) Danestat Consulting Ltd, Macclesfield, United Kingdom
Publisher
NLM (Medline)
Abstract
We studied 83 cardiac-surgery patients with nasal S. aureus carriage who
received 4 intranasal administrations of XF-73 nasal gel or placebo <24
hours before surgery. One hour before surgery, patients exhibited a S.
aureus nasal carriage reduction of 2.5 log10 with XF-73 compared to 0.4
log10 CFU/mL for those who received placebo (95% CI, -2.7 to -1.5; P <
.0001).

<30>
Accession Number
640842280
Title
Effect of different priming fluids on extravascular lung water, cell
integrity and oxidative stress in cardiopulmonary bypass surgery.
Source
Cardiovascular journal of Africa. 34 (pp 1-5), 2023. Date of Publication:
06 Mar 2023.
Author
Ulugol H.; Can M.G.; Aksu U.; Vardar K.; Okten M.; Toraman F.
Institution
(Ulugol) Department of Anesthesiology and Reanimation, Acibadem Mehmet Ali
Aydinlar University, Altunizade Hospital, Istanbul, Turkey
(Can, Toraman) Department of Anesthesiology and Reanimation, Acibadem
Mehmet Ali Aydinlar University, Altunizade Hospital, Istanbul, Turkey
(Aksu, Vardar) Department of Biology, Faculty of Science, University of
Istanbul, Istanbul, Turkey
(Okten) Department of Cardiovascular Surgery, Acibadem Mehmet Ali Aydinlar
University, Altunizade Hospital, Istanbul, Turkey
Publisher
NLM (Medline)
Abstract
BACKGROUND: Discussions continue on the ideal priming fluid in adult
cardiac surgery. The purpose of this prospective study was to evaluate the
effects of different types of priming fluids on extravascular lung water,
cell integrity and oxidative stress status. METHOD(S): Thirty
elective coronary artery bypass surgery patients were randomised
prospectively into two groups. The first group received colloid priming
fluid, while the second group received crystalloid priming fluid.
Extravascular lung water index, advanced oxidative protein products, total
thiol, free haemoglobin, ischaemic modified albumin and sialic acid levels
were measured. Moreover, intra-operative and postoperative outcomes were
reviewed. RESULT(S): There were no significant differences between
the groups with regard to extravascular lung water index, oxidative stress
parameters or cell integrity (p > 0.05). Similarly, no significant
differences were observed between the patients with regard to
intra-operative and postoperative outcomes (p > 0.05). CONCLUSION(S):
The presumed superiority of colloidal priming for cardiopulmonary bypass
could not be confirmed in our study.

<31>
Accession Number
362349596
Title
Impact of dronedarone on hospitalization burden in patients with atrial
fibrillation: Results from the ATHENA study.
Source
Europace. 13(8) (pp 1118-1126), 2011. Date of Publication: August 2011.
Author
Torp-Pedersen C.; Crijns H.J.G.M.; Gaudin C.; Page R.L.; Connolly S.J.;
Hohnloser S.H.
Institution
(Torp-Pedersen) Department of Cardiology, Gentofte Hospital, University of
Copenhagen, 2009 Hellerup, Denmark
(Crijns) Department of Cardiology, University Hospital Maastricht,
Maastricht, Netherlands
(Gaudin) Sanofi-aventis RandD, Frankfurt, Germany
(Page) Department of Medicine, University of Wisconsin, Madison, WI,
United States
(Connolly) Population Health Research Institute, McMaster University,
Hamilton, ON, Canada
(Hohnloser) Department of Cardiology, J. W. Goethe University, Frankfurt,
Germany
Publisher
Oxford University Press
Abstract
Aims: Cardiovascular (CV) hospitalization is a predictor of CV mortality
and has a negative impact on patients' quality of life. The primary
endpoint of A placebo-controlled, double-blind, parallel-arm Trial to
assess the efficacy of dronedarone 400 mg bid for the prevention of
cardiovascular Hospitalization or death from any cause in patiENTs with
Atrial fibrillation/atrial flutter (ATHENA), a composite of first CV
hospitalization or death from any cause, was significantly reduced by
dronedarone. This post hoc analysis evaluated the secondary endpoint of CV
hospitalization and the clinical benefit of dronedarone on the number and
duration of CV hospitalizations in patients with atrial fibrillation (AF).
 Methods and Results: ATHENA was a double-blind, parallel group study
in 4628 patients with a history of paroxysmal/persistent AF and additional
risk factors, treated with placebo or dronedarone. Dronedarone treatment
significantly reduced the risk of first CV hospitalization (P < 0.0001 vs.
placebo), while the risk of first non-CV hospitalization was similar in
both groups (P=0.77). About half of the CV hospitalizations were
AF-related, with a median duration of hospital stay of four nights. The
risk of any hospitalization for AF [hazard ratio (95 confidence interval)
0.626 (0.546-0.719)] and duration of hospital stay were significantly
reduced by dronedarone (P < 0.0001 vs. placebo). Dronedarone treatment
reduced total hospitalizations for acute coronary syndrome (P=0.0105) and
the time between the first AF/atrial flutter recurrence and CV
hospitalization/death (P=0.0048). Hospitalization burden was significantly
reduced across all levels of care (P < 0.05). Cumulative incidence data
indicated that the effects of dronedarone persisted for at least 24
months. Conclusion(s): Dronedarone reduced the risk for CV
hospitalization and the total hospitalization burden in this patient
group.The trial is registered under ClinicalTrials.#gov NCT 00174785.
© 2011 The Author.

<32>
[Use Link to view the full text]
Accession Number
2023069009
Title
Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases A
Mendelian Randomization Study.
Source
Clinical Journal of the American Society of Nephrology. 18(1) (pp 17-27),
2023. Date of Publication: 2023.
Author
Donovan K.; Herrington W.G.; Pare G.; Pigeyre M.; Haynes R.; Sardell R.;
Butterworth A.S.; Folkersen L.; Gustafsson S.; Wang Q.; Baigent C.;
Malarstig A.; Holmes M.V.; Staplin N.
Institution
(Donovan, Herrington, Haynes, Sardell, Baigent, Holmes, Staplin) Clinical
Trial Service Unit and Epidemiological Studies Unit, Nuffield Department
of Population Health (NDPH), University of Oxford, Oxford, United Kingdom
(Herrington, Haynes, Baigent, Holmes, Staplin) Medical Research Council
Population Health Research Unit at the University of Oxford, NDPH, Oxford,
United Kingdom
(Herrington, Haynes) Oxford Kidney Unit, Churchill Hospital, Oxford,
United Kingdom
(Pare, Pigeyre) Population Health Research Institute, McMaster University,
Hamilton, Canada
(Butterworth) BHF Cardiovascular Epidemiology Unit, Department of Public
Health and Primary Care, University of Cambridge, Cambridge, United
Kingdom
(Folkersen) Danish National Genome Center, Copenhagen, Denmark
(Gustafsson) Department of Medical Sciences, Molecular Epidemiology and
Science for Life Laboratory, Uppsala University, Uppsala, Sweden
(Wang) Systems Epidemiology, Baker Heart and Diabetes Institute,
Melbourne, VIC, Australia
(Malarstig) Department of Medical Epidemiology and Biostatistics,
Karolinska Institute, Solna, Sweden
(Holmes, Staplin) Big Data Institute, Li Ka Shing Centre for Health
Information and Discovery, University of Oxford, Oxford, United Kingdom
Publisher
American Society of Nephrology
Abstract
Background Fibroblast growth factor-23 (FGF-23) is associated with a range
of cardiovascular and noncardio-vascular diseases in conventional
epidemiological studies, but substantial residual confounding may exist.
Mendelian randomization approaches can help control for such confounding.
Methods SCALLOP Consortium data of 19,195 participants were used to
generate an FGF-23 genetic score. Data from 337,448 UK Biobank
participants were used to estimate associations between higher genetically
predicted FGF-23 concentration and the odds of any atherosclerotic
cardiovascular disease (n526,266 events), nonatherosclerotic
cardiovascular disease (n512,652), and noncardiovascular diseases
previously linked to FGF-23. Measurements of carotid intima-media
thickness and left ventricular mass were available in a subset.
Associations with cardiovascular outcomes were also tested in three large
case-control consortia: CARDIOGRAMplusC4D (coronary artery disease,
n5181,249 cases), MEGASTROKE (stroke, n534,217), and HERMES (heart
failure, n547,309). Results We identified 34 independent variants for
circulating FGF-23, which formed a validated genetic score. There were no
associations between genetically predicted FGF-23 and any of the
cardiovascular or non-cardiovascular outcomes. In UK Biobank, the odds
ratio (OR) for any atherosclerotic cardiovascular disease per 1-SD higher
genetically predicted logFGF-23 was 1.03 (95% confidence interval [95%
CI], 0.98 to 1.08), and for any nonatherosclerotic cardiovascular disease,
it was 1.01 (95% CI, 0.94 to 1.09). The ORs in the case-control consortia
were 1.00 (95% CI, 0.97 to 1.03) for coronary artery disease, 1.01 (95%
CI, 0.95 to 1.07) for stroke, and 1.00 (95% CI, 0.95 to 1.05) for heart
failure. In those with imaging, logFGF-23 was not associated with carotid
or cardiac abnormalities. Conclusions Genetically predicted FGF-23 levels
are not associated with atherosclerotic and nonatherosclerotic
cardiovascular diseases, suggesting no important causal
link. Copyright © 2022, American Society of Nephrology. All
rights reserved.

<33>
Accession Number
2022363755
Title
Low-Intensity vs. High-Intensity Antithrombotic Therapy After
Transcatheter Aortic Valve Replacement: Meta-Analysis of Randomized
Controlled Trials.
Source
Structural Heart. 7(2) (no pagination), 2023. Article Number: 100133. Date
of Publication: March 2023.
Author
Chakravarty T.; Leong D.; de la Rosa A.; Bhardwaj N.; Makkar R.R.
Institution
(Chakravarty, Leong, de la Rosa, Bhardwaj, Makkar) Smidt Heart Institute,
Cedars-Sinai Medical Center, Los Angeles, CA, United States
Publisher
Cardiovascular Research Foundation
Abstract
Background: The optimal antithrombotic therapy after transcatheter aortic
valve replacement (TAVR) is controversial. We performed a systematic
review and meta-analysis of randomized controlled trials comparing
high-intensity vs. low-intensity antithrombotic therapy after TAVR in the
absence of an established indication for anticoagulation. Method(s):
The primary efficacy and safety endpoints were a composite of death or
thromboembolic events and Valve Academic Research Consortium 2-defined
significant bleeding, respectively. All analyses were by intention to
treat. Risk ratios (RRs) were calculated using the inverse variance
random-effects model. Result(s): Four studies comprising 3358
patients (mean age 81 years, mean Society of Thoracic Surgery score 3.3%)
were identified. Two studies compared anticoagulation vs. antiplatelet
therapy after TAVR; the other 2 trials compared dual-antiplatelet therapy
vs. mono-antiplatelet therapy after TAVR. The incidence of death or
thromboembolic events (RR 0.66 [95% confidence interval (CI) 0.55-0.80], p
< 0.0001, I2 = 0%), death (RR 0.68 [95% CI 0.51-0.92],
I2 = 11%, p = 0.01), and Valve Academic Research Consortium
2-defined major bleeding (RR 0.69 [95% CI 0.48 - 1.00], p = 0.003,
I2 = 44%) was significantly lower in patients on low-intensity
antithrombotic therapy than in those on high-intensity antithrombotic
therapy. Conclusion(s): In an elderly patient population undergoing
TAVR, routine initiation of a high-intensity antithrombotic therapy in the
absence of a clinical indication for anticoagulation was associated with
increased risk of death or thromboembolic complications, increased risk of
death, and increased risk of significant bleeding. Routine initiation of
an anticoagulation therapy or dual-antiplatelet therapy after TAVR in the
absence of an established indication for anticoagulation may not be
advisable. Copyright © 2022

<34>
Accession Number
2013942013
Title
Comparative Safety and Effectiveness of Loading Doses of P2Y12 Inhibitors
in Patients Undergoing Elective PCI: a Network Meta-analysis.
Source
Cardiovascular Drugs and Therapy. 37(2) (pp 291-298), 2023. Date of
Publication: April 2023.
Author
Gupta R.; Malik A.H.; Briasoulis A.; Joshi A.M.; Guthier D.G.; Popli T.;
Aronow W.S.; Vyas A.V.; Patel N.C.; Ahmad H.; Kluck B.
Institution
(Gupta, Joshi, Vyas, Patel, Kluck) Lehigh Valley Heart Institute, Lehigh
Valley Health Network, Allentown, PA, United States
(Malik, Aronow, Ahmad) Department of Cardiology, Westchester Medical
Center and New York Medical College, Valhalla, NY, United States
(Briasoulis) Division of Cardiovascular Medicine, University of Iowa
Carver College of Medicine, Iowa City, IA, United States
(Guthier) Department of Internal Medicine, Lehigh Valley Health Network,
Allentown, PA, United States
(Popli) Department of Internal Medicine, Westchester Medical Center and
New York Medical College, Valhalla, NY, United States
Publisher
Springer
Abstract
Purpose: Effective platelet inhibition prior to elective percutaneous
coronary intervention (PCI) reduces the risk of ischemic complications.
Newer P2Y12 inhibitors are preferred agents over clopidogrel for patients
presenting with the acute coronary syndrome. However, the comparative
efficacy and safety of them over clopidogrel in elective PCI is unclear.
We performed a network meta-analysis to compare the safety and efficacy of
loading strategies of P2Y12 inhibitors in patients undergoing elective
PCI. Method(s): We conducted a systematic review of randomized
controlled trials (RCT) up to June 2021 to compare the safety and
effectiveness of different loading strategies of P2Y12 inhibitors before
elective PCI. The endpoints of interest were overall mortality, rates of
myocardial infarction (MI), stroke, revascularization, and major bleeding.
Random effects model using the frequentist approach was used to perform a
network meta-analysis using R software. Result(s): Five trials with a
total of 5194 patients were included in our analysis. For ischemic
outcomes, including MI, stroke, and revascularization, prasugrel had the
most favorable trend. However, clopidogrel had the highest probability of
being most effective for major bleeding and all-cause mortality. None of
these trends was statistically significant due to lack of power for each
outcome. Conclusion(s): Although prasugrel and ticagrelor are known
as more potent antiplatelet agents, their effects in preventing MI and
stroke are marginal and do not translate into improved overall mortality
and bleeding compared with clopidogrel. Copyright © 2021,
Springer Science+Business Media, LLC, part of Springer Nature.

<35>
Accession Number
640831320
Title
Impairment of the antiplatelet effect of acetylsalicylic acid in patients
early after cardiac surgery: Comparative impact of metamizole versus
paracetamol.
Source
Naunyn-Schmiedeberg's Archives of Pharmacology. Conference: 8th German
Pharm-Tox Summit 2023. Ulm Germany. 396(Supplement 1) (pp S42), 2023. Date
of Publication: 2023.
Author
Trenk D.; Hainke B.; Lehane C.; Niebergall-Joos E.; Leggewie S.; Twarock
S.; Hohlfeld T.; Schror K.; Siepe M.; Keyl C.
Institution
(Trenk, Leggewie) Universitatsklinikum Freiburg, Klinik fur Kardiologie
und Angiologie Bad Krozingen - Klinische Pharmakologie, Bad Krozingen,
Germany
(Hainke, Lehane, Niebergall-Joos, Keyl) Universitatsklinikum Freiburg,
Klinik fur Anasthesiologie und Intensivmedizin, Bad Krozingen, Germany
(Twarock, Hohlfeld, Schror) Heinrich-Heine-Universitat, Institut fur
Pharmakologie und Klinische Pharmakologie, Dusseldorf, Germany
(Siepe) Universitatsklinikum Freiburg, Klinik fur Herz- und
Gefaschirurgie, Bad Krozingen, Germany
Publisher
Springer Science and Business Media B.V.
Abstract
Background: Low-dose acetylsalicylic acid (ASA) is recommended in current
guidelines for a period of 3 months after surgical replacement of the
aortic valve by a bioprosthesis as well as after surgical reconstruction
of the mitral valve. Metamizole (dipyrone) and paracetamol (acetaminophen)
are frequently used non-opioid analgesics after surgery. The active
metabolite of metamizole (4-methylaminoantipyrine) is a reversible
inhibitor of cyclooxygenase-1 and an interaction with the antiplatelet
effect of ASA in more than 50 % of patients has been reported. Prospective
randomized studies investigating the potential drug-drug interaction
between ASA and high-dose metamizole in cardiac surgical patients are
lacking so far. Material(s) and Method(s): We enrolled 162 patients
in this prospective clinical study. Patients after surgical implantation
of a bioprosthetic valve in aortic position or after mitral valve repair
were eligible for enrollment. Patients were randomized at day 1 after
surgery to either 4 x 1 g metamizole iv/day or 4 x 1 g paracetamol iv/day.
All patients were on ASA 100 mg oid. The primary endpoint was the
proportion of patients with adequate antiplatelet response to ASA assessed
via determination of thromboxane B2 in platelet rich plasma after
stimulation with arachidonic acid (AA) at day 4/5 after surgery (cutpoint
<=209.8 ng/ml thromboxane B2). Key secondary endpoints comprised platelet
reactivity assessed by light transmission aggregometry [LTA] and by
multiple electrode impedance aggregometry [MEIA]. Result(s): 15
patients dropped out of the study. Thus, data from 71 patients randomized
to metamizole and 76 patients randomized to paracetamol were available for
data analysis. The primary endpoint analyzed at day 4/5 after surgery is
shown in the Figure. The proportion of non-responders in patients treated
with metamizole was lower than expected (12.5%) which is 4-fold higher
compared with patients on paracetamol. The difference between the
treatment groups was, however, of borderline statistical significance
only. Platelet reactivity at day 4/5 after surgery assessed by LTA or MEIA
was not statistically different between both treatment regimens. Summary
and conclusion: The proportion of non-responders to ASA is higher in
patients treated with metamizole compared to paracetamol. The proportion
of non-responders in the metamizole-treated group in our study is
substantially lower than reported in previous studies.

<36>
Accession Number
2023126120
Title
Contribution of Turkey in Heart Transplant Research: A Web of Science
Database Search.
Source
Experimental and Clinical Transplantation. 21(2) (pp 150-157), 2023. Date
of Publication: February 2023.
Author
Sahin S.; Alkan S.
Institution
(Sahin) Department of Cardiovascular Surgery, Canakkale Onsekiz Mart
University, Faculty of Medicine, Canakkale, Turkey
(Alkan) Department of Infection Diseases, Canakkale Onsekiz Mart
University, Faculty of Medicine, Canakkale, Turkey
Publisher
Baskent University
Abstract
Objectives: In 2001, Turkey performed its the first successful heart
transplant. Since 2011, 765 heart transplants have been conducted among 15
heart transplant centers. The scientific impact of Turkish articles on
heart transplantation remains uncertain. The purpose of this study was to
evaluate Turkey's contributions in international heart transplant
research. Material(s) and Method(s): The bibliometric study approach
was used to assess publications on heart transplantation, which included
analysis of year of publication, organizations/authors, sponsorship,
keywords, citations, and other characteristics. Titles, abstracts, and key
words were searched in the Web of Science database for terms that included
"heart" or "cardiac" and "transplantation." Methods for both quantitative
and qualitative data analysis were used. Result(s): During the
analysis period of 1970 through 2021, 6370 article publications were
retrieved with an average of 20.88 citations/article and 133 018 total
citations. H index was 129. Most of the retrieved articles were from
research areas of surgery (n = 2876; 45.14%), followed by transplantation
(n = 2818; 44.23%) and cardiovascular system cardiology (n = 2522;
39.59%). Annual citation growth showed slow growth until 1986. The highest
number of citations was seen in 2021 (n = 702). The United States led
countries on articles (n = 2924; 45.9%), followed by Germany (n = 458;
7.19%), England (n = 411; 6.45%), Canada (n = 384; 6.02%), France (n =
330; 5.18%), and Spain (n = 329; 5.16%). The other 84 countries totaled
753 (11.82%) articles. Turkey ranked eighteenth with 87 publications, with
Baskent University (n = 37) and Ege University (n = 13) being the leading
centers on heart transplant research in Turkey. Conclusion(s):
Publications from the United States continue to increase. The workload of
both transplant surgery and research and publishing is challenging and
Turkish researchers are encouraged to make strides at
innovations. Copyright © Baskent University 2023 Printed in
Turkey. All Rights Reserved.

<37>
Accession Number
640792941
Title
Systemic opioids versus other analgesics and sedatives for postoperative
pain in neonates.
Source
Cochrane Database of Systematic Reviews. 2023(3) (no pagination), 2023.
Article Number: CD014876. Date of Publication: 03 Mar 2023.
Author
Kinoshita M.; Stempel K.S.; Borges do Nascimento I.J.; Bruschettini M.
Institution
(Kinoshita) Department of Pediatrics, Clinical Sciences Lund, Lund
University, Lund, Sweden
(Kinoshita) Fetal Medicine Research Center, University of Barcelona,
Barcelona, Spain
(Stempel) Faculty of Medicine, Lund University, Lund, Sweden
(Borges do Nascimento) School of Medicine and University Hospital,
Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil
(Borges do Nascimento) Department of Medicine, Medical College of
Wisconsin, Milwaukee, WI, United States
(Bruschettini) Department of Clinical Sciences Lund, Paediatrics, Lund
University, Skane University Hospital, Lund, Sweden
(Bruschettini) Cochrane Sweden, Lund University, Skane University
Hospital, Lund, Sweden
Publisher
John Wiley and Sons Ltd
Abstract
Background: Neonates may undergo surgery because of malformations such as
diaphragmatic hernia, gastroschisis, congenital heart disease, and
hypertrophic pyloric stenosis, or complications of prematurity, such as
necrotizing enterocolitis, spontaneous intestinal perforation, and
retinopathy of prematurity that require surgical treatment. Options for
treatment of postoperative pain include opioids, non-pharmacological
interventions, and other drugs. Morphine, fentanyl, and remifentanil are
the opioids most often used in neonates. However, negative impact of
opioids on the structure and function of the developing brain has been
reported. The assessment of the effects of opioids is of utmost
importance, especially for neonates in substantial pain during the
postoperative period. Objective(s): To evaluate the benefits and
harms of systemic opioid analgesics in neonates who underwent surgery on
all-cause mortality, pain, and significant neurodevelopmental disability
compared to no intervention, placebo, non-pharmacological interventions,
different types of opioids, or other drugs. Search Method(s): We
searched Cochrane CENTRAL, MEDLINE via PubMed and CINAHL in May 2021. We
searched the WHO ICTRP, clinicaltrials.gov, and ICTRP trial registries. We
searched conference proceedings, and the reference lists of retrieved
articles for RCTs and quasi-RCTs. Selection Criteria: We included
randomized controlled trials (RCTs) conducted in preterm and term infants
of a postmenstrual age up to 46 weeks and 0 days with postoperative pain
where systemic opioids were compared to 1) placebo or no intervention; 2)
non-pharmacological interventions; 3) different types of opioids; or 4)
other drugs. Data Collection and Analysis: We used standard Cochrane
methods. Our primary outcomes were pain assessed with validated methods,
all-cause mortality during initial hospitalization, major
neurodevelopmental disability, and cognitive and educational outcomes in
children more than five years old. We used the fixed-effect model with
risk ratio (RR) and risk difference (RD) for dichotomous data and mean
difference (MD) for continuous data. We used GRADE to assess the certainty
of evidence for each outcome. Main Result(s): We included four RCTs
enrolling 331 infants in four countries across different continents. Most
studies considered patients undergoing large or medium surgical procedures
(including major thoracic or abdominal surgery), who potentially required
pain control through opioid administration after surgery. The randomized
trials did not consider patients undergoing minor surgery (including
inguinal hernia repair) and those individuals exposed to opioids before
the beginning of the trial. Two RCTs compared opioids with placebo; one
fentanyl with tramadol; and one morphine with paracetamol. No
meta-analyses could be performed because the included RCTs reported no
more than three outcomes within the prespecified comparisons. Certainty of
the evidence was very low for all outcomes due to imprecision of the
estimates (downgrade by two levels) and study limitations (downgrade by
one level). Comparison 1: opioids versus no treatment or placebo. Two
trials were included in this comparison, comparing either tramadol or
tapentadol with placebo. No data were reported on the following critical
outcomes: pain; major neurodevelopmental disability; or cognitive and
educational outcomes in children more than five years old. The evidence is
very uncertain about the effect of tramadol compared with placebo on
all-cause mortality during initial hospitalization (RR 0.32, 95%
Confidence Interval (CI) 0.01 to 7.70; RD -0.03, 95% CI -0.10 to 0.05, 71
participants, 1 study; I2 = not applicable). No data were reported on:
retinopathy of prematurity; or intraventricular hemorrhage. Comparison 2:
opioids versus non-pharmacological interventions. No trials were included
in this comparison. Comparison 3: head-to-head comparisons of different
opioids. One trial comparing fentanyl with tramadol was included in this
comparison. No data were reported on the following critical outcomes:
pain; major neurodevelopmental disability; or cognitive and educational
outcomes in children more than five years old. The evidence is very
uncertain about the effect of fentanyl compared with tramadol on all-cause
mortality during initial hospitalization (RR 0.99, 95% CI 0.59 to 1.64; RD
0.00, 95% CI -0.13 to 0.13, 171 participants, 1 study; I2 = not
applicable). No data were reported on: retinopathy of prematurity; or
intraventricular hemorrhage. Comparison 4: opioids versus other analgesics
and sedatives. One trial comparing morphine with paracetamol was included
in this comparison. The evidence is very uncertain about the effect of
morphine compared with paracetamol on COMFORT pain scores (MD 0.10, 95% CI
-0.85 to 1.05; 71 participants, 1 study; I2 = not applicable). No data
were reported on the other critical outcomes, i.e. major
neurodevelopmental disability; cognitive and educational outcomes in
children more than five years old, all-cause mortality during initial
hospitalization; retinopathy of prematurity; or intraventricular
hemorrhage. Authors' conclusions: Limited evidence is available on opioid
administration for postoperative pain in newborn infants compared to
either placebo, other opioids, or paracetamol. We are uncertain whether
tramadol reduces mortality compared to placebo; none of the studies
reported pain scores, major neurodevelopmental disability, cognitive and
educational outcomes in children older than five years old, retinopathy of
prematurity, or intraventricular hemorrhage. We are uncertain whether
fentanyl reduces mortality compared to tramadol; none of the studies
reported pain scores, major neurodevelopmental disability, cognitive and
educational outcomes in children older than five years old, retinopathy of
prematurity, or intraventricular hemorrhage. We are uncertain whether
morphine reduces pain compared to paracetamol; none of the studies
reported major neurodevelopmental disability, cognitive and educational
outcomes in children more than five years old, all-cause mortality during
initial hospitalization, retinopathy of prematurity, or intraventricular
hemorrhage. We identified no studies comparing opioids versus
non-pharmacological interventions. Copyright © 2023 The Cochrane
Collaboration. Published by John Wiley & Sons, Ltd.

<38>
Accession Number
2023147820
Title
The analgesic effect of erector spinae plane block in thoracic surgery: a
systematic review and meta-analysis of randomized controlled trials.
Source
Signa Vitae. 19(2) (pp 161-170), 2023. Date of Publication: March 2023.
Author
Li Y.; Hou Y.-L.; Guan H.-Y.; Luo H.-X.
Institution
(Li, Hou, Guan, Luo) Department of Anesthesiology, Yongchuan affiliated
Hospital of Chongqing Medical University, Yongchuan, Chongqing 402160,
China
Publisher
Pharmamed Mado Ltd
Abstract
The erector spinae plane block (ESPB) is a new analgesic technology that
came out for the first time in 2016. Some studies have shown that it can
provide effective analgesia in thoracic surgery. This systematic review
and meta-analysis is to evaluate the analgesic effect of ESPB in patients
undergoing thoracic surgery. Embase, PubMed, The Cochrane Library, VIP
database, CNKI, Wanfang database, CBM, were systematically searched, from
2010 to December, 2020. Randomised controlled trials (RCTs) were included
to assess the analgesic effect of the ESPB in thoracic surgery. Eighteen
studies with a total of 1303 patients were included. ESPB group reduced
postoperative 48-hour pain scores at rest or movement at different time
points compared with the control group. ESPB group also showed lower
incidence of postoperative nausea and vomiting (PONV) (odds ratio, OR =
0.48, 95% CI = 0.33 0.71, P < 0.05). ESPB group were better at the number
of patient-controlled intravenous analgesia (PCIA) pressing times (mean
difference, MD = -6.83, 95% CI = -8.73 -4.94, P < 0.05). This review has
shown that compared with simple general anesthesia (GA), GA combined with
ESPB significantly decreases postoperative pain, PONV and opioids
requirements following thoracic surgery. Copyright © 2023 The
Author(s).

<39>
Accession Number
2023126547
Title
Effects of Remote Ischemic Preconditioning on Decreasing Troponin Release
in Patients Not Taking Sulfonylureas After Cardiac Surgery - A
Meta-Analysis.
Source
Brazilian Journal of Cardiovascular Surgery. 38(2) (pp 289-299), 2023.
Date of Publication: 2023.
Author
Wang X.; Xiao S.; Hu Y.; Guo M.; Liu A.; Huan C.; Xu T.; Yin J.; Pan D.;
Zhu H.
Institution
(Wang, Xiao, Hu, Guo, Liu, Huan, Xu, Pan, Zhu) Department of Cardiology,
The Affiliated Hospital of Xuzhou Medical University, Jiangsu, Xuzhou,
China
(Yin) Department of General Practice, The Affiliated Hospital of Xuzhou
Medical University, Jiangsu, Xuzhou, China
Publisher
Sociedade Brasileira de Cirurgia Cardiovascular
Abstract
Introduction: Remote ischemic preconditioning (RIPC) is a new noninvasive
myocardial protection strategy that uses blood pressure cuff inflation to
simulate transient non-fatal ischemia to protect the myocardium and reduce
ischemia-reper-fusion injury. Sulfonylureas may mask the effects of RIPC
due to their cardioprotec-tive effect. This meta-analysis aimed to
evaluate whether RIPC, in the absence of sulfonylureas, reduces troponin
release in patients undergoing cardiac surgery. Method(s): We
conducted a meta-analysis of randomized controlled clinical trials to
determine whether RIPC can reduce postoperative troponin release in
cardiac surgery patients undergoing cardiopulmonary bypass without
treatment with sulfonylureas. The data were normalized to equivalent units
prior to the analysis. A random-effects model was used to provide more
conservative estimate of the effects in the presence of known or unknown
heterogeneity. Result(s): Six studies with a total of 570
participants were included. The analysis showed that troponin release was
lower in the RIPC group than in the control group at six hours (test of
standardized mean differences = 0, Z=3.64, P<0.001) and 48 hours (Z=2.72,
P=0.007) postoperatively. When the mean of cross-clamping time was > 60
minutes, RIPC reduced troponin release at six hours (Z=2.84, P=0.005), 24
hours (Z=2.64, P=0.008), and 48 hours (Z=2.87, P=0.004) postoperatively.
 Conclusion(s): In cardiac surgery patients who are not taking
sulfonylureas, RIPC can reduce troponin release at six and 48 hours
postoperatively; hence, RIPC may serve significant benefits in certain
cardiac surgery patients. Copyright © 2023, Sociedade Brasileira
de Cirurgia Cardiovascular. All rights reserved.

<40>
Accession Number
2023126533
Title
DEX, Delirium and Dilemma.
Source
Brazilian Journal of Cardiovascular Surgery. 38(2) (pp 305-308), 2023.
Date of Publication: 2023.
Author
Magoon R.; Mahajan S.; Jose J.
Institution
(Magoon) Department of Cardiac Anaesthesia, Atal Bihari Vajpayee Institute
of Medical Sciences (ABVIMS) and Dr. Ram Manohar Lohia Hospital, New
Delhi, India
(Mahajan) Department of Anaesthesia and Intensive Care, Post Graduate
Institute of Medical Education & Research (PGIMER), Chandigarh, India
(Jose) Department of Cardiac Anesthesiology, Sri Jayadeva Institute of
Cardiovascular Sciences and Research, Jayanagar, Karnataka, Bengaluru,
India
Publisher
Sociedade Brasileira de Cirurgia Cardiovascular
Abstract
Dexmedetomidine has been subjected to an extensive evaluation for its'
role in the prevention of postoperative delirium following cardiac
surgery. In striking contrast to the preexisting meta-analysis supporting
postoperative delirium-reduction with dexmedetomidine, few recently
concluded multicentric large scale randomized controlled trials suggest
otherwise. This article aims to present a nuanced perspective of the
evolving controversy by attempting to decode the apparent incongruences in
the literature accumulating off-late, which is particularly pertinent
amidst an ever-escalating heterogeneity in the current research
ecosystem. Copyright © 2023, Sociedade Brasileira de Cirurgia
Cardiovascular. All rights reserved.

<41>
Accession Number
2022218987
Title
Polymeric prosthetic heart valves: A review of current technologies and
future directions.
Source
Frontiers in Cardiovascular Medicine. 10 (no pagination), 2023. Article
Number: 1137827. Date of Publication: 2023.
Author
Singh S.K.; Kachel M.; Castillero E.; Xue Y.; Kalfa D.; Ferrari G.; George
I.
Institution
(Singh, Castillero, Xue, Kalfa, Ferrari, George) Division of
Cardiothoracic Surgery, New York Presbyterian Hospital, College of
Physicians and Surgeons of Columbia University, New York, NY, United
States
(Kachel) Cardiovascular Research Foundation, New York, NY, United States
(Kachel) American Heart of Poland, Center for Cardiovascular Research and
Development, Katowice, Poland
Publisher
Frontiers Media S.A.
Abstract
Valvular heart disease is an important source of cardiovascular morbidity
and mortality. Current prosthetic valve replacement options, such as
bioprosthetic and mechanical heart valves are limited by structural valve
degeneration requiring reoperation or the need for lifelong
anticoagulation. Several new polymer technologies have been developed in
recent years in the hope of creating an ideal polymeric heart valve
substitute that overcomes these limitations. These compounds and valve
devices are in various stages of research and development and have unique
strengths and limitations inherent to their properties. This review
summarizes the current literature available for the latest polymer heart
valve technologies and compares important characteristics necessary for a
successful valve replacement therapy, including hydrodynamic performance,
thrombogenicity, hemocompatibility, long-term durability, calcification,
and transcatheter application. The latter portion of this review
summarizes the currently available clinical outcomes data regarding
polymeric heart valves and discusses future directions of
research. Copyright © 2023 Singh, Kachel, Castillero, Xue, Kalfa,
Ferrari and George.

<42>
Accession Number
2022115315
Title
Comment on: "exercise training and cardiac autonomic function following
coronary artery bypass grafting: a systematic review and meta-analysis".
Source
Egyptian Heart Journal. 75(1) (no pagination), 2023. Article Number: 19.
Date of Publication: December 2023.
Author
Gois C.O.; Conceicao L.S.R.; de Andrade Guimaraes A.L.; Carvalho V.O.
Institution
(Gois, de Andrade Guimaraes, Carvalho) Postgraduate Program in Health
Science, Department of Physical Therapy, Federal University of Sergipe
(Universidade Federal de Sergipe - UFS), Av. Marechal Rondon, s/n -Jardim
Rosa Elze, Sergipe, Sao Cristovao 49100-000, Brazil
(Gois, Conceicao, de Andrade Guimaraes, Carvalho) The GrEAt Group (Grupo
de Estudos Em Atividade Fisicasica), Av. Marechal Rondon, s/n -Jardim Rosa
Elze, Sergipe, Sao Cristovao 49100-000, Brazil
Publisher
Springer Science and Business Media Deutschland GmbH
Abstract
Background: Low cardiorespiratory fitness is associated with poor
prognosis in individuals with coronary artery disease and after coronary
artery bypass grafting surgery. Thus, we comment about a meta-analysis
that adds important information about the effect of exercise training on
cardiac autonomic function in individuals following coronary artery bypass
grafting surgery. Main body: The study by Kushwaha et al. showed positive
effects for heart rate variability and heart rate recovery in subjects
after coronary artery bypass grafting surgery in response to acute
physical training. These data are relevant, since heart rate variability
is an independent predictor of for all-cause and cardiovascular mortality
for individuals with cardiovascular disorders. Additionally, attenuated
heart rate recovery is associated with increased risk for the same
outcomes. Moreover, we summarize the quantitative data from studies that
compared the effect of physical training in comparison with control group
in cardiorespiratory fitness in adults following coronary artery bypass
grafting. Conclusion(s): Our findings suggest that improvements in
peak oxygen consumption result in an additional benefit in adults
following coronary artery bypass grafting. Considered that, the increased
cardiorespiratory fitness is an independent predictor of longer survival
in coronary artery disease. Copyright © 2023, The Author(s).

<43>
Accession Number
2022110883
Title
The protocol for the prehabilitation for thoracic surgery study: a
randomized pragmatic trial comparing a short home-based multimodal program
to aerobic training in patients undergoing video-assisted thoracoscopic
surgery lobectomy.
Source
Trials. 24(1) (no pagination), 2023. Article Number: 194. Date of
Publication: December 2023.
Author
Liu Y.; Liu Z.; Zhang Y.; Cui Y.; Pei L.; Huang Y.
Institution
(Liu, Liu, Pei, Huang) Department of Anesthesiology, Chinese Academy of
Medical Sciences & Peking Union Medical College Hospital, Beijing 100730,
China
(Zhang) Department of Medical Research Center, Chinese Academy of Medical
Sciences & Peking Union Medical College Hospital, Beijing 100730, China
(Cui) Department of Thoracic Surgery, Chinese Academy of Medical Sciences
& Peking Union Medical College Hospital, Beijing 100730, China
Publisher
BioMed Central Ltd
Abstract
Background: Prehabilitation has been shown to have a positive effect on
the postoperative recovery of functional capacity in patients undergoing
video-assisted thoracoscopic surgery (VATS) lobectomy. The optimal way to
implement prehabilitation programs, such as the optimal forms of
prehabilitation, duration, intensity, and methods to improve compliance,
remained to be studied. This Prehabilitation for Thoracic Surgery Study
will compare the effectiveness of multimodal and aerobic training-only
programs in patients undergoing thoracoscopic lobectomy. Method(s):
This randomized pragmatic trial will be conducted in Peking Union Medical
College Hospital (PUMCH) and include 100 patients who are eligible to
undergo VATS lobectomy. Patients will be randomized to a multimodal or
aerobic training group. Prehabilitation training guidance will be provided
by a multidisciplinary care team. The patients in the multimodal group
will perform aerobic exercises, resistance exercises, breathing exercises,
psychological improvement strategies, and nutritional supplementation.
Meanwhile, the patients in the aerobic group will conduct only aerobic
exercises. The interventions will be home-based and supervised by medical
providers. The patients will be followed up until 30 days after surgery to
investigate whether the multimodal prehabilitation program differs from
the aerobic training program in terms of the magnitude of improvement in
functional capability pre- to postoperatively. The primary outcome will be
the perioperative 6-min walk distance (6MWD). The secondary outcomes will
include the postoperative pulmonary functional recovery status,
health-related quality of life score, incidence of postoperative
complications, and clinical outcomes. Discussion(s): Prehabilitation
remains a relatively new approach that is not widely performed by thoracic
surgery patients. The existing studies mainly focus on unimodal
interventions. While multimodal prehabilitation strategies have been shown
to be preferable to unimodal strategies in a few studies, the evidence
remains scarce for thoracic surgery patients. The results of this study
will contribute to the understanding of methods for thoracoscopic
lobectomy patients. Trial registration: ClinicalTrials.gov NCT04049942.
Registered on August 8, 2019. Copyright © 2023, The Author(s).

<44>
Accession Number
2022110824
Title
Individualized flow-controlled versus conventional pressure-controlled
ventilation in on-pump heart surgery (FLOWVENTIN HEARTSURG): study
protocol for a randomized controlled trial.
Source
Trials. 24(1) (no pagination), 2023. Article Number: 195. Date of
Publication: December 2023.
Author
Becker S.; Schnitzler R.; Rembecki M.; Geppert J.; Kurz C.T.; Wichelhaus
L.-M.; Timmesfeld N.; Zahn P.K.
Institution
(Becker, Schnitzler, Rembecki, Geppert, Kurz, Wichelhaus, Zahn) Department
of Anesthesiology, Intensive Care and Pain Medicine, BG University
Hospital Bergmannsheil, Ruhr-University Bochum, Buerkle de La Camp-Platz
1, Bochum 44789, Germany
(Timmesfeld) Department of Medical Informatics, Biometry & Epidemiology,
Ruhr-University Bochum, Bochum 44780, Germany
Publisher
BioMed Central Ltd
Abstract
Background: In on-pump cardiac surgery, lungs are at high risk of
periprocedural organ impairment because of atelectasis formation,
ventilator-induced lung injury, and hyperinflammation due to the
cardiopulmonary bypass which results in postoperative pulmonary
complications in half of this patient population. The new ventilation mode
flow-controlled ventilation (FCV) uniquely allows full control of ins- and
expiratory airway flows. This approach reduces the mechanical power of
invasive ventilation as a possible cause of ventilator-induced lung
injury. The scope of FLOWVENTIN HEARTSURG is to compare perioperative
individualized FCV with best clinical practice pressure-controlled
ventilation (PVC) modes in patients with elective on-pump cardiac surgery
procedures. We hypothesize that the postoperative inflammatory response
can be reduced by the perioperative application of FCV compared to PCV.
 Method(s): FLOWVENTIN HEARTSURG is a single-center, randomized,
parallel-group trial with two intervention arms: perioperative PCV modes
(n = 70, PCV group) with an individualized positive end-expiratory
pressure (PEEP) and a tidal volume of 6-8 ml/kg predicted bodyweight
compared to perioperative FCV (n = 70, FCV group) with an individualized
PEEP and driving pressure, resulting in a liberal tidal volume. As the
primary study endpoint interleukin 8 plasma level is assessed 6 h after
cardiopulmonary bypass as a surrogate biomarker of systemic and pulmonary
inflammation. As secondary aims clinically relevant patient outcomes are
analyzed, e.g., perioperative lung function regarding oxygenation indices,
postoperative pulmonary and extra-pulmonary complications, SIRS-free days
as well as ICU and total inpatient stays. As additional sub-studies with
an exploratory approach perioperative right ventricular function
parameters are assessed by echocardiography and perioperative lung
aeration by electrical impedance tomography. Discussion(s): Current
paradigms regarding protective low tidal volume ventilation are
consciously left in the FCV intervention group in order to reduce
mechanical power as a determinant of ventilator-induced lung injury in
this high-risk patient population and procedures. This approach will be
compared in a randomized controlled trial with current best clinical
practice PCV in FLOWVENTIN HEARTSURG. Trial registration: German Clinical
Trials Register DRKS00018956. Registered on 12 June 2020 (Version 1), last
update on 22 August 2022 (Version 4). Copyright © 2023, The
Author(s).

<45>
Accession Number
640836105
Title
Effect of intraoperative low vs. conventional tidal volume on the
incidence of postoperative acute kidney injury after noncardiac surgery: a
two-center randomized clinical trial.
Source
Minerva anestesiologica. (no pagination), 2023. Date of Publication: 21
Mar 2023.
Author
Jia X.-Y.; Wang X.-R.; Jiang Y.-Y.; An M.-Z.; Pei D.-Q.; Li Z.-P.; Zhou
Q.-H.
Institution
(Jia, Wang, An) Department of Anesthesia Medicine, Zhejiang Chinese
Medical University, Hangzhou, China
(Jia, Wang, Jiang, An, Li) Department of Anesthesiology and Pain Medicine,
Affiliated Hospital of Jiaxing University, Jiaxing, China
(Jiang) Department of Anesthesia Medicine, Bengbu Medical College, Bengbu,
China
(Pei) Department of Anesthesiology, Second Affiliated Hospital of Jiaxing
University, Jiaxing, China
(Zhou) Department of Anesthesiology and Pain Medicine, Affiliated Hospital
of Jiaxing University, Jiaxing, China
Publisher
NLM (Medline)
Abstract
BACKGROUND: In adults undergoing noncardiac surgery, the correlation
between intraoperative tidal volume and postoperative acute kidney injury
(AKI) is unclear. This study aimed to investigate the effects of low tidal
volume ventilation on the incidence of postoperative AKI compared with
conventional tidal volume in adults undergoing noncardiac surgery.
 METHOD(S): This was a two-center prospective randomized controlled
trial on adult patients who underwent noncardiac surgery and had a
mechanical ventilation of >60 min. Patients were randomized to receive
either a tidal volume of 6 mL/kg pre-predicted body weight (PBW, low tidal
volume) or a tidal volume of 10 mL/kg pre-predicted body weight
(conventional tidal volume). The primary outcome was the incidence of AKI
after non-cardiac surgery. Appropriate statistical methods were used for
this study. RESULT(S): Among the 1982 randomized patients, 943 with
low tidal volume and 958 with conventional tidal volume were evaluable for
the primary outcome. Postoperative AKI occurred in 12 patients (1.3%) in
the low tidal volume group and 11 patients (1.1%) in the conventional
tidal volume group, with an odds ratio of 0.889 (95%CI, 0.391-2.03) and a
relative risk of 0.999 ([95%CI, 0.989-1.01]; P=0.804). Postoperative serum
creatinine levels increased in 284 (30.0%) patients with low tidal volume
compared to 316 (32.0%) patients with conventional tidal volume (P=0.251).
No difference in postoperative serum creatinine levels was found between
the two groups (57.5 [49.0-68.2] mumol/L vs. 58.8[50.4-69.5] mumol/L,
P=0.056). CONCLUSION(S): Among adults undergoing noncardiac surgery,
low tidal volume mechanical ventilation did not significantly reduce the
incidence of postoperative AKI compared with conventional tidal volume.

<46>
Accession Number
640835578
Title
Atrial natriuretic peptide in the prevention of acute renal dysfunction
after heart transplantation - a randomized placebo-controlled double-blind
trial.
Source
Acta anaesthesiologica Scandinavica. (no pagination), 2023. Date of
Publication: 20 Mar 2023.
Author
Tholen M.; Kolsrud O.; Dellgren G.; Karason K.; Lannemyr L.; Ricksten
S.-E.
Institution
(Tholen, Lannemyr, Ricksten) Department of Anesthesiology and Intensive
Care Medicine, Institute of Clinical Sciences
(Kolsrud, Dellgren) Department of Cardiothoracic Surgery, Institute of
Medicine
(Dellgren, Karason) Transplant Institute
(Karason) Department of Cardiology, Institute of Medicine
Publisher
NLM (Medline)
Abstract
BACKGROUND: Acute kidney injury (AKI) and renal dysfunction after heart
transplantation are common and serious complications. Atrial natriuretic
peptide (ANP) has been shown to increase glomerular filtration rate (GFR)
and exert renoprotective effects when used for prevention/treatment of AKI
in cardiac surgery. We tested the hypothesis that intra- and postoperative
administration of ANP could prevent a postoperative decrease in renal
function early after heart transplantation. METHOD(S): Seventy
patients were randomized to receive either ANP (50 ng/kg/min) (n=33) or
placebo (n=37) starting after induction of anesthesia and continued for
4days after heart transplantation or until treatment with dialysis was
started. The primary end-point of the present study was measured GFR
(mGFR) at day 4, assessed by plasma clearance of a renal filtration
marker. Also, the incidence of postoperative AKI and dialysis were
assessed. RESULT(S): Median (IQR) mGFR at day 4 postoperatively was
60.0 (57.0) and 50.1 (36.3) ml/min/1.72 m2 for the placebo and ANP groups,
respectively (p=0.705). During ongoing ANP infusion, the need for dialysis
was 21.6% and 9.1% for the placebo and ANP groups, respectively (p=0.197).
The incidences of AKI for the placebo and the ANP groups were 76.5% and
63.6%, respectively (p=0.616). The incidences of AKI stage 1 were 32.4%
and 21.2% for the placebo and ANP groups, respectively (p=0.420) and for
AKI stage 2 or 3, 37.8% and 42.4%, respectively (p=0.808).
 CONCLUSION(S): The study failed to detect that ANP infusion
attenuates renal dysfunction or decreases the incidence of AKI after heart
transplantation. Copyright This article is protected by copyright. All
rights reserved.

<47>
Accession Number
640834138
Title
The Effects of Preoperative Pain Education on Pain Severity in Cardiac
Surgery Patients: A Pilot Randomized Control Trial.
Source
Pain management nursing : official journal of the American Society of Pain
Management Nurses. (no pagination), 2023. Date of Publication: 18 Mar
2023.
Author
Sinderovsky A.; Grosman-Rimon L.; Atrash M.; Nakhoul A.; Saadi H.; Rimon
J.; Birati E.Y.; Carasso S.; Kachel E.
Institution
(Sinderovsky) Ruth and Bruce Rappaport Faculty of Medicine,
Technion-Israel Institute of Technology, Haifa, Israel
(Grosman-Rimon) Division of Cardiovascular Medicine and Surgery, Tzafon
Medical Center, Tiberias, Israel; School of Graduate Studies, The Academic
Center Levinsky-Wingate, Wingate Institute, Netanya, Israel
(Atrash, Nakhoul, Saadi) Division of Cardiovascular Medicine and Surgery,
Tzafon Medical Center, Tiberias, Israel
(Rimon) Faculty of Health, York University, Toronto, Canada
(Birati) Division of Cardiovascular Medicine and Surgery, Tzafon Medical
Center, Tiberias, Israel; The Azrieli Faculty of Medicine, Bar-Ilan
University, Zefat, Israel
(Carasso) The Azrieli Faculty of Medicine, Bar-Ilan University, Zefat,
Israel; The Jesselson Integrated Heart Center, Shaare Zedek Medical
Center, Jerusalem
(Kachel) Division of Cardiovascular Medicine and Surgery, Tzafon Medical
Center, Tiberias, Israel; The Azrieli Faculty of Medicine, Bar-Ilan
University, Zefat, Israel; Department of Cardiac Surgery, Sheba Medical
Centre, Tel Hashomer, Israel
Publisher
NLM (Medline)
Abstract
BACKGROUND: There is minimal research on the effect of individualized
preoperative education on postoperative pain and postoperative pain
medication intake. AIM: The study objective was to assess the effect of
individually tailored preoperative education on postoperative pain
severity, number of pain breakthroughs, and use of pain medication in
participants receiving the intervention compared to controls.
 METHOD(S): A pilot study with 200 participants was conducted. The
experimental group received an informational booklet and discussed their
ideas surrounding pain and pain medication with the researcher. Controls
received no intervention. Postoperative pain severity was measured by a
Numerical Rating System (NRS), which was divided into mild (NRS 1-3),
moderate (NRS 4-6), and severe (NRS 7-10). RESULT(S): In the
participant cohort, 68.8% of participants were male, and the average age
was 60.48+/-10.7. Average postoperative 48-hour cumulative pain scores
were lower in those who received the intervention compared to controls;
50.0 (IQR 35.8-60.0) vs. 65 (IQR 51.0-73.0; p < .01) participants who
received the intervention had less frequent pain breakthroughs when
compared to controls (3.0 [IQR 2.0-5.0] vs. 6.0 [IQR 4.0-8.0; p < .01]).
There was no significant difference in the amount of pain medication taken
by either group. CONCLUSION(S): Participants who receive
individualized preoperative pain education are more likely to have
decreased postoperative pain. Copyright © 2023. Published by
Elsevier Inc.

<48>
Accession Number
2020931239
Title
Impact of pharmacological interventions on intrapulmonary shunt during
one-lung ventilation in adult thoracic surgery: a systematic review and
component network meta-analysis.
Source
British Journal of Anaesthesia. 130(1) (pp e92-e105), 2023. Date of
Publication: January 2023.
Author
Schorer R.; Dombret A.-L.; Hagerman A.; Bedat B.; Putzu A.
Institution
(Schorer, Dombret, Hagerman, Putzu) Department of Acute Medicine, Geneva
University Hospitals, Geneva, Switzerland
(Bedat) Division of Thoracic and Endocrine Surgery, Geneva University
Hospitals, Geneva, Switzerland
Publisher
Elsevier Ltd
Abstract
Background: Intrapulmonary shunt is a major determinant of oxygenation in
thoracic surgery under one-lung ventilation. We reviewed the effects of
available treatments on shunt, PaO<inf>2</inf>/FiO<inf>2</inf> and
haemodynamics through systematic review and network meta-analysis.
 Method(s): Online databases were searched for RCTs comparing
pharmacological interventions and intrapulmonary shunt in thoracic surgery
under one-lung ventilation up to March 30, 2022. Random-effects
(component) network meta-analysis compared 24 treatments and 19 treatment
components. The Confidence in Network Meta-Analysis (CINeMA) framework
assessed evidence certainty. The primary outcome was intrapulmonary shunt
fraction during one-lung ventilation. Result(s): A total of 55 RCTs
were eligible for systematic review (2788 participants). The addition of
N<inf>2</inf>O (mean difference [MD]=-15%; 95% confidence interval [CI],
-25 to -5; P=0.003) or almitrine (MD=-13%; 95% CI, -20 to -6; P<0.001) to
propofol anaesthesia were efficient at decreasing shunt. Combined epidural
anaesthesia (MD=3%; 95% CI, 1-5; P=0.005), sevoflurane (MD=5%; 95% CI,
2-8; P<0.001), isoflurane (MD=6%; 95% CI, 4-9; P<0.001), and desflurane
(MD=9%; 95% CI, 4-14; P=0.001) increased shunt vs propofol. Almitrine
(MD=147 mm Hg; 95% CI, 58-236; P=0.001), dopexamine (MD=88 mm Hg; 95% CI,
4-171; P=0.039), and iloprost (MD=81 mm Hg; 95% CI, 4-158; P=0.038)
improved PaO<inf>2</inf>/FiO<inf>2</inf>. Certainty of evidence ranged
from very low to moderate. Conclusion(s): Adding N<inf>2</inf>O or
almitrine to propofol anaesthesia reduced intrapulmonary shunt during
one-lung ventilation. Halogenated anaesthetics increased shunt in
comparison with propofol. The effects of N<inf>2</inf>O, iloprost, and
dexmedetomidine should be investigated in future research. N<inf>2</inf>O
results constitute a research hypothesis currently not backed by any
direct evidence. The clinical availability of almitrine is limited.
Systematic review protocol: PROSPERO CRD42022310313. Copyright ©
2022 British Journal of Anaesthesia

<49>
Accession Number
2021623615
Title
SODIUM BICARBONATE INFUSION: TO PREVENT CARDIAC SURGERY-ASSOCIATED ACUTE
KIDNEY INJURY.
Source
International Journal of Academic Medicine and Pharmacy. 4(5) (pp 27-30),
2022. Date of Publication: 2022.
Author
Namdev H.
Institution
(Namdev) Department of Cardiothoracic and Vascular Surgery,
Superspeciality Hospital, MGMMC, Madhya Pradesh, Indore, India
Publisher
Necati Ozpinar
Abstract
Background: Acute kidney injury (AKI) is a frequent and severe
postoperative complication in patients undergoing cardiac surgery with an
incidence varying from 36.3 to 52.0%. With increasing interest, this topic
has been specifically referred to as cardiac surgery-associated acute
kidney injury (CSA-AKI). CSA-AKI could contribute to increased in-hospital
mortality, 5-year mortality, 30-day readmission, requirement for renal
replacement therapy (RRT), ICU length of stay, and total postoperative
cost. Material(s) and Method(s): Study was done in the period of
February 2019 to February 2020 at Super speciality hospital GMC Nagpur.
This study was a double-blind, randomized controlled trial designed to
assess if the administration of sodium bicarbonate as a continuous
infusion commenced prior to cardiopulmonary bypass would result in less
postoperative acute renal dysfunction in patients undergoing cardiac
surgery. This prospective study enrolled 70 consecutive patients who
underwent on pump cardiac surgery. A Microsoft Excel-based (Microsoft
Corp., Redmond, WA) random-number generator was used to create the
randomization list. Allocation concealment to patients, anesthesiologists,
cardiac surgeons, intensive care specialists, bedside nurses, and
investigators was ensured. Treatment allocation was only revealed after
the study had been completed, the database locked, and statistical
analysis completed. Result(s): No statistical difference between the
groups was detected in terms of age (41.84 +/- 13.762 vs 46.77 +/- 13.249)
days, P=0.331; age range, 16 year -80 years), weight (49.17 +/- 10.413vs
56.17 +/- 17.666 kg, P =0.183, and duration of CPB (93.2857 +/- 33.79913
vs 105.8429 +/- 41.68955 minutes, P=0.270) and in cross clamp time
(67.1143 +/- 27.20110 vs 75.9143 +/- 37.93539 minutes, P=0.079) which is
shown in Table.1, 3. Conclusion(s): Perioperative alkalization of
blood and urine using an infusion of sodium bicarbonate did not result in
a decrease in the incidence of acute kidney injury in patients undergoing
cardiac surgery. Copyright © 2022 University of Agriculture. All
rights reserved.

<50>
Accession Number
2021623614
Title
HYPOMAGNESAEMIA AND ROLE OF MAGNESIUM SUPPLEMENTATION DURING
CARDIOPULMONARY BYPASS IN PEDIATRICS CARDIAC SURGERY.
Source
International Journal of Academic Medicine and Pharmacy. 4(5) (pp 23-26),
2022. Date of Publication: 2022.
Author
Namdev H.; Goel A.; Piyushgupta
Institution
(Namdev, Goel, Piyushgupta) Department of Cardiothoracic and Vascular
Surgery, Superspeciality Hospital, MGMMC, Madhya Pradesh, Indore, India
Publisher
Necati Ozpinar
Abstract
Background: A significant source of morbidity and mortality following
cardiac surgery for congenital heart disease is postoperative arrhythmias.
Patients with congenital cardiac disease are particularly susceptible to
rhythm abnormalities in the early postoperative period. Little is known
about the prevalence, danger signs, treatment, and prevention of early
postoperative arrhythmias in juvenile cardiac surgery. An incidence of
between 15% and 17.7% was observed in a recent report by Roos-Hesselink
and Karamermer. Material(s) and Method(s): This prospective study was
conducted at Super speciality hospital GMC Nagpur, All patients with
tetralogy of Fallot undergoing intra-cardiac repair in the Department of
Cardiothoracic and Vascular Surgery between February 2019 to February 2020
were enrolled in this study. A total of 90 patients were included in this
study.The patients receiving any antiarrhythmic medication either prior to
surgery or intraoperative were excluded from the study.The patients were
randomly assigned to one of the following groups: Group 1 (Mg0), receiving
normal saline (placebo), group 2 (Mg25), receiving 25mg/kg of MgSO4, and
group 3 (Mg50), and receiving 50mg/kg of MgSO4. Maximum total dose of
MgSO4 did not exceed 2g. All subjects received a single bolus of either
placebo or drug into the CPB circuit at the initiation of the rewarming
period. MgSO4 (500mg/mL; 4mEq/mL). The composition of the bypass circuit
and perfusion protocols were according to established institutional
practices. Patients receiving antiarrhythmics preoperatively or
intraoperatively were excluded from the study. Result(s):
Hypomagnesaemia was present in 28% of patients. None of the patients who
were administered magnesium developed hypomagnesaemia. The incidence of
JET was found to be increased (53.3%) in the placebo group as compared to
13.3% and 6.7% in the groups receiving 25 and 50mg/kg of magnesium
(p<.001). 22 patients having JET 14 (64%) had hypomagnesaemia and rest of
the 8(36%) occurred in patients with normal magnesium levels (p<.001). The
mean mechanical ventilation time and the mean length of ICU stay were both
prolonged those with hypomagnesaemia. The mean mechanical ventilation time
and length of ICU stay were both prolonged in the patients with JET.
 Conclusion(s): Hypomagnesemia is one of the factors responsible for
JET and in turn with prolonged ICU stay and prolonged mechanical
ventilation time. Our study suggests that supplementation of MgSO4 during
CPB reduces the incidence of hypomagnesaemia and reduces the overall
incidence of JET. Copyright © 2022 University of Agriculture. All
rights reserved.

<51>
Accession Number
2022257116
Title
Prevalence and progression of intraductal papillary mucinous neoplasms of
the pancreas in solid organ transplant recipients: A systematic review.
Source
American Journal of Transplantation. 23(3) (pp 429-436), 2023. Date of
Publication: March 2023.
Author
Sugawara T.; Franco S.R.; Ishida J.; Kalra A.; Saben J.L.; Galvez K.N.;
Kirsch M.J.; Al-Musawi M.H.; Kaplan B.; Pomfret E.A.; Schulick R.D.; Del
Chiaro M.
Institution
(Sugawara, Franco, Ishida, Galvez, Del Chiaro) Division of Surgical
Oncology, Department of Surgery, University of Colorado School of
Medicine, Aurora, CO, United States
(Sugawara) Department of Hepatobiliary and Pancreatic Surgery, Graduate
School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan
(Kalra) Division of Gastroenterology and Hepatology, Department of
Medicine, University of Colorado School of Medicine, Aurora, CO, United
States
(Saben, Kaplan, Pomfret) Division of Transplant Surgery, Department of
Surgery, University of Colorado School of Medicine, Aurora, CO, United
States
(Kirsch, Al-Musawi, Schulick) Department of Surgery, University of
Colorado School of Medicine, Aurora, CO, United States
(Schulick, Del Chiaro) University of Colorado Cancer Center, Aurora, CO,
United States
Publisher
Elsevier B.V.
Abstract
Solid organ transplantation (SOT) recipients are known to carry an
increased risk of malignancy because of long-term immunosuppression.
However, the progression of intraductal papillary mucinous neoplasm of the
pancreas (IPMN) in this population remains unclear. We performed a
systematic review by searching PubMed, Embase, Scopus, and Google Scholar.
All studies containing IPMNs in solid organ transplantation recipients
were screened. We included 11 studies in our final analysis, totaling 274
patients with IPMNs of the 8213 SOT recipients. The prevalence from 8
studies was 4.7% (95% CI 2.4%-7.7%) in a random-effects model with median
study periods of 24 to 220 months. The median rate for all progressions
from 10 studies was 20% (range, 0%-88%) within 13 to 41 months of the
median follow-up time. By utilizing the results of 3 case-control studies,
the relative risk from a random-effects model for progression (worrisome
features and high-risk stigmata) of IPMNs was 0.39 (95% CI 0.12-1.31). No
adenocarcinoma derived from IPMN was reported in the included studies.
Overall, this study indicates that the progression of pretransplant IPMN
does not increase drastically compared with the general nontransplant
population. However, considering the limited literature, further studies
are required for confirmation. Copyright © 2022 American Society
of Transplantation & American Society of Transplant Surgeons

<52>
Accession Number
2023130781
Title
Design and rationale of re-energize fontan: Randomized exercise
intervention designed to maximize fitness in fontan patients.
Source
American Heart Journal. 259 (pp 68-78), 2023. Date of Publication: May
2023.
Author
Selamet Tierney E.S.; Palaniappan L.; Leonard M.; Long J.; Myers J.;
Davila T.; Lui M.C.; Kogan F.; Olson I.; Punn R.; Desai M.; Schneider
L.M.; Wang C.-H.; Cooke J.P.; Bernstein D.
Institution
(Selamet Tierney, Davila, Lui, Olson, Punn, Bernstein) Department of
Pediatrics, Division of Pediatric Cardiology, Stanford University, School
of Medicine, Palo Alto, CA, United States
(Palaniappan) Department of Medicine, Stanford University, School of
Medicine, Palo Alto, CA, United States
(Leonard, Long) Department of Pediatrics, Division of Pediatric
Nephrology, Stanford University, School of Medicine, Palo Alto, CA, United
States
(Myers) Department of Medicine, Health Research Science, Palo Alto VA
Health Care System, Palo Alto, CA, United States
(Kogan) Department of Radiology, Stanford University, School of Medicine,
Palo Alto, CA, United States
(Desai) Department of Biomedical Data Science, Stanford University, School
of Medicine, Palo Alto, CA, United States
(Schneider) Psychiatry and Behavioral Sciences - Child & Adolescent
Psychiatry and Child Development, Palo Alto, CA, United States
(Wang) Department of Pediatrics, Health Policy, Stanford University,
School of Medicine, United States
(Cooke) Houston Methodist Research Institute Houston Methodist Hospital &
Research Institute, Houston, Texas, United States
Publisher
Elsevier Inc.
Abstract
In this manuscript, we describe the design and rationale of a randomized
controlled trial in pediatric Fontan patients to test the hypothesis that
a live-video-supervised exercise (aerobic+resistance) intervention will
improve cardiac and physical capacity; muscle mass, strength, and
function; and endothelial function. Survival of children with single
ventricles beyond the neonatal period has increased dramatically with the
staged Fontan palliation. Yet, long-term morbidity remains high. By age
40, 50% of Fontan patients will have died or undergone heart
transplantation. Factors that contribute to onset and progression of heart
failure in Fontan patients remain incompletely understood. However, it is
established that Fontan patients have poor exercise capacity which is
associated with a greater risk of morbidity and mortality. Furthermore,
decreased muscle mass, abnormal muscle function, and endothelial
dysfunction in this patient population is known to contribute to disease
progression. In adult patients with 2 ventricles and heart failure,
reduced exercise capacity, muscle mass, and muscle strength are powerful
predictors of poor outcomes, and exercise interventions can not only
improve exercise capacity and muscle mass, but also reverse endothelial
dysfunction. Despite these known benefits of exercise, pediatric Fontan
patients do not exercise routinely due to their chronic condition,
perceived restrictions to exercise, and parental overprotection. Limited
exercise interventions in children with congenital heart disease have
demonstrated that exercise is safe and effective; however, these studies
have been conducted in small, heterogeneous groups, and most had few
Fontan patients. Critically, adherence is a major limitation in pediatric
exercise interventions delivered on-site, with adherence rates as low as
10%, due to distance from site, transportation difficulties, and missed
school or workdays. To overcome these challenges, we utilize live-video
conferencing to deliver the supervised exercise sessions. Our
multidisciplinary team of experts will assess the effectiveness of a
live-video-supervised exercise intervention, rigorously designed to
maximize adherence, and improve key and novel measures of health in
pediatric Fontan patients associated with poor long-term outcomes. Our
ultimate goal is the translation of this model to clinical application as
an "exercise prescription" to intervene early in pediatric Fontan patients
and decrease long-term morbidity and mortality. Copyright © 2023
Elsevier Inc.

<53>
Accession Number
2023176109
Title
A Systematic Review and Meta-Analysis of Influences of Chronic Kidney
Disease on Patients after Percutaneous Coronary Intervention for Chronic
Total Occlusions.
Source
Computational and Mathematical Methods in Medicine. 2023 (no pagination),
2023. Article Number: 9450752. Date of Publication: 2023.
Author
Wu W.; Gao M.; Wu X.
Institution
(Wu, Gao, Wu) Department of Nephrology, Huzhou Central Hospital,
Affiliated Central Hospital Huzhou University, No. 1558, Sanhuan North
Road, Wuxing District, Zhejiang, Huzhou 313000, China
Publisher
Hindawi Limited
Abstract
Objective. Chronic kidney disease (CKD) is a clinical collective term for
kidney disease with glomerular filtration rate GFR<60 mL/min for more than
three months due to various factors and is usually associated with
coronary heart disease and is also an independent risk factor for coronary
heart disease. This study is aimed at systematically reviewing the
influence of CKD on the outcomes of patients after percutaneous coronary
intervention (PCI) for chronic total occlusions (CTOs). Methods. The
Cochrane Library, PubMed, Embase, China biomedical literature database
(SinoMed), China National Knowledge Infrastructure, and Wanfang database
were searched for case-control studies on the influence of CKD on outcomes
after PCI for CTOs. After screening the literature, extracting data, and
evaluating the quality of literature, RevMan 5.3 software was used for
meta-analysis. Results. There were 11 articles with a total of 558,440
patients included. Meta-analysis results indicated that left ventricular
ejection fraction (LVEF) level, diabetes, smoking, hypertension, coronary
artery bypass grafting, angiotensin converting enzyme inhibitor
(ACEI)/angiotensin receptor blocker (ARB), beta-blockers, age, and renal
insufficiency were the factors affecting outcomes after PCI for CTOs [risk
ratio and 95% confidence interval were: 0.88 (0.86, 0.90), 0.96 (0.95,
0.96), 0.76 (0.59, 0.98), 1.39 (0.89, 2.16), 0.73 (0.38, 1.40), 0.24
(0.02, 3.9), 0.78 (0.77, 0.79), 0.81 (0.80, 0.82), and 1.50 (0.47, 4.79)].
Conclusion. LVEF level, diabetes, smoking, hypertension, coronary artery
bypass grafting, ACEI/ARB, beta-blockers, age, renal insufficiency, etc.
are important risk factors for outcomes after PCI for CTOs. Controlling
these risk factors is of great significance for the prevention, treatment,
and prognosis of CKD. Copyright © 2023 Weifei Wu et al.

<54>
Accession Number
2023167440
Title
Naltrexone-bupropion combinations do not affect cocaine
self-administration in humans.
Source
Pharmacology Biochemistry and Behavior. 224 (no pagination), 2023. Article
Number: 173526. Date of Publication: March 2023.
Author
Regnier S.D.; Stoops W.W.; Lile J.A.; Alcorn J.L.; Bolin B.L.; Reynolds
A.R.; Hays L.R.; Rayapati A.O.; Rush C.R.
Institution
(Regnier, Stoops, Lile, Alcorn, Bolin, Reynolds, Rush) Department of
Behavioral Science, University of Kentucky College of Medicine, 1100
Veterans Drive, Medical Behavioral Science Building, Lexington, KY
40536-0086, United States
(Stoops, Lile, Hays, Rayapati, Rush) Department of Psychiatry, University
of Kentucky College of Medicine, 245 Fountain Court, Lexington, KY
40509-1810, United States
(Stoops, Lile, Rush) Department of Psychology, University of Kentucky
College of Arts and Sciences, 171. Funkhouser Drive, Lexington, KY
40506-0044, United States
(Stoops) Center on Drug and Alcohol Research, University of Kentucky
College of Medicine, 845 Angliana Ave, Lexington, KY 40508, United States
Publisher
Elsevier Inc.
Abstract
The FDA has not yet approved a pharmacotherapy for cocaine use disorder
despite nearly four decades of research. This study determined the initial
efficacy, safety, and tolerability of naltrexone-bupropion combinations as
a putative pharmacotherapy for cocaine use disorder. Thirty-one (31)
non-treatment seeking participants with cocaine use disorder completed a
mixed-design human laboratory study. Participants were randomly assigned
to the naltrexone conditions (i.e., 0, 50 mg/day; between-subject factor)
and maintained on escalating doses of bupropion (i.e., 0, 100, 200, 400
mg/day; within-subject factor) for at least four days prior to the conduct
of experimental sessions. Cocaine self-administration (IN, 0, 40, 80 mg)
was then determined using a modified progressive ratio and relapse
procedure. Subjective and cardiovascular effects were also measured.
Cocaine produced prototypical dose-related increases in
self-administration, subjective outcomes (e.g., "Like Drug"), and
cardiovascular indices (e.g., heart rate, blood pressure) during placebo
maintenance. Naltrexone and bupropion alone, or in combination, did not
significantly decrease self-administration on either procedure. Low doses
of bupropion (i.e., 100 mg) blunted the effects of the cocaine on
subjective measures of "Like Drug" and "Stimulated". No unexpected adverse
effects were observed with naltrexone and bupropion, alone and combined,
in conjunction with cocaine. Together, these results do not support the
use of these bupropion-naltrexone combinations for the treatment of
cocaine use disorder. Future research should determine if novel drug
combinations may decrease cocaine self-administration. Copyright
© 2023

<55>
Accession Number
2023349802
Title
EFFICACY OF INTRAVENOUS ESMOLOL WITH INTRANASAL NITROGLYCERINE SPRAY GIVEN
BEFORE ENDOTRACHEAL EXTUBATION ON THE ATTENUATION OF PRESSOR RESPONSE: A
COMPARATIVE STUDY.
Source
Asian Journal of Pharmaceutical and Clinical Research. 16(3) (pp 62-66),
2023. Date of Publication: March 2023.
Author
Kokate M.V.; Kokate V.R.; Mahure S.M.; Jumade P.P.
Institution
(Kokate, Mahure) Department of Anesthesiology, Dr. Punjabrao Deshmukh
Medical College, Maharashtra, Amravati, India
(Kokate) Department of Medicine, Dr. Punjabrao Deshmukh Medical College,
Maharashtra, Amravati, India
(Jumade) Department of Community Medicine, Karpagam Faculty of Medical
Sciences and Research, Tamil Nadu, Coimbatore, India
Publisher
Innovare Academics Sciences Pvt. Ltd
Abstract
Objectives: The aim of the study was to compare the effects of intravenous
esmolol and intranasal nitroglycerine spray on attenuation of extubation
pressor response in terms of hemodynamic parameters and to compare the
adverse effects, if any, of either drug. Method(s): This was a
randomized comparative study conducted in a tertiary care medical college
in which 64 patients of ASA Grade I with age between 18 and 60 years,
including both males and females undergoing elective non cardiac surgeries
under general anesthesia with orotracheal intubation were included in this
study on the basis of a predefined inclusion and exclusion criteria.
Patients were divided into two groups (Depending on whether they received
Intravenous Esmolol or NTG spray) of 32 patients each. Attenuation of
extubation pressor response in terms of hemodynamic parameters (systolic
blood pressure [SBP], diastolic blood pressure [DBP], mean arterial
pressure [MAP], heart rate, and rate pressure product) were recorded and
compared before induction, during surgery and postoperatively up to 10 min
after surgery. Result(s): The gender distribution was comparable in
both the groups. The mean age of patients in Group A and Group B was found
to be 36.90+/-10.12 and 35.20+/-11.32 years, respectively. The mean age of
both the groups was found to be comparable with no statistically
significant difference. Both the study groups were comparable in base line
parameters with no significant difference seen in mean age, mean heart
rate, mean SBP and DBP, MAP, anesthesia time, and surgery time. Both drugs
controlled the blood pressure changes effectively; however, NTG group had
a better control of systolic as well as DBP. Heart rate was better
controlled in esmolol group. Conclusion(s): Intranasal
nitro-glycerine and intravenous esmolol before tracheal extubation in ASA
Grade I patients are simple, effective, and practical methods of blunting
cardiovascular responses to tracheal extubation. Copyright © 2023
The Authors. Published by Innovare Academic Sciences Pvt Ltd.

<56>
[Use Link to view the full text]
Accession Number
2023310425
Title
Implementation of the Maryland Global Budget Revenue Model and Variation
in the Expenditures and Outcomes of Surgical Care: A Systematic Review and
Meta-analysis.
Source
Annals of Surgery. 277(4) (pp 542-548), 2023. Date of Publication: 01 Apr
2023.
Author
Shammas R.L.; Coroneos C.J.; Ortiz-Babilonia C.; Graton M.; Jain A.;
Offodile A.C.
Institution
(Shammas) Division of Plastic and Reconstructive Surgery, Department of
Surgery, Duke University, Durham, NC, United States
(Coroneos) Department of Surgery and Health Research Methods, Evidence,
and Impact, McMaster University, Hamilton, ON, Canada
(Ortiz-Babilonia, Jain) Department of Orthopedic Surgery, Johns Hopkins
University, Baltimore, MD, United States
(Graton) Medical Center Library and Archives, Duke University School of
Medicine, Durham, NC, United States
(Offodile) Department of Plastic Surgery, University of Texas Md Anderson
Cancer Center, Houston, TX, United States
(Offodile) Department of Health Services Research, University of Texas Md
Anderson Cancer Center, Houston, TX, United States
Publisher
Wolters Kluwer Health
Abstract
Objective: To assess the effect of the Global Budget Revenue (GBR) program
on outcomes after surgery. Background(s): There is limited data
summarizing the effect of the GBR program on surgical outcomes as compared
with traditional fee-for-service systems. Method(s): The Medline,
Embase, Scopus, and Web of Science databases were used to conduct a
systematic literature search on April 5, 2022. We identified full-length
reports of comparative studies involving patients who underwent surgery in
Maryland after implementation of the GBR program. A random effects model
calculated the overall pooled estimate for each outcome which included
complications, rates of readmission and mortality, length of stay, and
costs. Result(s): Fourteen studies were included in the qualitative
synthesis, with 8 unique studies included in the meta-analysis. Our
analytical sample was comprised of 170,011 Maryland patients, 78,171
patients in the pre-GBR group, and 91,840 patients in the post-GBR group.
The pooled analysis identified modest reductions in costs [standardized
mean difference (SMD) -0.34; 95% CI, -0.42, -0.25; P<0.001], complications
[odds ratio (OR): 0.57; 95% CI, 0.36-0.92, P=0.02], readmission (OR: 0.78;
95% CI, 0.72-0.85, P<0.001), mortality (OR: 0.58; 95% CI, 0.47-0.72,
P<0.001), and length of stay (standardized mean difference: -0.26; 95% CI,
-0.32, -0.2, P<0.001) after surgery. Conclusion(s): Implementation of
the GBR program is associated with improved outcomes and reductions in
costs among Maryland patients who underwent surgical procedures. This is
particularly salient given the increasing need to disseminate and scale
population-based payment models that improve patient care while
controlling health care costs. Copyright © 2023 Lippincott
Williams and Wilkins. All rights reserved.

<57>
Accession Number
2021595413
Title
The impact of postoperative cognitive training on health-related quality
of life and cognitive failures in daily living after heart valve surgery:
A randomized clinical trial.
Source
Brain and Behavior. 13(3) (no pagination), 2023. Article Number: e2915.
Date of Publication: March 2023.
Author
Butz M.; Gerriets T.; Sammer G.; El-Shazly J.; Tschernatsch M.; Schramm
P.; Doeppner T.R.; Braun T.; Boening A.; Mengden T.; Choi Y.-H.;
Schoenburg M.; Juenemann M.
Institution
(Butz, Gerriets, Sammer, Tschernatsch, Schramm, Braun, Schoenburg,
Juenemann) Heart and Brain Research Group, Kerckhoff Heart and Thorax
Center, Bad Nauheim, Germany
(Butz, Gerriets, Tschernatsch, Schramm, Doeppner, Braun, Schoenburg,
Juenemann) Department of Neurology, University Hospital Giessen and
Marburg, Giessen, Germany
(Sammer) Cognitive Neuroscience at the Centre of Psychiatry, University
Giessen, Giessen, Germany
(Sammer) Department of Psychology, Justus-Liebig University, Giessen,
Germany
(El-Shazly) Department of Psychocardiology, Kerckhoff Heart and Thorax
Center, Bad Nauheim, Germany
(Boening) Department of Cardiovascular Surgery, University Hospital
Giessen and Marburg, Giessen, Germany
(Mengden) Department of Rehabilitation, Kerckhoff Heart and Thorax Center,
Bad Nauheim, Germany
(Choi, Schoenburg) Department of Cardiac Surgery, Kerckhoff Heart and
Thorax Center, Bad Nauheim, Germany
Publisher
John Wiley and Sons Ltd
Abstract
Background: Heart surgery is a risk factor for objectively and
subjectively assessable postoperative cognitive decline (POCD), which is
relevant for everyday life. The aim of this study was to investigate
whether early postoperative cognitive training has an impact on
health-related quality of life and cognitive failures in daily living
after cardiac surgery. Method(s): The study was a two-arm,
randomized, controlled, outcome-blinded trial involving older patients
undergoing elective heart valve surgery with extracorporeal circulation
(ECC). Recruitment took place at the Departments of Cardiac Surgery of the
Kerckhoff Clinic in Bad Nauheim (Germany) and the University Hospital in
Giessen (Germany). The patients were randomized (1:1 ratio) to either a
paper-and-pencil-based cognitive training group or a control group. We
applied the Short Form Health Survey (SF-36) and the Cognitive Failures
Questionnaire (CFQ) prior to surgery and 3 months after the cognitive
training. Data were analyzed in a per-protocol fashion. Result(s):
Three months after discharge from rehabilitation, the training group (n =
31) showed improvement in health-related quality of life compared to the
control group (n = 29), especially in role limitations due to emotional
problems (U = -2.649, p =.008, eta2 = 0.121), energy and
fatigue (F[2.55] = 5.72, p =.020, eta2 = 0.062), social
functioning (U = -2.137, p =.033, eta2 = 0.076), the average of
all SF-36 factors (U = -2.374, p =.018, eta2 = 0.094), health
change from the past year to the present time (U = -2.378, p =.017,
eta2 = 0.094), and the mental component summary (U = -2.470, p
=.013, eta2 = 0.102). Conclusion(s): As our cognitive
training has shown beneficial effects, this intervention could be a
promising method to enhance health-related quality of life after cardiac
surgery. Copyright © 2023 The Authors. Brain and Behavior
published by Wiley Periodicals LLC.

<58>
Accession Number
2021799351
Title
Cutting balloon to optimize predilation for stent implantation: The COPS
randomized trial.
Source
Catheterization and Cardiovascular Interventions. 101(4) (pp 798-805),
2023. Date of Publication: 01 Mar 2023.
Author
Mangieri A.; Nerla R.; Castriota F.; Reimers B.; Regazzoli D.; Leone P.P.;
Gasparini G.L.; Khokhar A.A.; Laricchia A.; Giannini F.; Casale F.;
Bezzeccheri A.; Briguori C.; Colombo A.
Institution
(Mangieri, Reimers, Regazzoli, Leone, Gasparini) Department of Cardio
Center IRCCS, Humanitas Research Hospital, Rozzano, Italy
(Nerla, Castriota, Giannini) Department of Cardio-Thoracic GVM Care and
Research, Maria Cecilia Hospital, Cotignola, Italy
(Khokhar) Department of Cardio-Thoracic Cardiology Service, Imperial
College Healthcare NHS Trust, London, United Kingdom
(Laricchia) Department of Cardiovascular, ASST Santi Paolo Carlo, Milano,
Italy
(Casale, Bezzeccheri, Briguori) Department of Cardiology, Mediterranea
Cardiocentro, Naples, Italy
(Colombo) Department of Biomedical Sciences, Humanitas University, Milan,
Italy
(Colombo) Department of Cardiology Cardio Center IRCCS, Humanitas Research
Hospital, Rozzana, Italy
Publisher
John Wiley and Sons Inc
Abstract
Objectives: The objective of this study is to investigate the use of
cutting balloon (CB) inflated at high pressure compared with noncompliant
balloon (NCB) for the treatment of calcified coronary lesions.
 Background(s): No data are available regarding the safety and
efficacy of CB inflated at high pressure in coronary artery
calcifications. Method(s): Patients with calcified lesions (more than
100degree of calcium demonstrated at baseline intravascular ultrasound)
were randomized. Primary endpoint of the study was the final minimal stent
area (MSA) and stent symmetry in the calcific segment. Secondary endpoints
included rate of device failure and the 1-year rate of target lesion
revascularization, target vessel revascularization, and major adverse
cardiovascular events. Result(s): From September 2019 to June 2021, a
total of 100 patients were included and randomized; 13 patients were
excluded for major protocol deviations. Lesions were complex (type B2/C n
= 61 [71.2%]) with a mean arch of calcium of 266 +/- 84degree, a calcium
length of 12 +/- 6.6 mm. CB was inflated at comparable atmospheres when
compared with NCB (18.3 +/- 5 vs. 19 +/- 4.5, p = 0.46). In the
per-protocol population, the final MSA at the level of the calcium site
was significantly higher in the CB group (8.1 +/- 2 vs. 7.3 +/- 2.1, p =
0.035) with a higher eccentricity index achieved in the CB group (0.84 +/-
0.07 vs. 0.8 +/- 0.08, p = 0.013). Three device failure occurred in the CB
group. One-year follow-up outcomes were comparable. Conclusion(s):
Treatment of calcified lesions with high-pressure CB has a good safety
profile and is associated with a larger MSA and higher eccentricity of the
stent at the level of the calcium site compared with NCB. Copyright
© 2023 The Authors. Catheterization and Cardiovascular Interventions
published by Wiley Periodicals LLC.

<59>
Accession Number
2021959424
Title
The LIMA: A Drug-Eluting Graft and Coronary Flow Shock Absorber.
Source
Mayo Clinic Proceedings. 98(1) (pp 15-17), 2023. Date of Publication:
January 2023.
Author
Pesce M.; Pompilio G.; Bartunek J.
Institution
(Pesce, Pompilio) Centro Cardiologico Monzino, IRCCS, Milan, Italy
(Pompilio) Universita di Milano, Milan, Italy
(Bartunek) Cardiovascular Center, OLV Hospital, Aalst, Belgium
Publisher
Elsevier Ltd

<60>
Accession Number
2022110521
Title
Preoperative optimization of cardiac valve patients' expectations: Study
protocol of the randomized controlled ValvEx-trial.
Source
Frontiers in Cardiovascular Medicine. 10 (no pagination), 2023. Article
Number: 1105507. Date of Publication: 2023.
Author
Horn N.; Gartner L.; Rastan A.J.; Andrasi T.B.; Lenz J.; Boning A.;
Salzmann-Djufri M.; Puvogel U.; Genovese M.; Kus S.; Rief W.; Salzmann S.
Institution
(Horn, Gartner, Genovese, Kus, Rief, Salzmann) Division of Clinical
Psychology and Psychotherapy, Philipps University of Marburg, Marburg,
Germany
(Rastan, Andrasi, Lenz) Department of Cardiovascular Surgery, Heart
Center, Philipps University of Marburg, Marburg, Germany
(Boning, Salzmann-Djufri, Puvogel) Department of Cardiovascular Surgery,
Justus Liebig University, Giessen, Germany
Publisher
Frontiers Media S.A.
Abstract
Introduction: Complete recovery after surgery depends on psychological
factors such as preoperative information, expectations, and
surgery-associated anxiety. Prior studies have shown that even a short
preoperative psychological intervention aiming at optimized expectations
(EXPECT) can improve postoperative outcomes in coronary artery bypass
patients. However, this intervention may benefit only a small subgroup of
heart surgery patients since implementing preoperative psychological
interventions into the daily clinical routine is difficult due to the
additional time and appointments. It is unclear whether the EXPECT
intervention can be shortened and whether heart valve patients would also
benefit from interventions that optimize patients' expectations. The
multicenter ValvEx trial aims (i) to adapt an effective preoperative
psychological intervention (EXPECT) to make it brief enough to be easily
integrated into the preoperative routine of heart valve patients and (ii)
to examine if the adapted preoperative psychological intervention improves
the subjectively perceived illness-related disability (PDI) up to 3 months
after surgery. Materials and analysis: In two German university hospitals,
N = 88 heart valve patients who undergo heart surgery are randomized into
two groups [standard of care (SOC) vs. standard of care plus
interventional expectation manipulation (SOC and EXPECT)] after baseline
assessment. Patients in the EXPECT group additionally to standard of care
participate in the preoperative psychological intervention (30-40 min),
focusing on optimizing expectations and have two booster-telephone calls
(4 and 8 weeks after the surgery, approx. 15 min). Both groups have
assessments again on the evening before the surgery, 4 to 6 days, and 3
months after the surgery. Discussion(s): The trial demonstrates
excellent feasibility in the clinical routine and a high interest by the
patients. Ethics and dissemination: The Ethics Committees of the
Department of Medicine of the Philipps University of Marburg and the
Department of Medicine of the University of Giessen approved the study
protocol. Study results will be published in peer-reviewed journals and
presented at congresses. Clinical trial registration: ClinicalTrials.gov,
identifier NCT04502121. Copyright © 2023 Horn, Gartner, Rastan,
Andrasi, Lenz, Boning, Salzmann-Djufri, Puvogel, Genovese, Kus, Rief and
Salzmann.

<61>
Accession Number
2022009898
Title
Effect of mini-dose dexmedetomidine supplemented intravenous analgesia on
sleep structure in older patients after major noncardiac surgery: A
randomized trial.
Source
Sleep Medicine. 102 (pp 9-18), 2023. Date of Publication: February 2023.
Author
Zhang Z.-F.; Su X.; Zhao Y.; Zhong C.-L.; Mo X.-Q.; Zhang R.; Wang K.; Zhu
S.-N.; Shen Y.-E.; Zhang C.; Wang D.-X.
Institution
(Zhang, Su, Zhao, Zhong, Mo, Zhang, Wang, Wang) Department of
Anesthesiology and Critical Care Medicine, Peking University First
Hospital, Beijing, China
(Zhu) Department of Biostatistics, Peking University First Hospital,
Beijing, China
(Shen, Zhang) Department of Respiratory and Critical Medicine, Peking
University First Hospital, Beijing, China
Publisher
Elsevier B.V.
Abstract
Study objectives: In previous studies, low-dose dexmedetomidine
supplemented opioid analgesia improved sleep architecture but increased
sedation level. Herein we tested the hypothesis that mini-dose
dexmedetomidine supplemented analgesia improves sleep structure without
increasing sedation. Method(s): In this randomized trial, 118 older
patients (>=65 years) following major noncardiac surgery were randomized
to receive patient-controlled intravenous analgesia supplemented with
either placebo or dexmedetomidine (median 0.02 mug kg-1
h-1) for up to 3 days. Polysomnogram was monitored from 9:00
p.m. on the day of surgery until 6:00 a.m. on the first day after surgery.
Our primary outcome was the percentage of non-rapid eye movement stage 2
(N2) sleep. Secondary outcomes included other sleep structure parameters
during the night of surgery and the sedation score during the first five
postoperative days. Result(s): All 118 patients completed the study;
of these, 85 were included in sleep structure analysis. Dexmedetomidine
supplemented analgesia increased the percentage of N2 sleep (median
difference, 10%; 95% CI, 1%-20%; P = 0.03). It also prolonged total sleep
time (median difference, 78 min; 95% CI, 21 to 143; P = 0.01), increased
sleep efficiency (median difference, 14%; 95% CI, 4%-26%; P = 0.01),
decreased percentage of N1 sleep (median difference, -10%; 95% CI, -20% to
-1%; P = 0.04), and lowered sleep fragmentation index (median difference,
-1.6 timesh-1; 95% CI, -3.7 to 0.1; P = 0.04). Sedation score
within 5 days did not differ between the two groups. Conclusion(s):
Supplementing intravenous analgesia with mini-dose dexmedetomidine
improved sleep structure without increasing sedation in older patients
recovering from major surgery. Clinical trials: www.clinicaltrials.gov
(NCT03117790), registered 2 April 2017. Copyright © 2022 The
Authors

<62>
Accession Number
2020579077
Title
New insights into immunomodulatory properties of lactic acid bacteria
fermented herbal medicines.
Source
Frontiers in Microbiology. 13 (no pagination), 2022. Article Number:
1073922. Date of Publication: 28 Nov 2022.
Author
Zhu H.; Guo L.; Yu D.; Du X.
Institution
(Zhu, Guo, Yu, Du) College of Pharmacy, Heilongjiang University of Chinese
Medicine, Harbin, China
Publisher
Frontiers Media S.A.
Abstract
The COVID-19 pandemic has brought more attention to the immune system, the
body's defense against infectious diseases. The immunomodulatory ability
of traditional herbal medicine has been confirmed through clinical trial
research, and has obvious advantages over prescription drugs due to its
high number of potential targets and low toxicity. The active compounds of
herbal drugs primarily include polysaccharides, saponins, flavonoids, and
phenolics and can be modified to produce new active compounds after lactic
acid bacteria (LAB) fermentation. LAB, primary source of probiotics, can
produce additional immunomodulatory metabolites such as
exopolysaccharides, short-chain fatty acids, and bacteriocins. Moreover,
several compounds from herbal medicines can promote the growth and
production of LAB-based immune active metabolites. Thus, LAB-mediated
fermentation of herbal medicines has become a novel strategy for
regulating human immune responses. The current review discusses the
immunomodulatory properties and active compounds of LAB fermented herbal
drugs, the interaction between LAB and herbal medicines, and changes in
immunoregulatory components that occur during fermentation. This study
also discusses the mechanisms by which LAB-fermented herbal medicines
regulate the immune response, including activation of the innate or
adaptive immune system and the maintenance of intestinal immune
homeostasis. Copyright © 2022 Zhu, Guo, Yu and Du.

<63>
Accession Number
2020481741
Title
Low-density lipoprotein-cholesterol lowering effect of a nutraceutical
regimen with or without ezetimibe in hypercholesterolaemic patients with
statin intolerance.
Source
Frontiers in Cardiovascular Medicine. 9 (no pagination), 2022. Article
Number: 1060252. Date of Publication: 25 Nov 2022.
Author
Ward N.C.; Reid C.M.; Watts G.F.
Institution
(Ward) Dobney Hypertension Centre, Medical School, University of Western
Australia, Perth, WA, Australia
(Reid) School of Population Health, Curtin University, Perth, WA,
Australia
(Watts) Medical School, University of Western Australia, Perth, WA,
Australia
(Watts) Lipid Disorders Clinic, Department of Cardiology, Royal Perth
Hospital, Perth, WA, Australia
Publisher
Frontiers Media S.A.
Abstract
Background: Statins are the most widely prescribed medication to lower
low-density lipoprotein cholesterol (LDL-c). However, a significant
portion of patients are unable to tolerate them due to side effects, most
commonly muscle related. Nutraceuticals, natural plant derivatives with
lipid-lowering properties, may provide an alternative to lower LDL-c in
these patients. Aim(s): To investigate whether a nutraceutical
regimen, either alone or in combination with ezetimibe, can lower LDL-c in
patients with hypercholesterolemia who are intolerant to statins.
 Method(s): Participants were recruited into a double-blind,
randomized, placebo-controlled intervention study. Treatments were (i)
placebo, (ii) nutraceutical (500 mg berberine, 200 mg red yeast rice
(RYR), 2 g plant sterols)/daily, (iii) ezetimibe (10 mg)/daily, or (iv)
the combination of nutraceutical and ezetimibe/daily. At baseline and week
8, all participants provide a fasting blood sample for assessment of lipid
profile and safety bloods. Result(s): Fifty participants were
randomized, with 44 completing the treatment period. Following adjustment
for baseline levels and compared with placebo, LDL-c was significantly
reduced (all p < 0.0001) with ezetimibe (-1.02 mmol/L), nutraceutical
(-1.15 mmol/L) and the nutraceutical and ezetimibe combination (-1.92
mmol/L). Non-HDL cholesterol was significantly reduced (all p < 0.0001)
with ezetimibe (-1.29 mmol/L), nutraceutical (-1.37 mmol/L) and the
nutraceutical and ezetimibe combination (-2.18 mmol/L). Remnant
cholesterol and triglycerides was significantly reduced with the
nutraceutical and ezetimibe combination (p = 0.018). Conclusion(s): A
nutraceutical regimen (berberine, RYR and plant sterols) and ezetimibe
independently and additively lower LDL-c in patients with
hypercholesterolemia who are intolerant to statins. Copyright ©
2022 Ward, Reid and Watts.

<64>
[Use Link to view the full text]
Accession Number
2021848289
Title
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Source
New England Journal of Medicine. 387(21) (pp 1923-1934), 2022. Date of
Publication: 24 Nov 2022.
Author
Das Pradhan A.; Glynn R.J.; Fruchart J.-C.; MacFadyen J.G.; Zaharris E.S.;
Everett B.M.; Campbell S.E.; Oshima R.; Amarenco P.; Blom D.J.; Brinton
E.A.; Eckel R.H.; Elam M.B.; Felicio J.S.; Ginsberg H.N.; Goudev A.;
Ishibashi S.; Joseph J.; Kodama T.; Koenig W.; Leiter L.A.; Lorenzatti
A.J.; Mankovsky B.; Marx N.; Nordestgaard Bo.G.; Pall D.; Ray K.K.; Santos
R.D.; Soran H.; Susekov A.; Tendera M.; Yokote K.; Paynter N.P.; Buring
J.E.; Libby P.; Ridker P.M.
Institution
(Das Pradhan) Center for Cardiovascular Disease Prevention, Division of
Preventive Medicine, United States
(Glynn, Blom) Division of Cardiovascular Medicine, Brigham and Women s
Hospital, United States
(Fruchart) Division of Cardiovascular Medicine, Veteran Affairs Boston
Health Care System
(MacFadyen) Kowa Pharma Development, Boston, United States
(Zaharris) University of Lille, Lille, France
(Everett) Department of Neurology and Stroke Center, Paris Cit University,
Paris, France
(Campbell) Kowa Research Institute, Morrisville, NC, United States
(Oshima) Division of Lipidology, Department of Medicine, University of
Cape Town, Cape Town, South Africa
(Amarenco) Utah Lipid Center, Salt Lake City ; the University of Colorado
School of Medicine, Aurora, United States
(Brinton) The University of Tennessee Health Science Center, Memphis,
United States
(Eckel) Division of Endocrinology, Universit rio Hospital Jo o de Barros
Barreto, Belm, Brazil
(Elam, Joseph) Heart Institute, University of S o Paulo Medical School
Hospital, Hospital Israelita Albert Einstein, So Paulo, Brazil
(Felicio, Kodama) Columbia University Vagelos, College of Physicians and
Surgeons, New York, United States
(Ginsberg, Koenig) Queen Giovanna University Hospital, Sofia, Bulgaria
(Goudev, Leiter) Jichi Medical University, Shimotsuke, Research Center for
Advanced Science and Technology, University of Tokyo, Tokyo, Japan
(Ishibashi, Mankovsky) Chiba University Graduate School of Medicine,
Chiba, Japan
(Marx) Deutsches Herzzentrum M nchen, Technische Universit t M nchen and
German Center for Cardiovascular Research, Partner Site Munich Heart
Alliance, Munich, Germany
(Lorenzatti, Nordestgaard) Institute of Epidemiology and Medical Biometry,
University of Ulm, Ulm, Germany
(Pall) Rheinisch Westf lische Technische Hochschule Aachen, University
Hospital Aachen, Aachen, Germany
(Ray) McMaster University and Population Health Research Institute,
Hamilton, ON, Canada
(Santos) Division of Endocrinology and Metabolism, St. Michael s Hospital,
University of Toronto, Toronto, Canada
(Soran) Docencia, Asistencia M dica e Investigaci n Cl nica Med. Inst.
Rusculleda Foundation for Research, Cordoba, Argentina
(Susekov) Shupyk Na Tional Healthcare University of Ukraine, Kyiv, Ukraine
(Tendera) Copenhagen University Hospital Herlev Gentofte, University of
Copenhagen, Copenhagen, Denmark
(Yokote) Department of Medical Clinical Pharmacology, University of
Debrecen, Debrecen, Hungary
(Paynter) Department of Primary Care and Public Health, Imperial College
London, London, United Kingdom
(Buring) Department of Endocrinology, Diabetes, and Metabolism, Manchester
University Hospital Nhs Foundation Trust, Manchester, United Kingdom
(Libby) Russian Academy of Postgraduate Medical Education, Moscow, Russian
Federation
(Ridker) Department of Cardiology and Structural Heart Diseases, Medical
University of Silesia, Katowice, Poland
Publisher
Massachussetts Medical Society
Abstract
Background High triglyceride levels are associated with increased
cardiovascular risk, but whether reductions in these levels would lower
the incidence of cardiovascular events is uncertain. Pemafibrate, a
selective peroxisome proliferator-activated receptor alpha modulator,
reduces triglyceride levels and improves other lipid levels. Methods In a
multinational, double-blind, randomized, controlled trial, we assigned
patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia
(triglyceride level, 200 to 499 mg per deciliter), and high-density
lipoprotein (HDL) cholesterol levels of 40 mg per deciliter or lower to
receive pemafibrate (0.2-mg tablets twice daily) or matching placebo.
Eligible patients were receiving guideline-directed lipid-lowering therapy
or could not receive statin therapy without adverse effects and had
low-density lipoprotein (LDL) cholesterol levels of 100 mg per deciliter
or lower. The primary efficacy end point was a composite of nonfatal
myocardial infarction, ischemic stroke, coronary revascularization, or
death from cardiovascular causes. Results Among 10,497 patients (66.9%
with previous cardiovascular disease), the median baseline fasting
triglyceride level was 271 mg per deciliter, HDL cholesterol level 33 mg
per deciliter, and LDL cholesterol level 78 mg per deciliter. The median
follow-up was 3.4 years. As compared with placebo, the effects of
pemafibrate on lipid levels at 4 months were -26.2% for triglycerides,
-25.8% for very-low-density lipoprotein (VLDL) cholesterol, -25.6% for
remnant cholesterol (cholesterol transported in triglyceride-rich
lipoproteins after lipolysis and lipoprotein remodeling), -27.6% for
apolipoprotein C-III, and 4.8% for apolipoprotein B. A primary end-point
event occurred in 572 patients in the pemafibrate group and in 560 of
those in the placebo group (hazard ratio, 1.03; 95% confidence interval,
0.91 to 1.15), with no apparent effect modification in any prespecified
subgroup. The overall incidence of serious adverse events did not differ
significantly between the groups, but pemafibrate was associated with a
higher incidence of adverse renal events and venous thromboembolism and a
lower incidence of nonalcoholic fatty liver disease. Conclusions Among
patients with type 2 diabetes, mild-to-moderate hypertriglyceridemia, and
low HDL and LDL cholesterol levels, the incidence of cardiovascular events
was not lower among those who received pemafibrate than among those who
received placebo, although pemafibrate lowered triglyceride, VLDL
cholesterol, remnant cholesterol, and apolipoprotein C-III levels. (Funded
by the Kowa Research Institute; PROMINENT ClinicalTrials.gov number,
NCT03071692.) Copyright © 2022 Massachusetts Medical Society.

<65>
Accession Number
2023289106
Title
The effect of prone positioning on surgical pleth index in patients
undergoing spine surgery under general anesthesia - A prospective
observational study.
Source
Journal of Anaesthesiology Clinical Pharmacology. 38(4) (pp 646-651),
2022. Date of Publication: October 2022.
Author
Musti S.; Chakrabarti D.; Bansal S.
Institution
(Musti, Chakrabarti, Bansal) Department of Neuroanaesthesia and
Neurocritical Care, National Institute of Mental Health and Neurosciences
(NIMHANS), Karnataka, Bangalore, India
Publisher
Wolters Kluwer Medknow Publications
Abstract
Background and Aims: Surgical Pleth Index (SPI) provides an objective
assessment of nociception - anti-nociception balance but is influenced by
multiple confounders. The effect of change of position on SPI, has not
been studied extensively. The aim of the study was to observe the effect
of prone positioning on SPI and its correlation with hemodynamic
variables, in patients undergoing lumbar and thoracic spine surgery.
 Material(s) and Method(s): This prospective observational pilot study
included 14 patients. In addition to hemodynamic monitoring, SPI, entropy
and pulse pressure variability (PPV) were monitored. Propofol and Fentanyl
infusions were used for maintenance of anesthesia. The patients were made
prone on bolsters and all the variables were recorded every 5 minutes in
supine position and after making prone for 20 minutes, before and after
incision, muscle splitting and laminectomy. Result(s): Comparing the
last value of the variables in the supine position with those immediately
after making prone, SPI increased by 16.36 units (P = 0.003), followed by
gradual reduction over the next 20 minutes. Mean arterial pressure and
heart rate increased transiently (Pvalue = 0.028 and 0.025, respectively)
without any significant change in PPV. Surgical incision also led to a
significant increase in SPI. Conclusion(s): Prone positioning leads
to significant increase in SPI, probably due to increased sympathetic
tone. Copyright © 2022 Endodontology Published by Wolters
Kluwer - Medknow.

<66>
[Use Link to view the full text]
Accession Number
639092291
Title
Efficacy of Prehabilitation Before Cardiac Surgery: A Systematic Review
and Meta-analysis.
Source
American journal of physical medicine & rehabilitation. 102(4) (pp
323-330), 2023. Date of Publication: 01 Apr 2023.
Author
Steinmetz C.; Bjarnason-Wehrens B.; Walther T.; Schaffland T.F.; Walther
C.
Institution
(Steinmetz) From the Department of Geriatrics, University Medical Center
Gottingen, Georg August University, Gottingen, Germany (CS); Institute of
Cardiology and Sports Medicine, Department Preventive and Rehabilitative
Sport and Exercise Medicine, German Sport University, Cologne, Germany
(BBW); Department of Cardiothoracic Surgery, University of Frankfurt,
Frankfurt am Main, Germany (TW); Methods Center Tubingen, University of
Tubingen, Tubingen, Germany (TFS); and Cardiovascular Centrum Bethanien,
Department of Cardiology, Frankfurt am Main, Germany (CW)
Publisher
NLM (Medline)
Abstract
OBJECTIVE: Patients awaiting cardiac surgery seem to benefit from
exercise-based prehabilitation, but the impact on different perioperative
outcomes compared with standard care is still unclear. DESIGN: Eligible
nonrandomized/randomized controlled studies investigating the impact of
exercise-based prehabilitation in adults scheduled for elective cardiac
surgery were searched on December 16, 2020, from electronic databases,
including MEDLINE, CENTRAL, and CINAHL. The data were pooled and a
meta-analysis was conducted. RESULT(S): Of 1490 abstracts, six
studies ( n = 665) were included into the review and meta-analysis. At
postintervention interval and at postsurgery interval, 6-min-walking
distance improved significantly in exercise-based prehabilitation group
compared with controls (mean difference, 75.4 m; 95% confidence interval,
13.7 to 137.1 m, P = 0.02, and 30.5 m, 95% confidence interval, 8.5 to
52.6 m, P = 0.007, respectively). Length of hospital stay was
significantly shorter in exercise-based prehabilitation group (mean
difference, -1.00 day; 95% confidence interval, -1.78 to -0.23 day, P =
0.01). Participation in exercise-based prehabilitation revealed a
significant decrease in the risk of postoperative atrial fibrillation in
patients 65 yrs or younger (risk ratio, 0.34; 95% confidence interval,
0.14 to 0.83, P = 0.02). CONCLUSION(S): The participation in
exercise-based prehabilitation significantly improves postintervention and
postsurgery 6-min walking distance, length of hospital stay, and decreases
the risk of postoperative atrial fibrillation in patients 65 yrs or
younger compared with controls. Copyright © 2022 The Author(s).
Published by Wolters Kluwer Health, Inc.

<67>
Accession Number
2020121924
Title
Risk factors for venous thromboembolism following surgical treatment of
fractures: A systematic review and meta-analysis.
Source
International Wound Journal. 20(4) (pp 995-1007), 2023. Date of
Publication: April 2023.
Author
Xia Z.-H.; Chen W.-H.; Wang Q.
Institution
(Xia, Chen, Wang) Department of Surgery, Shanghai Shidong Hospital,
Shanghai, China
Publisher
John Wiley and Sons Inc
Abstract
This study aimed to determine the risk factors for postoperative venous
thromboembolism (VTE) in patients treated surgically for fractures using a
meta-analytic approach. Electronic searches were performed in PubMed,
Embase, and the Cochrane library from inception until February 2022. The
odds ratio (OR) and 95% confidence interval (CI) were applied to calculate
the pooled effect estimate using the random-effects model. Sensitivity,
subgroup, and publication bias tests were also performed. Forty-four
studies involving 3 239 291 patients and reporting 11 768 VTE cases were
selected for the meta-analysis. We found that elderly (OR: 1.72; 95% CI:
1.38-2.15; P <.001), American Society of Anesthesiologists (ASA) >= 3 (OR:
1.82; 95% CI: 1.46-2.29; P <.001), blood transfusion (OR: 1.82; 95% CI:
1.14-2.92; P =.013), cardiovascular disease (CVD) (OR: 1.40; 95% CI:
1.22-1.61; P <.001), elevated D-dimer (OR: 4.55; 95% CI: 2.08-9.98; P
<.001), diabetes mellitus (DM) (OR: 1.36; 95% CI: 1.19-1.54; P <.001),
hypertension (OR: 1.31; 95% CI: 1.09-1.56; P =.003), immobility (OR: 3.45;
95% CI: 2.23-5.32; P <.001), lung disease (LD) (OR: 2.40; 95% CI:
1.29-4.47; P =.006), obesity (OR: 1.52; 95% CI: 1.27-1.82; P <.001),
peripheral artery disease (PAD) (OR: 2.13; 95% CI: 1.21-3.73; P =.008),
prior thromboembolic event (PTE) (OR: 5.17; 95% CI: 3.14-8.50; P <.001),
and steroid use (OR: 2.37; 95% CI: 1.73-3.24; P <.001) were associated
with an increased risk of VTE. Additionally, regional anaesthesia (OR:
0.66; 95% CI: 0.45-0.96; P =.029) was associated with a reduced risk of
VTE following surgical treatment of fractures. However, alcohol intake,
cancer, current smoking, deep surgical site infection, fusion surgery,
heart failure, hypercholesterolemia, liver and kidney disease, sex, open
fracture, operative time, preoperative anticoagulant use, rheumatoid
arthritis, and stroke were not associated with the risk of VTE.
Post-surgical risk factors for VTE include elderly, ASA >= 3, blood
transfusion, CVD, elevated D-dimer, DM, hypertension, immobility, LD,
obesity, PAD, PTE, and steroid use. Copyright © 2022 The Authors.
International Wound Journal published by Medicalhelplines.com Inc (3M) and
John Wiley & Sons Ltd.

<68>
Accession Number
640792150
Title
CGA AND RELATED INTERVENTIONS TO IMPROVE OUTCOMES FOR OLDER PATIENTS
UNDERGOING TRANSCATHETER AORTIC VALVE IMPLANTATION.
Source
Age and Ageing. Conference: British Geriatrics Society Autumn Meeting.
London United Kingdom. 52(Supplement 1) (pp i2-i3), 2023. Date of
Publication: January 2023.
Author
Jones R.; Lester E.; Schiff R.
Institution
(Jones, Lester, Schiff) Department of Ageing and Health, Guys and St
Thomas' NHS Foundation Trust, London SEI 7EH, United Kingdom
Publisher
Oxford University Press
Abstract
Introduction The number of transcatheter aortic valve implantations
(TAVIs) performed in the UK is increasing exponentially, providing a new
treatment avenue for patients with severe symptomatic aortic stenosis
previously deemed too frail for surgical intervention. Frailty is known to
be associated with poor outcomes following TAVI, however little is known
as to whether comprehensive geriatric assessment (CGA), the gold standard
intervention for older adults in a range of clinical settings, can change
outcomes for older adults undergoing this procedure. Methods Databases
EMBASE, MEDLINE, CINAHL and Cochrane CENTRAL, along with the World Health
Organisation clinical trials registry platform and Clinicaltrials.gov
registry were searched for relevant reports between 01/01/1980 -
26/01/2022 using a pre-specified search strategy. Patients had to be 65 or
over and studies had to evaluate single- or multi-domain interventions
that may form part of a CGA. Studies were not limited to those only
looking at patients living with or at risk of frailty. Results No studies
of adequate quality evaluated the effect of CGA on outcomes for older
adults undergoing TAVI. 18 studies evaluating CGA-related interventions
were identified that met eligibility criteria, with the majority
evaluating cardiac rehabilitation (CR) as a post-procedural intervention.
Other interventions evaluated included cognitive behavioural therapy,
alternative exercise-based interventions and post-procedural protocols
that promoted early mobilisation and allied health professional
involvement. A high risk of bias and significant methodological flaws were
found in the included studies. There was little evidence that
post-procedural CR reduces mortality and to support the role of
occupational and physical therapy for improving in-hospital outcomes for
these patients. Conclusion(s) There is no convincing evidence to support
CGA or related single domain interventions to improve outcomes for older
adults undergoing TAVI. Further robust research is required to establish
whether CGA improves outcomes for this group.

<69>
Accession Number
2022149950
Title
Impact of high intensity interval and moderate continuous training on
plasma ratios of ProBNP<inf>1-108</inf>/BNP<inf>1-32</inf> and
NT-pro-BNP<inf>1-76</inf>/BNP<inf>1-32</inf> after coronary artery bypass
grafting surgery.
Source
Frontiers in Physiology. 14 (no pagination), 2023. Article Number:
1114813. Date of Publication: 2023.
Author
Zare Karizak S.; Kashef M.; Gaeini A.A.; Nejatian M.
Institution
(Zare Karizak) Sport Science Department, Faculty of Literature and
Humanities, Persian Gulf University, Boushehr, Iran, Islamic Republic of
(Kashef) Exercise Physiology Department, Sport Science Faculty, Shahid
Rajaee Teacher Training University, Tehran, Iran, Islamic Republic of
(Gaeini) Exercise Physiology Department, Sport Science Faculty, Tehran
University, Tehran, Iran, Islamic Republic of
(Nejatian) Cardiac Rehabilitation Specialist and Head of Rehabilitation
Clinic of Tehran Heart Center Hospital, Tehran, Iran, Islamic Republic of
Publisher
Frontiers Media S.A.
Abstract
Background: ProBNP<inf>1-108</inf>/BNP<inf>1-32</inf>, and
NT-pro-BNP<inf>1-76</inf>/BNP<inf>1-32</inf> ratios are significant
indices for predicting complications after coronary artery bypass grafting
(CABG) surgery. However, the effect of aerobic training types on these
biomarkers has not been fully understood. So, the current study aimed to
determine the impact of aerobic interval and continuous training programs
on plasma ratios of ProBNP<inf>1-108</inf>/BNP<inf>1-32</inf> and
NT-pro-BNP<inf>1-76</inf>/BNP<inf>1-32</inf> after coronary artery bypass
grafting surgery. Method(s): 36 patients were selected purposive (27
men and 9 women with mean of age 60.32 +/- 5.81 years, height 164.64 +/-
9.25 cm, weight 73.86 +/- 14.23 kg, fat 32.30 +/- 4.28, SBP 142.67 +/-
6.49, DBP 84.5 +/- 5.16 mmHg in seated position at rest situation and
functional capacity of 7.08 +/- 2.49 METs) and then divided randomly into
three groups: control (C) group (without training program) moderate
continuous training (MCT) and high intensity interval training (HIIT)
(exercise training program was performed 3 days/week for 8 weeks) with
intensities 65%-80% and 80%-95% of reserve heart rate in order. Blood
samples were taken 48 h before the first session and 48 h after the last
training session to measure the plasma levels of ProBNP<inf>1-108</inf>,
corin enzyme, BNP<inf>1-32</inf>, and NT-pro-BNP<inf>1-76</inf> using the
enzyme-linked immunosorbent assay (ELISA) technique. Wilcoxin and kruskal
wallis tests were used for analyzing data. Result(s): The plasma
corin enzyme was increased, and the ratios of
proBNP<inf>1-108</inf>/BNP<inf>1-32</inf> and
NT-pro-BNP<inf>1-76</inf>/BNP<inf>1-32</inf> were reduced in both training
groups in compared with control group (p = 0.004, p = 0000, p = 0.016, p =
0.003, p = 0.009, and p = 0.016) when there was no significant difference
was found between training groups (p = 0.074, p = 450, and p = 0.295).
 Conclusion(s): Both high intensity interval training and moderate
continuous training in compared with inactivity have positive effects on
ratios of ProBNP<inf>1-108</inf>/BNP<inf>1-32</inf>,
NT-pro-BNP<inf>1-76</inf>/BNP<inf>1-32</inf> and could be effective to
promote the health of coronary arteries and prevention of HF in post-CABG
patients. Copyright © 2023 Zare Karizak, Kashef, Gaeini and
Nejatian.

<70>
Accession Number
2022074737
Title
Corticosteroid in anti-inflammatory treatment of pediatric acute
myocarditis: a systematic review and meta-analysis.
Source
Italian Journal of Pediatrics. 49(1) (no pagination), 2023. Article
Number: 30. Date of Publication: December 2023.
Author
Yao Q.; Zhan S.
Institution
(Yao) Department of Cardiology, The First Hospital of Jiaxing / Affiliated
Hospital of Jiaxing University, Zhejiang, Jiaxing, China
(Zhan) Department of Pediatrics, The First Hospital of Jiaxing /
Affiliated Hospital of Jiaxing University, Zhejiang, Jiaxing, China
Publisher
BioMed Central Ltd
Abstract
Background: To evaluate the efficacy of corticosteroids in
anti-inflammatory treatment of pediatric acute myocarditis.
 Method(s): We searched PubMed, Embase and Cochrane library and
included studies before October 2022 for clinical trials, observational
studies and retrospective studies which reported on children with acute
myocarditis treated with corticosteroid anti-inflammatory therapy. The
quality of the clinical trials was assessed by Jadad score as an exclusion
criterion. Result(s): This systematic review included 6 studies
involving 604 pediatric patients with acute myocarditis. Corticosteroid
therapy was not associated with reduced risk of mortality due to acute
myocarditis (P = 0.53; RR = 0.87; 95% CI = 0.58 to 1.33) compared to
anti-failure treatment. There was a significant improvement in pediatric
patients' left ventricular function measured by left ventricular ejection
fraction in the group on corticosteroid anti-inflammatory treatment (P =
0.0009; MD = 11.93%; 95% CI = 4.87% to 18.99%). No conclusion can be drawn
due to the high heterogeneity in meta-analyses of risk of getting to a
clinical endpoint (death or heart transplantation) and changes in left
ventricular end-diastolic diameter (LVEDD). Conclusion(s):
Corticosteroid anti-inflammatory therapy in pediatric acute myocarditis
patients showed no significant improvement in reducing the risk of
mortality, but showed significant improvement in LVEF. Copyright
© 2023, The Author(s).

<71>
Accession Number
2021934379
Title
Periprocedural, short-term, and long-term outcomes following transcatheter
tricuspid valve repair: a systemic review and meta-analysis.
Source
Therapeutic Advances in Chronic Disease. 14 (no pagination), 2023. Date of
Publication: January-December 2023.
Author
Wu Z.; Zhu W.; Kaisaier W.; Kadier M.; Li R.; Tursun G.; Dong Y.; Liu C.;
Chen Y.
Institution
(Wu, Zhu, Kaisaier, Kadier, Li, Tursun, Dong) Department of Cardiology,
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
(Wu, Zhu, Dong, Liu, Chen) NHC Key Laboratory of Assisted Circulation, Sun
Yat-sen University, Guangzhou, China
(Liu, Chen) Department of Cardiology, The First Affiliated Hospital, Sun
Yat-sen University, Guangzhou 510080, China
Publisher
SAGE Publications Ltd
Abstract
Background: There has been an increasing use of transcatheter tricuspid
valve repair (TTVR) recently. However, the periprocedural, short-term, and
long-term outcomes of TTVR remain unclear. Objective(s): To determine
the clinical outcomes in patients with significant tricuspid regurgitation
undergoing TTVR. Design(s): Systematic review and meta-analysis. Data
Source and Methods: The systematic review and meta-analysis is reported
according to Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines. PubMed and EMBASE were searched for
clinical trials and observational studies until March 2022. Studies
reporting the incidence of clinical outcomes after TTVR were included. The
clinical outcomes included periprocedural, short-term (in-hospital or
within 30 days), and long-term (>6-month follow-up) outcomes. The primary
outcome was all-cause mortality whereas the secondary outcomes included
technical success, procedural success, cardiovascular mortality,
rehospitalization for heart failure (HHF), major bleeding, and single
leaflet device attachment. The incidence of these outcomes across studies
was pooled by a random-effects model. Result(s): A total of 21
studies with 896 patients were included. A total of 729 (81.4%) patients
underwent isolated TTVR while only 167 (18.6%) patients underwent combined
mitral and tricuspid valve repair. Over 80% of the patients used
coaptation devices while approximately 20% used annuloplasty devices. The
median follow-up duration was 365 days. Technical and procedural success
was high at 93.9% and 82.1%, respectively. The pooled perioperative,
short-term, and long-term all-cause mortality for patients undergoing TTVR
was 1.0%, 3.3%, and 14.1%, respectively. The long-term cardiovascular
mortality rate was 5.3% while the HHF rate was 21.5%. Major bleeding and
single leaflet device attachment were two major complications, accounting
for 14.3% and 6.4%, respectively, during long-term follow-up.
 Conclusion(s): TTVR is associated with high procedural success and
low procedural and short-term mortality. However, all-cause mortality,
cardiovascular mortality, and HHF rates remain high during long-term
follow-up. Registration: PROSPERO (CRD42022310020). Copyright ©
The Author(s), 2023.

<72>
Accession Number
2021978337
Title
Association between serum albumin and outcomes in heart failure and
secondary mitral regurgitation: the COAPT trial.
Source
European Journal of Heart Failure. (no pagination), 2023. Date of
Publication: 2023.
Author
Feng K.Y.; Ambrosy A.P.; Zhou Z.; Li D.; Kong J.; Zaroff J.G.; Mishell
J.M.; Ku I.A.; Scotti A.; Coisne A.; Redfors B.; Mack M.J.; Abraham W.T.;
Lindenfeld J.; Stone G.W.
Institution
(Feng, Ambrosy, Kong, Zaroff, Mishell, Ku) Department of Cardiology,
Kaiser Permanente San Francisco Medical Center, San Francisco, CA, United
States
(Ambrosy) Division of Research, Kaiser Permanente Northern California,
Oakland, CA, United States
(Zhou, Li, Scotti, Coisne, Redfors) Clinical Trials Center, Cardiovascular
Research Foundation, New York, NY, United States
(Redfors) Department of Cardiology, Sahlgrenska University Hospital,
Gothenburg, Sweden
(Redfors) NewYork-Presbyterian Hospital/Columbia University Medical
Center, New York, NY, United States
(Mack) Department of Cardiothoracic Surgery, Baylor Scott & White Health,
Plano, TX, United States
(Abraham) Division of Cardiovascular Medicine, Ohio State University
Medical Center, Columbus, OH, United States
(Lindenfeld) Advanced Heart Failure and Cardiac Transplantation Section,
Vanderbilt Heart and Vascular Institute, Nashville, TN, United States
(Stone) The Zena and Michael A. Wiener Cardiovascular Institute, Icahn
School of Medicine at Mount Sinai, New York, NY, United States
Publisher
John Wiley and Sons Ltd
Abstract
Aims: Low serum albumin levels are associated with poor prognosis in
numerous chronic disease states but the relationship between albumin and
outcomes in patients with heart failure (HF) and secondary mitral
regurgitation (SMR) has not been described. Methods and Results: The
randomized COAPT trial evaluated the safety and effectiveness of
transcatheter edge-to-edge repair (TEER) with the MitraClipTM
plus guideline-directed medical therapy (GDMT) versus GDMT alone in
patients with symptomatic HF and moderate-to-severe or severe SMR.
Baseline serum albumin levels were measured at enrolment. Among 614
patients enrolled in COAPT, 559 (91.0%) had available baseline serum
albumin levels (median 4.0 g/dl, interquartile range 3.7-4.2 g/dl).
Patients with albumin <4.0 g/dl compared with >=4.0 g/dl were older and
more likely to have ischaemic cardiomyopathy and a hospitalization within
the year prior to enrolment. After multivariable adjustment, patients with
albumin <4.0 g/dl had higher 4-year rates of all-cause death (63.7% vs.
47.6%; adjusted hazard ratio 1.34, 95% confidence interval 1.02-1.74; p =
0.032), but there were no significant differences in HF hospitalizations
(HFH) or all-cause hospitalizations according to baseline serum albumin
level. The relative effectiveness of TEER plus GDMT versus GDMT alone was
consistent in patients with low and high albumin levels
(p<inf>interaction</inf> = 0.19 and 0.35 for death and HFH, respectively).
 Conclusion(s): Low baseline serum albumin levels were independently
associated with reduced 4-year survival in patients with HF and severe SMR
enrolled in the COAPT trial, but not with HFH. Patients treated with TEER
derived similarly robust reductions in both death and HFH regardless of
baseline albumin level. Copyright © 2023 European Society of
Cardiology.

<73>
Accession Number
2021965281
Title
Three-year clinical outcomes of the novel sirolimus-eluting bioresorbable
scaffold for the treatment of de novo coronary artery disease: A
prospective patient-level pooled analysis of NeoVas trials.
Source
Catheterization and Cardiovascular Interventions. (no pagination), 2023.
Date of Publication: 2023.
Author
Wang X.; Li Y.; Fu G.; Xu B.; Zhou Y.; Su X.; Liu H.; Zhang Z.; Yu B.; Tao
L.; Zheng Q.; Li L.; Xu K.; Han Y.
Institution
(Wang, Li, Xu, Han) General Hospital of Northern Theater Command,
Liaoning, Shenyang, China
(Fu) Department of Cardiology, Sir Run Run Shaw Hospital, College of
Medicine, Zhejiang University, Zhejiang, Hangzhou, China
(Xu) State Key Laboratory of Cardiovascular Disease, Department of
Cardiology, Centre for Coronary Heart Disease, Fuwai Hospital, National
Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences
and Peking Union Medical College, Beijing, China
(Zhou) Department of Cardiology, Beijing Anzhen Hospital, Capital Medical
University, Beijing, China
(Su) Department of Cardiology, Wuhan Asia Heart Hospital, Affiliated to
Wuhan University of Science and Technology, Hubei, Wuhan, China
(Liu) Beijing CAPF General Hospital, Beijing, China
(Zhang) Department of Cardiology, the First Hospital of Lanzhou
University, Gansu, Lanzhou, China
(Yu) The Key Laboratory of Myocardial Ischemia, Department of Cardiology,
2nd Affiliated Hospital of Harbin Medical University, Chinese Ministry of
Education, Harbin, China
(Tao) Department of Cardiology, Xijing Hospital, Air Force Medical
University, Shaanxi, Xi'an, China
(Zheng) Department of Cardiology, Halison International Peace Hospital,
Shijiazhuang, Hengshui, China
(Li) Department of Cardiology, the First Affiliated Hospital of Guangxi
Medical University, Guangxi, Nanning, China
Publisher
John Wiley and Sons Inc
Abstract
Objectives: We aimed to evaluate the long-term outcomes of the novel
NeoVas sirolimus-eluting bioresorbable scaffold (BRS) for the treatment of
de novo coronary artery disease. Background(s): The long-term safety
and efficacy of the novel NeoVas BRS are still needed to be elucidated.
 Method(s): A total of 1103 patients with de novo native coronary
lesions for coronary stenting were enrolled. The primary endpoint of
target lesion failure (TLF) was defined as a composite of cardiac death
(CD), target vessel myocardial infarction (TV-MI), or
ischemia-driven-target lesion revascularization (ID-TLR). Result(s):
A three-year clinical follow-up period was available for 1,091 (98.9%)
patients. The cumulative TLF rate was 7.2% with 0.8% for CD, 2.6% for
TV-MI, and 5.1% for ID-TLR. Additionally, 128 (11.8%) patient-oriented
composite endpoint and 11 definite/probable stent thromboses (1.0%) were
recorded. Conclusion(s): The extended outcomes of the NeoVas
objective performance criterion trial demonstrated a promising 3-year
efficacy and safety of the NeoVas BRS in low-risk patients with low
complexity in terms of lesions and comorbidities. Copyright ©
2022 Wiley Periodicals LLC.

<74>
Accession Number
640825336
Title
Evaluation of the Effectiveness and Safety of a Multifaceted Computerized
Antimicrobial Stewardship Intervention in Surgical Settings: A
Single-center Cluster-randomized Controlled Trial.
Source
International journal of antimicrobial agents. (pp 106787), 2023. Date of
Publication: 17 Mar 2023.
Author
Yuan X.; Chen K.; Yuan J.; Chu Q.; Gao Y.; Yu F.; Diao X.; Chen X.; Li Y.;
Sun H.; Shu C.; Wang W.; Pan X.; Zhao W.; Hu S.
Institution
(Yuan, Chen, Chu, Li, Sun, Shu, Wang, Pan, Hu) State Key Laboratory of
Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular
Diseases, Chinese Academy of Medical Sciences and Peking Union Medical
College, Beijing, China; Department of Cardiac Surgery, Fuwai Hospital,
Chinese Academy of Medical Sciences and Peking Union Medical College,
Beijing, China
(Yuan, Yu, Diao, Zhao) Information Center, Fuwai Hospital, Chinese Academy
of Medical Sciences and Peking Union Medical College, Beijing, China
(Hu, Gao) National Clinical Research Center of Cardiovascular Diseases,
State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National
Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences
and Peking Union Medical College, Beijing, China
(Chen) Department of Pharmacy, Fuwai Hospital, Chinese Academy of Medical
Sciences and Peking Union Medical College, Beijing, China
Publisher
NLM (Medline)
Abstract
BACKGROUND: Inappropriate antimicrobial use is common for patients
undergoing surgery. Whether a multifaceted computerized antimicrobial
stewardship program is effective and safe in reducing inappropriate
antimicrobial use in surgical settings is unclear. METHOD(S): We
developed a multifaceted computerized antimicrobial stewardship
intervention system, and conducted an open-label, cluster-randomized,
controlled trial among 18 surgical teams that enrolled 2470 patients with
open-chest cardiovascular surgery. The surgical teams were randomly
divided into intervention and control groups at a ratio of 1:1. The
primary endpoints were days of therapy (DOT)/1000 patient-days, DDDs
(measured by defined daily dose)/1000 patient-days, and length of therapy
(LOT)/1000 patient-days. RESULT(S): The means of DOT, DDDs, and LOT
per 1000 patient-days in the intervention group were significantly lower
than those in the control group (472.2 versus 539.8, 459.5 versus 553.8,
and 438.4 versus 488.7, p<0.05), with a 14.2% (95% CI, 11.8% to 16.7%),
18.7% (95% CI, 15.9% to 21.4%), and 11.9% (95% CI, 9.6% to 14.1%)
reduction, respectively. The daily risk of inappropriate antimicrobial use
after the intensive care unit decreased by 23.9% (95% CI, 15.5% to 31.5%
[incidence risk ratio 0.76, 95% CI 0.69 to 0.85]) in the intervention
group. There was no significant difference in rates of infection or
surgical-related complications between the groups. The median (IQR)
antimicrobial costs were significantly lower in the intervention group
(873.4 [684.5-1,255.4] RMB versus 1,178.7 [869.1-1,814.5] RMB, p<0.001).
 CONCLUSION(S): The multifaceted computerized antimicrobial
stewardship interventions safely reduced inappropriate antimicrobial use.
TRIAL REGISTRATION: Clinicaltrials.gov: NCT04328090. Copyright ©
2023. Published by Elsevier Ltd.

<75>
Accession Number
640825210
Title
Perioperative individualized hemodynamic optimization according to
baseline mean arterial pressure in cardiac surgery patients: Rationale and
design of the OPTIPAM randomized trial.
Source
American heart journal. (no pagination), 2023. Date of Publication: 17
Mar 2023.
Author
Descamps R.; Amour J.; Besnier E.; Bougle A.; Charbonneau H.; Charvin M.;
Cholley B.; Desebbe O.; Fellahi J.-L.; Frasca D.; Labaste F.; Lena D.;
Mahjoub Y.; Mertes P.-M.; Molliex S.; Mouri P.-H.; Moussa M.D.; Oilleau
J.-F.; Ouattara A.; Provenchere S.; Rozec B.; Parienti J.-J.; Fischer
M.-O.
Institution
(Descamps) Department of Anesthesiology and Critical Care Medicine, Caen
University Hospital, Caen 14000, France
(Amour) Critical Care Medicine and Anesthesiology in Cardiac Surgery
(IPRA), Hopital Prive Jacques Cartier, Massy, France
(Besnier) Normandie Univ, UNIROUEN, INSERM U1096, CHU Rouen, Department of
Anesthesiology and Critical Care, Rouen, France
(Bougle) Sorbonne Universite, Departement d'Anesthesie et Reanimation,
Institut de Cardiologie, Hopital La Pitie-Salpetriere, Assistance Publique
- Hopitaux de Paris, Paris, France
(Charbonneau) Department of Anesthesiology and Intensive Care Unit, 45
avenue de Lombez BP27617 31076 Toulouse cedex 03, Clinique Pasteur, France
(Charvin) CHU Clermont-Ferrand, Medecine Peri-Operatoire (MC, FL, PJ,
A-LC, EF); Universite Clermont-Auvergne (EF), France
(Cholley) AP-HP, Hopital Europeen Georges Pompidou, Paris F-75015, France
(Desebbe) Department of Anesthesiology and Intensive Care, Ramsay Sante
Sauvegarde Clinic, Lyon, France
(Fellahi) Service d'anesthesie-Reanimation, Hopital Louis Pradel, Hospices
Civils de Lyon; 59, Boulevard Pinel, 69677, Bron Cedex, France
(Frasca) Department of Anaesthesia and Intensive Care, University Hospital
of Poitiers, France
(Labaste) Anesthesiology and Intensive Care Department, University
Hospital of Toulouse, Toulouse, France
(Lena) Institut Arnault Tzanck, Cardiologie Medico-chirurgicale, Avenue du
Dr Donat, 06700 Saint Laurent du Var, France
(Mahjoub) Anesthesia and Critical Care Medicine Department, Amiens
University Medical Center, rue du Professeur Christian Cabrol, Amiens
80054, France
(Mertes) Service d'Anesthesie-Reanimation, Nouvel Hopital Civil, Hopitaux
Universitaires de Strasbourg, Strasbourg 67000, France
(Molliex) Department of Anaesthesiology and Critical Care Medicine,
Hopital Nord, France
(Mouri) Pole Anesthesie-Reanimation, CHU Grenoble Alpes, CS 10217,
Grenoble CEDEX 9, France
(Moussa) Pole d'Anesthesie-Reanimation, CHU Lille, Lille F-59000, France
(Oilleau) Department of Anaesthesia and Critical Care, Brest University
Hospital, Brest 29000, France
(Ouattara) CHU Bordeaux, Department of Anaesthesia and Critical Care,
Magellan Medical Surgical Centre, Bordeaux, France
(Provenchere) Anesthesiology and surgical critical care department, AP-HP,
Bichat Hospital, Paris, France
(Rozec) Service d'Anesthesie-Reanimation, Hopital Laennec, Centre
Hospitalier Universitaire, Nantes F 44093, France
(Parienti) Department of Biostatistics and Clinical Research, Caen
University Hospital, Caen 14000, France
(Fischer) clinique Saint Augustin, 114 avenue d'Ares, France
Publisher
NLM (Medline)
Abstract
BACKGROUND: Postoperative morbidity and mortality after cardiac surgery
with cardiopulmonary bypass (CPB) remain high despite recent advances in
both anesthesia and perioperative management. Among modifiable risk
factors for postoperative complications, optimal arterial pressure during
and after surgery has been under debate for years. Recent data suggest
that optimizing arterial pressure to the baseline of the patient may
improve outcomes. We hypothesize that optimizing the mean arterial
pressure (MAP) to the baseline MAP of the patient during cardiac surgery
with CPB and during the first 24 hours postoperatively may improve
outcomes. STUDY DESIGN: The OPTIPAM trial (NCT05403697) will be a
multicenter, randomized, open-label controlled trial testing the
superiority of optimized MAP management as compared with a MAP of 65mmHg
or more during both the intraoperative and postoperative periods in 1100
patients scheduled for cardiac surgery with CPB. The primary composite end
point is the occurrence of acute kidney injury, neurological complications
including stroke or postoperative delirium, and death. The secondary
endpoints are hospital and intensive care unit lengths of stay, Day 7 and
Day 90 mortality, postoperative cognitive dysfunction on Day 7 and Day 90,
and quality of life at Day 7 and Day 90. An interim analysis will assess
the safety of the intervention. CONCLUSION(S): The OPTIPAM trial will
assess the effectiveness of an individualized target of mean arterial
pressure in cardiac surgery with CPB in reducing postoperative morbidity.
CLINICAL TRIAL REGISTRATION: NCT05403697. Copyright © 2023.
Published by Elsevier Inc.

<76>
Accession Number
2021679348
Title
Outcomes with plug-based versus suture-based vascular closure device after
transfemoral transcatheter aortic valve replacement: A systematic review
and meta-analysis.
Source
Catheterization and Cardiovascular Interventions. 101(4) (pp 817-827),
2023. Date of Publication: 01 Mar 2023.
Author
Sedhom R.; Dang A.T.; Elwagdy A.; Megaly M.; Elgendy I.Y.; Zahr F.; Gafoor
S.; Mamas M.; Elbadawi A.
Institution
(Sedhom) Division of Cardiology, Loma Linda University Health, Loma Linda,
CA, United States
(Dang) Department of Internal Medicine, University of Texas Medical
Branch, Galveston, TX, United States
(Elwagdy) Department of Internal Medicine, Rochester General Hospital,
Rochester, NY, United States
(Megaly) Division of Cardiology, Henry Ford Hospital, Detroit, MI, United
States
(Elgendy) Division of Cardiovascular Medicine, Gill Heart Institute,
University of Kentucky, Lexington, KY, United States
(Zahr) Division of Cardiology, Oregon Health and Science University,
Portland, OR, United States
(Gafoor) Swedish Heart and Vascular Institute, Seattle, WA, United States
(Mamas) Centre for Prognosis Research, Keele Cardiovascular Research
Group, Keele University, Keele, United Kingdom
(Mamas) Department of Cardiology, Royal Stoke University Hospital,
Stoke-on-Trent, United Kingdom
(Elbadawi) Division of Cardiology, Baylor College of Medicine, Houston,
TX, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Studies comparing plug-based (i.e., MANTA) with suture-based
(i.e., ProStar XL and ProGlide) vascular closure devices (VCDs) for
large-bore access closure after transcatheter aortic valve replacement
(TAVR) have yielded mixed results. Aim(s): To examine the comparative
safety and efficacy of both types of VCDs among TAVR recipients.
 Method(s): An electronic database search was performed through March
2022 for studies comparing access-site related vascular complications with
plug-based versus suture-based VCDs for large-bore access site closure
after transfemoral (TF) TAVR. Result(s): Ten studies (2 randomized
controlled trials [RCTs] and 8 observational studies) with 3113 patients
(MANTA = 1358, ProGlide/ProStar XL = 1755) were included. There was no
difference between plug-based and suture-based VCD in the incidence of
access-site major vascular complications (3.1% vs. 3.3%, odds ratio [OR]:
0.89; 95% confidence interval [CI]: 0.52-1.53). The incidence of VCD
failure was lower in plug-based VCD (5.2% vs. 7.1%, OR: 0.64; 95% CI:
0.44-0.91). There was a trend toward a higher incidence of unplanned
vascular intervention in plug-based VCD (8.2% vs. 5.9%, OR: 1.35; 95% CI:
0.97-1.89). Length of stay was shorter with MANTA. Subgroup analyses
suggested significant interaction based on study designs such that there
was higher incidence of access-site vascular complications and bleeding
events with plug-based versus suture-based VCD among RCTs.
 Conclusion(s): In patients undergoing TF-TAVR, large-bore access site
closure with plug-based VCD was associated with a similar safety profile
as suture-based VCD. However, subgroup analysis showed that plug-based VCD
was associated with higher incidence of vascular and bleeding
complications in RCTs. Copyright © 2023 The Authors.
Catheterization and Cardiovascular Interventions published by Wiley
Periodicals LLC.

<77>
Accession Number
2019735490
Title
Comparative study of neointimal coverage between titanium-nitric
oxide-coated and everolimus-eluting stents in acute coronary syndromes.
Source
Revista Espanola de Cardiologia. 76(3) (pp 150-156), 2023. Date of
Publication: March 2023.
Author
Sia J.; Nammas W.; Collet C.; De Bruyne B.; Karjalainen P.P.
Institution
(Sia) Department of Cardiology, Kokkola Central Hospital, Kokkola, Finland
(Nammas, Karjalainen) Heart Center, Satakunta Central Hospital, Pori,
Finland
(Collet, De Bruyne) Cardiovascular Center Aalst, OLV-Clinic, Aalst,
Belgium
(Karjalainen) Heart and Lung Center, Helsinki University Hospital,
Helsinki, Finland
Publisher
Ediciones Doyma, S.L.
Abstract
Introduction and objectives: To evaluate by optical coherence tomography
neointimal healing response after implantation of cobalt-chromium-based
titanium-nitride-oxide-coated (TiNO) stents and platinum-chromium-based
biodegradable-polymer-coated everolimus-eluting stents (EES) in patients
with acute coronary syndrome. Method(s): Patients were randomized
(1:1) to receive either a TiNO-stent or EES. Optical coherence tomography
images were obtained at 30-day (cohort A, n = 52) and 6-month (cohort B, n
= 30) follow-up. The primary endpoint was the percentage of uncovered
struts per patient. Result(s): In cohort A, the percentage of
uncovered struts was lower with TiNO-stents vs EES (3.2% vs 19.6%, P
<.001). The percentage of malapposed struts was 0.4% in the TiNO-group and
2.1% in the EES group (P <.001). In cohort B, the percentage of uncovered
struts was also lower with TiNO-stents (0.0% vs 8.7% (P <.001). The
percentage of malapposed struts was 0% in the TiNO-stent group and 0.3% in
the EES group (P =.008). None of the patients had repeat revascularization
during the 6 months of follow-up. Conclusion(s): Following
percutaneous intervention for acute coronary syndrome, TiNO stent
implantation was associated with a lower percentage of uncovered and
malapposed struts per patient, compared with EES, at early and mid-term
follow-up. This study is registered under ClinicalTrials.gov, with number
NCT02464397. Copyright © 2022 Sociedad Espanola de Cardiologia

<78>
Accession Number
2020699980
Title
Outcomes of concomitant aortic valve procedures and left ventricular
assist device implantation: A systematic review and meta-analysis.
Source
Artificial Organs. 47(3) (pp 470-480), 2023. Date of Publication: March
2023.
Author
Iqbal K.; Arif T.B.; Rathore S.S.; Ahmed J.; Kumar P.; Shahid I.; Iqbal
A.; Shariff M.; Kumar A.
Institution
(Iqbal, Arif, Ahmed, Kumar, Iqbal) Department of Internal Medicine, Dow
Medical College, Dow University of Health Sciences, Karachi, Pakistan
(Rathore) Department of Internal Medicine, Dr. Sampurnanand Medical
College, Jodhpur, India
(Shahid) Department of Internal Medicine, Ziauddin Medical University,
Karachi, Pakistan
(Shariff) Department of Surgery, Mayo Clinic, Rochester, NY, United States
(Kumar) Department of Internal Medicine, Cleveland Clinic Akron General,
Akron, OH, United States
(Kumar) Section of Cardiovascular Research, Heart, Vascular and Thoracic
Department, Cleveland Clinic Akron General, Akron, OH, United States
Publisher
John Wiley and Sons Inc
Abstract
Background: Left ventricular assist device (LVAD) implantation is
frequently employed in patients with end-stage heart failure. The outcomes
of addressing the repair of all substantial aortic valvular disease at the
time of LVAD implantation remain unclear. We sought to assess the clinical
outcomes in patients undergoing LVAD implantation concomitant with aortic
valve procedures (AVPs) compared with isolated LVAD implantation.
 Method(s): A literature search was performed using PubMed, Embase,
and Cochrane library from inception till June 2022. Primary outcomes
included short-term mortality and long-term survival. Random effects
models were used to compute mean differences and odds ratios with 95%
confidence intervals (CIs). Result(s): A total of 14 observational
studies (N = 52 693) met our inclusion criteria. Concomitant LVAD
implantation and AVPs were associated with higher short-term mortality (OR
= 1.61 [95% CI, 1.06-2.42]; p = 0.02) and mean CPBt (MD = 43.25 [95% CI,
22.95-63.56]; p < 0.0001), and reduced long-term survival (OR = 0.70 [95%
CI, 0.55-0.88]; p = 0.003) compared with isolated LVAD implantation. No
difference in the odds of cerebrovascular accident (OR = 1.05 [95% CI,
0.79-1.39]; p = 0.74) and mean length of hospital stay (MD = 2.89 [95% CI,
-4.04 to 9.82]; p = 0.41) was observed between the two groups. On adjusted
analysis, short-term mortality was significantly higher in the LVAD group
with concurrent AVPs when compared with the isolated LVAD group (aHR =
1.50 [95% CI, 1.20-1.87]; p = 0.0004). Conclusion(s): Concurrent AVPs
were associated with higher short-term mortality and reduced long-term
survival in patients undergoing LVAD implantation compared with isolated
LVAD implantation. Copyright © 2022 The Authors. Artificial
Organs published by International Center for Artificial Organ and
Transplantation (ICAOT) and Wiley Periodicals LLC.

<79>
Accession Number
2023088446
Title
Immediate versus staged complete revascularization in patients with
ST-segment elevation myocardial infarction and multivessel coronary artery
disease: results from a prematurely discontinued randomized multicenter
trial.
Source
American Heart Journal. 259 (pp 58-67), 2023. Date of Publication: May
2023.
Author
Park S.; Rha S.-W.; Choi B.G.; Cho J.H.; Park S.H.; Kim Y.H.; Park S.M.;
Choi J.W.; Park J.Y.; Shin E.-S.; Lee J.B.; Suh J.; Chae J.K.; Choi Y.J.;
Jeong M.H.; Cha K.S.; Lee S.W.; Kim U.; Kim G.C.; Choi W.-G.; Cho Y.-H.;
Cho D.-K.; Ahn J.; Suh S.-Y.; Choi S.Y.; Byun J.K.; Cha J.A.; Hyun S.J.;
Kim J.B.; Choi C.U.; Park C.G.
Institution
(Park, Rha, Kim, Choi, Park) Cardiovascular Center, Korea University Guro
Hospital, Seoul, South Korea
(Rha, Choi, Choi, Byun, Cha, Hyun) Cardiovascular Research Institute,
Korea University, Seoul, South Korea
(Cho) Saint Carollo Hospital, Suncheon, South Korea
(Park) Soonchunhyang University Hospital, Cheonan, South Korea
(Lee) Daegu Catholic University Medical Center, Daegu, South Korea
(Kim) Kangwon National University School of Medicine, Chuncheon, South
Korea
(Park, Choi, Park) Nowon Eulji University Hospital, Seoul, South Korea
(Shin) Ulsan University Hospital, Ulsan, South Korea
(Lee) Sam Anyang Hospital, Anyang, South Korea
(Suh) Soonchunhyang University Hospital, Bucheon, South Korea
(Chae) Jeonbuk National University Hospital, Jeonju, South Korea
(Choi) Bucheon Sejong Hospital, Bucheon, South Korea
(Jeong) Chonnam National University Hospital, Gwangju, South Korea
(Cha) Pusan National University Hospital, Busan, South Korea
(Lee) Kwangju Christian Hospital, Gwangju, South Korea
(Kim) Yeungnam University, Daegu, South Korea
(Kim) Shihwa General Hospital, Siheung, South Korea
(Choi) Chungbuk National University Hospital, Cheongju, South Korea
(Cho) Myongji Hospital, Goyang, South Korea
(Cho) Yongin Severance Hospital, Yongin, South Korea
(Ahn) Daejeon Eulji Medical Center, Eulji University Hospital, Daejeon,
South Korea
(Suh) Gachon University Gil Hospital, Incheon, South Korea
Publisher
Elsevier Inc.
Abstract
Background: We aimed to compare clinical outcomes between immediate and
staged complete revascularization in primary percutaneous coronary
intervention (PCI) for treating ST-segment elevation myocardial infarction
(STEMI) and multivessel disease (MVD). Method(s): A total of 248
patients were enrolled in a prospective, randomized, and multicenter
registry. Immediate revascularization was defined as one-time PCI of
culprit and non-culprit lesions at the initial procedure. Staged
revascularization was defined as PCI of non-culprit lesions at a later
date (mean, 4.4 days; interquartile range, 1-11.4), following initial
culprit revascularization. The end points were major adverse
cardiovascular events (MACE; composite of total death, recurrent
myocardial infarction, and revascularization), any individual components
of MACE, cardiac death, stent thrombosis, and stroke at 12 months.
 Result(s): During a follow-up of 1 year, MACE occurred in 12 patients
(11.6%) in the immediate revascularization group and in 8 patients (7.5%)
in staged revascularization group (hazard ratio [HR] 1.60, 95% confidence
interval [CI] 0.65-3.91). The incidence of total death was numerically
higher in the immediate group than in the staged group (9.7% vs 2.8%, HR
3.53, 95% CI 0.97-12.84); There were no significant differences between
the 2 groups in risks of any individual component of MACE, cardiac death,
stroke, and in-hospital complications, such as need for transfusion,
bleeding, acute renal failure, and acute heart failure. This study was
prematurely terminated due to halt of production of everolimus-eluting
stents (manufactured as PROMUS Element by Boston Scientific, Natick,
Massachusetts). Conclusion(s): Due to its limited power, no definite
conclusion can be drawn regarding complete revascularization strategy from
the present study. Further large randomized clinical trials would be
warranted to confirm optimal timing of complete revascularization for
patients with STEMI and MVD. Copyright © 2023 Elsevier Inc.

<80>
Accession Number
2022876342
Title
Low-Dose vs Standard Warfarin After Mechanical Mitral Valve Replacement: A
Randomized Trial.
Source
Annals of Thoracic Surgery. 115(4) (pp 929-938), 2023. Date of
Publication: April 2023.
Author
Chu M.W.A.; Ruel M.; Gerdisch M.W.; Damiano R.J.; Smith R.L.; Keeling
W.B.; Wait M.A.; Hagberg R.C.; Quinn R.D.; Sethi G.K.; Floridia R.;
Barreiro C.J.; Pruitt A.L.; Accola K.D.; Dagenais F.; Markowitz A.H.; Ye
J.; Sekela M.E.; Tsuda R.Y.; Duncan D.A.; Swistel D.G.; Harville L.E.;
DeRose J.J.; Lehr E.J.; Alexander J.H.; Puskas J.D.; Choi C..; Pettersson
G.; Gerdisch M.; Frazier O.H.; Askew J.; Damiano R.; Pruitt A.; Duncan D.;
Segurola R.; Shoukfeh M.F.; Gregoric I.; Meyer S.; Chu M.; Chu D.; Hagberg
R.; Tsuda R.; Kirker E.; Swistel D.; Landvater L.; Barreiro C.; Castlemain
B.; Tutuska P.; Quinn R.; Beaver T.; Accola K.; Sethi G.; Graeve A.; Liu
D.; Wait M.; Whitson B.; Harville L.; DeRose J.; Lehr E.; Markowitz A.;
Sekela M.; Smith R.; Shults C.; Shekar P.; Badhwar V.
Institution
(Chu) London Health Sciences Centre, Western University, London, ON,
Canada
(Ruel) University of Ottawa Heart Institute, Ottawa, ON, Canada
(Graeve) MultiCare Health System, Tacoma, Washington
(Gerdisch) Franciscan St. Francis Health, Indianapolis, IN, United States
(Damiano) Washington University in St. Louis, St. Louis, Missouri, United
States
(Smith) The Heart Hospital Baylor Plano, Plano, Texas, United States
(Keeling) Emory University Hospital Midtown, Georgia, Atlanta, Georgia
(Wait) University of Texas Southwestern Medical Center (St. Paul's),
Dallas, Texas, United States
(Hagberg) Hartford Hospital, Hartford, Connecticut, United States
(Quinn) Maine Medical Center, Portland, Maine
(Sethi) Tucson Heart Center, University of Arizona, Tucson, AZ, United
States
(Floridia) Loma Linda University Medical Center, Loma Linda, California,
United States
(Barreiro) Sentara Norfolk General Hospital, Norfolk, Virginia
(Pruitt) St. Joseph Mercy Hospital, Ann Arbor, MI, United States
(Accola) Florida Hospital, Orlando, Florida, United States
(Dagenais) Institut universitaire de cardiologie et de pneumologie de
Quebec (IUCPQ), Quebec City, QC, Canada
(Markowitz) University Hospitals-Cleveland, Cleveland, Ohio, United States
(Ye) St. Paul's and Vancouver General Hospital, Vancouver, BC, Canada
(Sekela) University of Kentucky, Lexington, Kentucky
(Tsuda) Southern Arizona Veterans Affairs Medical Center, Tucson, AZ,
United States
(Duncan) Novant Clinical Research Institute, Winston-Salem, NC, United
States
(Swistel) New York University Langone Hospitals, New York, New York,
United States
(Harville) University of Oklahoma Health Sciences Center, Oklahoma City,
OK, United States
(DeRose) Montefiore Medical Center, Bronx, NY, United States
(Lehr) Swedish Medical Center, Seattle, WA, United States
(Alexander) Duke University Medical Center, Durham, North Carolina, United
States
(Puskas) Mount Sinai Saint Luke's, New York, New York, United States
Publisher
Elsevier Inc.
Abstract
Background: Current guidelines recommend a target international normalized
ratio (INR) range of 2.5 to 3.5 in patients with a mechanical mitral
prosthesis. The Prospective Randomized On-X Anticoagulation Clinical Trial
(PROACT) Mitral randomized controlled noninferiority trial assessed safety
and efficacy of warfarin at doses lower than currently recommended in
patients with an On-X (Artivion, Inc) mechanical mitral valve.
 Method(s): After On-X mechanical mitral valve replacement, followed
by at least 3 months of standard anticoagulation, 401 patients at 44 North
American centers were randomized to low-dose warfarin (target INR,
2.0-2.5) or standard-dose warfarin (target INR, 2.5-3.5). All patients
were prescribed aspirin, 81 mg daily, and encouraged to use home INR
testing. The primary end point was the sum of the linearized rates of
thromboembolism, valve thrombosis, and bleeding events. The design was
based on an expected 7.3% event rate and 1.5% noninferiority margin.
 Result(s): Mean patient follow-up was 4.1 years. Mean INR was 2.47
and 2.92 (P <.001) in the low-dose and standard-dose warfarin groups,
respectively. Primary end point rates were 11.9% per patient-year in the
low-dose group and 12.0% per patient-year in the standard-dose group
(difference, -0.07%; 95% CI, -3.40% to 3.26%). The CI >1.5%, thus
noninferiority was not achieved. Rates (percentage per patient-year) of
the individual components of the primary end point were 2.3% vs 2.5% for
thromboembolism, 0.5% vs 0.5% for valve thrombosis, and 9.13% vs 9.04% for
bleeding. Conclusion(s): Compared with standard-dose warfarin,
low-dose warfarin did not achieve noninferiority for the composite primary
end point. (PROACT Clinicaltrials.gov number, NCT00291525). Copyright
© 2023 The Society of Thoracic Surgeons

<81>
Accession Number
2021973905
Title
Edoxaban Monotherapy in Nonvalvular Atrial Fibrillation Patients with
Coronary Artery Disease.
Source
Journal of Interventional Cardiology. 2022 (no pagination), 2022. Article
Number: 5905022. Date of Publication: 2022.
Author
Fukamachi D.; Okumura Y.; Matsumoto N.; Tachibana E.; Oiwa K.; Ichikawa
M.; Haruta H.; Nomoto K.; Arima K.; Hirayama A.
Institution
(Fukamachi, Okumura) Division of Cardiology, Nihon University Itabashi
Hospital, Tokyo, Japan
(Matsumoto) Department of Cardiology, Nihon University Hospital, Tokyo,
Japan
(Tachibana) Kawaguchi Municipal Medical Center, Saitama, Japan
(Oiwa) Yokohama Central Hospital, Kanagawa, Yokohama, Japan
(Ichikawa) Sekishindo Hospital, Saitama, Japan
(Haruta) Tmg Asaka Hospital, Saitama, Japan
(Nomoto) Tokyo Rinkai Hospital, Tokyo, Japan
(Arima) Kasukabe Municipal Hospital, Saitama, Japan
(Hirayama) Osaka Police Hospital, Osaka, Japan
Publisher
Hindawi Limited
Abstract
Background. Current guidelines recommend an oral anticoagulant (OAC)
monotherapy in patients with nonvalvular atrial fibrillation (NVAF) and
stable coronary artery disease (CAD) 1 year postpercutaneous coronary
intervention (PCI). It might be possible to shorten the time for
de-escalation from a dual therapy to monotherapy, but data regarding
de-escalation to an edoxaban monotherapy are lacking. This study aimed to
assess the clinical safety of an edoxaban monotherapy in patients with
NVAF and stable CAD. Methods. A multicenter, prospective, randomized,
open-label, and parallel group study was established to investigate the
safety of an edoxaban monotherapy in patients with NVAF and stable CAD
including over 6 months postimplantation of a third-generation DES and 1
year postimplantation of other stents (PRAEDO AF study). Between March
2018 and June 2020, 147 patients from 8 institutions in Japan were
randomized to receive either an edoxaban monotherapy (n = 74) or
combination therapy (edoxaban plus clopidogrel, n = 73). The primary study
endpoint was the composite incidence of major bleeding and clinically
significant bleeding, defined according to the ISTH criteria. Results.
Major or clinically significant bleeding occurred in 2 patients in the
monotherapy group (1.67% per patient-year) and in 5 patients in the
combination therapy group (4.28% per patient-year) (hazard ratio, 0.39;
95% confidence interval, 0.08-2.02). There was no incidence of a
myocardial infarction, stent thrombosis, unstable angina requiring
revascularization, ischemic stroke, systemic stroke, or hemorrhagic stroke
in either of the groups. Conclusions. The edoxaban monotherapy was shown
to have acceptable clinical safety in patients with NVAF and stable CAD.
The study was registered with the Japan Registry of Clinical Trials
(jRCTs031180119). Copyright © 2022 Daisuke Fukamachi et al.

<82>
Accession Number
2015199630
Title
Prophylactic dexmedetomidine use did not decrease the incidence of
delirium in patients undergoing cardiac surgery: A meta-analysis.
Source
Perfusion (United Kingdom). 38(3) (pp 539-546), 2023. Date of Publication:
April 2023.
Author
Li W.; Liu H.; Yang C.
Institution
(Li, Liu, Yang) Department of Cardiovascular Medicine, Affiliated Hospital
of Shandong University of Traditional Chinese Medicine, Shandong, Jinan,
China
Publisher
SAGE Publications Ltd
Abstract
Objective: The benefits of prophylactic dexmedetomidine use in patients
undergoing cardiac surgery remain controversial. The aim of this
meta-analysis was to investigate the short-term clinical outcomes of
dexmedetomidine use versus non-dexmedetomidine use. Method(s):
Systematic searches using PubMed, Embase, and the Cochrane Library were
carried out for English articles published from inception to 23 September
2021. This was followed by a meta-analysis investigating delirium, the
length of delirium, mortality, bradycardia, hypotension, the length of
intensive care unit (ICU) and hospital stay, and the duration of
mechanical ventilation. Result(s): Ten randomized controlled trials
(RCTs) totaling 2550 patients were included. In the dexmedetomidine group
incidence of delirium was 13.5%, compared with 16.1% in the control group.
The risk ratio (RR) for the comparison was 0.69 (95% CI, 0.47 - 1.00; p
=.052). In addition, there were no differences in mortality (RR, 0.56; 95%
CI, 0.27 - 1.14; p =.109), the incidence of bradycardia (RR, 1.20; 95% CI,
0.91 - 1.57; p =.201), the incidence of hypotension (RR, 0.90; 95% CI,
0.57 - 1.44; p =.674), and the length of delirium mean difference (MD,
-0.99; 95% CI, -2.20 to 0.21; p =.106). However, prophylactic
dexmedetomidine use significantly reduced the duration of mechanical
ventilation (MD, -2.03; 95% CI, -3.35 to -0.70; p =.003), length of ICU
stay (MD, -3.17; 95% CI, -5.10 to -1.24; p =.001), and length of hospital
stay (MD, -1.76; 95% CI, -2.88 to -0.66; p =.002). Conclusion(s):
Prophylactic dexmedetomidine use did not decrease the incidence of
delirium in patients undergoing cardiac surgery, but significantly reduced
the duration of mechanical ventilation, length of ICU stay, and length of
hospital stay. Copyright © The Author(s) 2022.

<83>
Accession Number
2015199578
Title
Network meta-analysis comparing blood cardioplegia, Del Nido cardioplegia
and custodiol cardioplegia in minimally invasive cardiac surgery.
Source
Perfusion (United Kingdom). 38(3) (pp 464-472), 2023. Date of Publication:
April 2023.
Author
Chan J.; Oo S.; Butt S.; Benedetto U.; Caputo M.; Angelini G.D.; Vohra
H.A.
Institution
(Chan, Oo, Benedetto, Angelini, Vohra) Department of Cardiac Surgery,
Bristol Heart Institute, Bristol, United Kingdom
(Butt) Department of Perfusion Sciences, St George's Hospital, London,
United Kingdom
(Caputo) Department of Cardiac Surgery, Bristol Royal Hospital for
Children, Bristol, United Kingdom
Publisher
SAGE Publications Ltd
Abstract
Introduction: Minimally invasive cardiac surgery has been evolving, with
the intention of reducing surgical trauma, improve cosmesis and patient
satisfaction. Single dose, crystalloid cardioplegia such as Del Nido
cardioplegia and Custoidol solution have been increasingly used to reduce
the interruption from repeating cardioplegia dosing to minimise the
cardiopulmonary bypass and cross clamp time. However, the best
cardioplegia for myocardial protection in adult minimally invasive cardiac
surgery remains controversial. We aimed to conduct a meta-analysis to
analyse the current evidence in the literature. Method(s): A
systematic review and meta-analysis was performed following the updated
2020 PRISMA guideline. Articles published in the five major electronic
databases up 1st of April 2021 were identified and reviewed. The primary
outcome was in-hospital or 30-day mortality. Traditional pairwise and
Bayesian network meta-analyses were conducted. Result(s): Nine
articles were included in this study. The use of Del Nido cardioplegia was
associated with a lower volume of cardioplegia used (Del Nido vs Blood,
1105.62 mL+/-123.47 vs 2569.46 mL+/-1515.52, p<0.001), cardiopulmonary
bypass (Del Nido vs Custoidol vs Blood: 91.67+/-14.78 vs 138.05 +/- 21.30
vs 119.38+/-26.91 minutes, p<0.001) and cross-clamp time (Del Nido vs
Custoidol vs Blood: 74.99+/-18.55 vs 82.01 +/- 17.28 vs 93.66+/-8.88
minutes, p < 0.001). No differences were observed in the incidence of
in-hospital/30-day mortality rate, new onset of atrial fibrillation and
stroke. Ranking analysis showed the Custoidol solution has the highest
probability to be the first ranked cardioplegia. Conclusion(s): No
differences were found between blood and crystalloid cardioplegia in adult
minimally invasive cardiac surgery in several clinical outcomes. The
cardioplegia of choice in minimally invasive cardiac surgery remains the
surgeons' decision and preference. Copyright © The Author(s)
2022.

<84>
Accession Number
2014996366
Title
Goal-directed perfusion for reducing acute kidney injury in cardiac
surgery: A systematic review and meta-analysis.
Source
Perfusion (United Kingdom). 38(3) (pp 591-599), 2023. Date of Publication:
April 2023.
Author
Gao P.; Liu J.; Zhang P.; Bai L.; Jin Y.; Li Y.
Institution
(Gao, Liu, Zhang, Bai, Jin, Li) Department of Cardiopulmonary Bypass,
Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union
Medical College and Chinese Academy of Medical Sciences, Beijing, China
Publisher
SAGE Publications Ltd
Abstract
Background: Acute kidney injury (AKI) is a common complication following
cardiopulmonary bypass (CPB) which can affect morbidity and mortality.
Goal-directed perfusion (GDP) intended to avoid the nadir oxygen delivery
index below the critical value is associated with reduced postoperative
AKI. However, current studies suggested that GDP can only decrease the
incidence of AKI stage 1 but showed no effects on AKI stages 2-3 and
mortality. The objective of the present meta-analysis is to deter the
effects of GDP on postoperative AKI in any stage and mortality following
cardiac surgery. Method(s): MEDLINE, Embase, and the Cochrane Library
were searched to identify all clinical trials comparing GDP with control
(standard care) during cardiopulmonary bypass conducting in adults
undergoing cardiac surgery. The primary outcome was postoperative acute
kidney injury. Secondary outcomes included postoperative mortality and
length of ICU stay. Data synthesis was obtained by using risk ratio with
95% confidence interval by a random-effects model. Result(s): From
1094 potential studies, 3 trials enrolling 777 patients were included.
Meta-analysis suggested the GDP strategy based on DO<inf>2</inf>i reduced
postoperative AKI compared with standard CPB management (RR = 0.52; 95%
CI: 0.38-0.70; p <.0001), especially in AKI stage I (RR = 0.47; 95% CI:
0.33-0.66; p <.0001). But the GDP strategy did not reduce the incidence of
severe AKI (stages 2-3) and postoperative mortality. Conclusion(s):
The GDP strategy based on DO<inf>2</inf>i during CPB obviously reduces AKI
stage 1 and thus reduces overall AKI incidence. But it shows no effects on
severe AKI (stages 2-3) and mortality. Copyright © The Author(s)
2022.

<85>
Accession Number
2014841234
Title
Kinetics of tissue oxygenation index during fast and slow cardiopulmonary
bypass initiation.
Source
Perfusion (United Kingdom). 38(3) (pp 574-579), 2023. Date of Publication:
April 2023.
Author
Turra J.; Bauer A.; Mobius A.; Wojdyla J.; Eisner C.
Institution
(Turra, Mobius) Department of Cardiothoracic Surgery, University Hospital
Heidelberg, Heidelberg, Germany
(Bauer) Department of Cardiovascular Surgery, Mediclin Heartcenter Coswig,
Coswig, Germany
(Wojdyla) Department of Cardiothoracic Surgery, Sunnyside Medical Center,
OR, United States
(Eisner) Department of Anesthesiology, University Hospital Heidelberg,
Heidelberg, Germany
Publisher
SAGE Publications Ltd
Abstract
Introduction: Despite being a daily clinical application in cardiac
operating theaters, an evidence-based approach on how to optimally
initiate the heart-lung machine (HLM) to prevent critical phases of
cerebral ischemia is still lacking. We therefore designed a study
comparing two different initiation times for starting the cardiopulmonary
bypass (CPB). Method(s): We conducted a monocentric, randomized, and
prospective study comparing the impact of two initiation times, a rapid
initiation of 15 s and a slow initiation of 180 s to reach the full target
flow rate of 2.5 L/min/m2 times the body surface area, on
cerebral tissue oxygenation by near infrared spectroscopy measurements.
 Result(s): The absolute values in tissue oxygenation index (TOI)
showed no difference between the groups before and after the CPB with a
10% drop in oxygenation index in both groups due to the hemodilution
through the HLM priming. Looking at the kinetics a rapid initiation of CPB
produced a higher negative rate of change in TOI with a total of 21% in
critical oxygenation readings compared to 6% in the slow initiation group.
 Conclusion(s): In order to avoid critical phases of cerebral ischemia
during the initiation of CPB for cardiac procedures, we propose an
initiation time of at least 90 s to reach the 100% of target flow rate of
the HLM. Copyright © The Author(s) 2022.

<86>
Accession Number
2023291728
Title
Levosimendan or Milrinone for Ventricular Septal Defect Repair With
Pulmonary Arterial Hypertension.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2023.
Date of Publication: 2023.
Author
Nag P.; Chowdhury S.R.; Behera S.K.; Das M.; Narayan P.
Institution
(Nag, Chowdhury) Department of Cardiac Anesthesia, Rabindranath Tagore
International Institute of Cardiac Sciences, Narayana Health, Kolkata,
India
(Behera, Das, Narayan) Department of Cardiac Surgery, Rabindranath Tagore
International Institute of Cardiac Sciences, Narayana Health, Kolkata,
India
Publisher
W.B. Saunders
Abstract
Objective: Both milrinone and levosimendan have been used in patients
undergoing surgical closure of ventricular septal defects (VSD) with
pulmonary artery hypertension (PAH); however, the evidence base for their
use is limited. In the present study, the authors sought to compare the
role of levosimendan and milrinone in the prevention of low-cardiac-output
syndrome in the early postoperative period. Design(s): A prospective,
randomized, controlled trial. Setting(s): At a tertiary-care center.
 Participant(s): Children between 1 month and 12 years presenting with
VSD and PAH between 2018 and 2020. Intervention(s): A total of 132
patients were randomized into the following 2 groups: Group L
(levosimendan group) and Group M (milrinone group). Measurements and
Main Results: In addition to conventional hemodynamic parameters, the
authors also included a myocardial performance index assessment to compare
the groups. The levosimendan group had significantly lower mean arterial
pressure while coming off cardiopulmonary bypass, after shifting to
intensive therapy unit, as well as at 3 and 6 hours postoperatively. The
duration of ventilation (29.6 +/- 13.9 hours v 23.2 +/- 13.3 hours; p =
0.012), as well as postoperative intensive care unit stay, were
significantly prolonged in the levosimendan group (5.48 +/- 1.2 v 4.7 +/-
1.3 days, p = 0.003). There were 2 (1.6%) in-hospital deaths in the entire
cohort, 1 in each arm. There was no difference in the myocardial
performance index of the left or right ventricle. Conclusion(s): In
patients undergoing surgical repair for VSD with PAH, levosimendan does
not confer any additional benefit compared to milrinone. Both milrinone
and levosimendan appear to be safe in this cohort. Copyright ©
2023 Elsevier Inc.

<87>
Accession Number
2023023926
Title
Long term outcomes of percutaneous coronary intervention vs coronary
artery bypass grafting in patients with diabetes mellitus with multi
vessels diseases: A meta-analysis.
Source
IJC Heart and Vasculature. (no pagination), 2023. Article Number: 101185.
Date of Publication: 2023.
Author
Jaiswal V.; Sattar Y.; Peng Ang S.; Ishak A.; Naz S.; Minahil Nasir Y.;
Song DO D.; Titus A.; Huang H.; Chaudhary G.; Rubinstein D.; Elgendy I.Y.;
Raina S.; Alam M.; Balla S.; Daggubati R.
Institution
(Jaiswal) Department of Research, Larkin Community Hospital, South Miami,
FL, United States
(Sattar, Raina, Balla, Daggubati) Division of Cardiovascular Medicine,
West Virginia University, WV, Morgantown, United States
(Peng Ang) Division of Internal Medicine, Rutgers Health/Community Medical
Center, NJ, United States
(Ishak) European University Cyprus - School of Medicine, Nicosia, Cyprus
(Naz) Division of Internal Medicine, BIDMC/Harvard Medical School, Boston,
United States
(Minahil Nasir) Division of Internal Medicine, Montefiore Medical Center,
NY, United States
(Song DO) Division of Internal Medicine, Icahn School of Medicine at Mount
Sinai Elmhurst Hospital Center, Queens, NY, United States
(Titus) Department of Internal Medicine, Saint Vincent Hospital,
Worcester, MA, United States
(Huang) Royal College of Surgeons in Ireland, University of Medicine and
Health Science, Dublin, Ireland
(Chaudhary) Department of Cardiology, King George Medical University,
Lucknow, India
(Rubinstein) Department of Cardiovascular Medicine, Icahn School of
Medicine at Mount Sinai Elmhurst Hospital Center, Queens, NY, United
States
(Elgendy) Division of Cardiovascular Medicine, Gill Heart Institute,
University of Kentucky, Lexington, KY, United States
(Alam) Department of Medicine, Division of Cardiology, Baylor Medical
Center, TX, United States
Publisher
Elsevier Ireland Ltd
Abstract
Aims: Long term cardiovascular outcome comparison of multivessel coronary
disease among patients with diabetes mellitus (DM) undergoing percutaneous
coronary intervention (PCI) or coronary artery bypass graft (CABG) is
limited. The objective of this study was to compare the long-term
cardiovascular outcome PCI vs CABG among DM patients with multivessel
disease. Method and results: Online databases were explored to identify
studies that compared cardiovascular outcomes between PCI and CABG among
patients with DM. The primary outcome was all-cause mortality. Secondary
outcomes included major adverse cardiovascular and cerebrovascular events
(MACCE), myocardial infarction (MI), rate of revascularization, cardiac
death, and cerebrovascular accident (CVA). A total of 27 studies with
37,091 (PCI n = 19,838 (53 %) and CABG n = 17,253 (47 %)) patients were
included. The mean age was 64 +/- 5.9 years for PCI group and 63.8 +/- 5.3
years for CABG group; and, predominantly male (71.22 % vs 74.29 %) for PCI
and CABG respectively. The most common comorbidity was hypertension (64.35
% vs 62.88 %) in both PCI and CABG respectively. Compared with CABG, PCI
group had a higher odds of overall all-cause mortality (OR 1.18, 95 % CI
1.02-1.37, p = 0.03), MACCE (OR 1.52, 95 % CI 1.31-1.75, p = 0.00), MI (OR
1.85, 95 % CI 1.46-2.36, p = 0.00), repeat revascularization (OR 3.08, 95
% CI 2.34-4.05, p = 0.00) and cardiac death (OR 1.27, 95 % 1.02-1.59, p =
0.04), while CVA (0.57, 95 % CI 0.37-0.86, p = 0.01) was higher with CABG.
 Conclusion(s): Diabetic patients with multivessel coronary artery
disease have worse outcomes undergoing PCI as compared to CABG. However,
CVA was significantly higher with CABG. CABG remains the preferred
management among eligible patients with multivessel disease and
DM. Copyright © 2023 The Authors

<88>
Accession Number
2022937147
Title
Systematic Review of a Novel Approach to Prevent Pain After Chest Surgery.
Source
Journal of Cardiothoracic and Vascular Anesthesia. (no pagination), 2023.
Date of Publication: 2023.
Author
Anwar S.
Institution
(Anwar) Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom
(Anwar) William Harvey Research Institute, NIHR Biomedical Research
Centre, London, United Kingdom
(Anwar) Cleveland Clinic London, London, United Kingdom
(Anwar) Outcomes Research Consortium, Cleveland, OH
Publisher
W.B. Saunders

<89>
Accession Number
2022827259
Title
Tissue engineering in pediatric population: A hope for the treatment of
congenital mitral valve diseases.
Source
Cirugia Cardiovascular. (no pagination), 2023. Date of Publication: 2023.
Author
Ospina M.Y.; Jimenez A.N.; Beltran L.N.; Gachancipa J.F.; Steffens G.;
Gonzalez M.M.; Gonzalez M.I.
Institution
(Ospina, Jimenez, Beltran, Gachancipa, Steffens, Gonzalez, Gonzalez)
Facultad de Medicina, Universidad Antonio Narino, Sede Circunvalar,
Bogota, D.C., Colombia
Publisher
Sociedad Espanola de Cirugia Cardiovascular y Endovascular (SECCE)
Abstract
Mitral heart valve pathology in newborns has high prevalence worldwide.
Conventional treatment is valve replacements, mechanical implants or
bioprostheses. The aim of this review is to identify the design parameters
of a pediatric mitral valve implant based on tissue engineering treatments
applied to congenital heart disease of the mitral valve in articles
published between 2010 and 2021. A literature review on the treatment of
mitral valve congenital heart disease with tissue engineering was carried
out through a structured search in databases (Pubmed, Elsevier, Scielo,
Chrocaine, LILACS and Scopus) between 2011 and 2021. Were reviewed 92
articles according to inclusion criteria. Valve tissue engineering has
developed mitral constructs with biomaterials of synthetic, natural or
hybrid origin on supports or hydrogels used in 3D bioprinters in which
valve endothelial cells or valve interstitial cells differentiated or not
from mesenchymal stem cells or induced stem cells can be used with
specific growth factors. Functional requirements identified for the
development of a new mitral valve implant were: a) durability, b)
mechanical characteristics, c) mimic native mitral valve tissue, d)
antithrombogenicity, e) safety, f) controlled biodegradability, g)
transcatheter approach, h) biocompatibility, i) precise, anatomical and
personalized adaptation, j) synchronous growth of the valve with the
child. Copyright © 2022 Sociedad Espanola de Cirugia
Cardiovascular y Endovascular

<90>
Accession Number
2021965729
Title
Advantages and feasibility of intercostal nerve block in uniportal
video-assisted thoracoscopic surgery (VATS).
Source
Postgraduate Medicine. (no pagination), 2023. Date of Publication: 2023.
Author
Wang L.; Ge L.; Ren Y.
Institution
(Wang, Ren) Department of Thoracic Surgery, Shenyang Chest Hospital &
Tenth People's Hospital, Shenyang, China
(Ge) Department of Health Management, Shengjing Hospital of China Medical
University, Shenyang, China
Publisher
Taylor and Francis Ltd.
Abstract
Objectives: Uniportal video-assisted thoracic surgery (VATS) has been
successfully used worldwide as a minimally invasive method of
thoracoscopic surgery. Although pain was significantly reduced after VATS,
acute postoperative pain was still significant. This study aimed to assess
the advantages and feasibility of intercostal nerve block in uniportal
VATS. Method(s): We conducted a retrospective analysis of
perioperative data from 280 consecutive patients who underwent uniportal
VATS at our institution between May 2021 and February 2022. The patients
were assigned to either Group A (142 patients with 3 intercostal nerves
blocked) or Group B (138 patients with 5 intercostal nerves blocked). We
analyzed the perioperative data of both groups and utilized repeated
measures ANOVA to determine the difference in postoperative pain between
the two groups across time. Result(s): A total of 280 patients
underwent successful uniportal VATS during the study period. There were no
significant differences between Group A and Group B in terms of age,
gender, pulmonary function, arterial blood gas analysis, laterality,
incision location, nodule size, nodule location, operative time, blood
loss, drainage time, length of hospital stays, tumor stage, or
postoperative complications. Furthermore, no surgical or 30-day
postoperative mortalities occurred. Using repeated measures ANOVA, we
found that the intercostal nerve block had significant effects on the
group, time, and interaction terms group x time (P < 0.05).
 Conclusion(s): Intercostal nerve block is safe and effective, and is
associated with simple, accurate, and high patient satisfaction as opposed
to other postoperative analgesics in uniportal VATS. Blocking five
intercostal nerves may be more beneficial for effective postoperative pain
management. Nevertheless, further confirmation through prospective
randomized controlled trials is required. Copyright © 2023
Informa UK Limited, trading as Taylor & Francis Group.

<91>
Accession Number
640766392
Title
Venous External Support in Coronary Artery Bypass Surgery: A Systematic
Review and Meta-Analysis.
Source
Current problems in cardiology. (pp 101687), 2023. Date of Publication:
15 Mar 2023.
Author
Gemelli M.; Gallo M.; Addonizio M.; Pahwa S.; Van den Eynde J.; Trivedi
J.; Slaughter M.S.; Gerosa G.
Institution
(Gemelli, Addonizio, Gerosa) Cardiac Surgery Unit, Department of Cardiac,
Thoracic, Vascular Sciences and Public Health, University of Padua, Italy
(Gallo, Pahwa, Trivedi, Slaughter) Department of Cardiothoracic Surgery,
University of Louisville, Louisville, KY, United States
(Van den Eynde) Department of Cardiovascular Sciences, KU Leuven, Leuven,
Belgium
Publisher
NLM (Medline)
Abstract
OBJECTIVES: Neointimal hyperplasia and lumen irregularities are major
contributors to vein graft failure and the use of VEST(R) should prevent
this. In this review, we aim to evaluate the angiographic outcomes of
externally supported vein grafts. METHOD(S): Medline, Embase and
Cochrane Library were systematically reviewed for randomized clinical
trials published by August 2022. The primary outcome was graft failure.
Secondary outcomes included graft ectasia, intimal hyperplasia area and
thickness, and graft non-uniformity. Odds ratios (OR) for dichotomous
variables and mean difference (MD) for continuous variables with 95%
confidence intervals (CI) were pooled using a fixed-effects model.
 RESULT(S): Three randomized controlled trials with a total of 437
patients were included with follow-up ranging from 1 to 2 years. The odds
of graft failure were similar in the two groups (OR 1.22; 95%CI 0.88 to
1.71; I2=0%). Intimal hyperplasia area [MD -0.77 mm2; 95%CI -1.10 to
-0.45; I2=0%] and thickness [MD -0.06 mm; 95%CI -0.08 to -0.04; I2=0%]
were significantly lower in the VEST group. Fitzgibbon Patency Scale of II
or III (representing angiographic conduit non-uniformity; OR 0.67; 95%CI
0.48 to 0.94; I2=0%) and graft ectasia (OR 0.53; 95%CI 0.32 to 0.88;
I2=33%) were also significantly lower in the VEST group.
 CONCLUSION(S): At short-term follow-up, VEST does not seem to reduce
the incidence of graft failure, although it is associated with attenuation
of intimal hyperplasia and non-uniformity. Longer angiographic follow-up
is warranted to determine whether these positive effects might translate
into a positive effect in graft failure and in long-term clinical
outcomes. Copyright © 2023 Elsevier Ltd. All rights reserved.

<92>
Accession Number
640764342
Title
Transcatheter versus Surgical Aortic Valve Replacement Outcomes among
Solid Organ Transplant Patients: A Systematic Review and Meta-Analysis.
Source
Current problems in cardiology. (pp 101685), 2023. Date of Publication:
15 Mar 2023.
Author
Jaiswal V.; Ang S.P.; Ishak A.; Joshi A.; Chia J.E.; Lnu K.; Attia A.M.;
Sharma P.; Biswas M.; Grubb K.J.
Institution
(Jaiswal, Joshi) Department of Cardiovascular Research, Larkin Community
Hospital, South Miami, Fl, United States
(Ang) Department of Internal Medicine, Rutgers Health/Community Medical
Center, NJ, United States
(Ishak) Department of Research and Academic affairs, Larkin Community
Hospital, South Miami, Fl, United States
(Chia) Department of Medicine, International Medical University, Malaysia
(Lnu) Department of Cardiology, Medstar Washington Hospital Center, United
States
(Attia) Department of Medicine, Cairo University, Egypt
(Sharma) Department of Cardiology, King George's Medical University,
Lucknow, India
(Biswas) General Cardiology & Advanced Heart Failure, Wellspan Cardiology,
Lancaster, Pennsylvania, USA & University of Maryland Medical Center,
Baltimore
(Grubb) Division of Cardiothoracic Surgery, Department of Surgery, Emory
University School of Medicine, Atlanta, GA, United States
Publisher
NLM (Medline)
Abstract
BACKGROUND: The safety and clinical outcomes of transcatheter aortic valve
replacement (TAVR) compared to surgical aortic valve replacement (SAVR)
among patients with solid organ transplants (SOT) is not well understood.
 OBJECTIVE(S): This study aimed to evaluate the clinical outcomes of
TAVR and SAVR among patients with a history of solid organ
transplantation. METHOD(S): We performed a systematic literature
search of databases for relevant articles from inception until May 1st,
2022. Unadjusted odds ratios (OR) were pooled using a random-effect model,
and a p-value of <0.05 was considered statistically significant.
 RESULT(S): A total of 3240 studies were identified of which 3 studies
with a total of 2960 patients were included in the final analysis. For SOT
patients, the odds of in-hospital mortality (OR 0.37, 95% CI 0.20 to 0.71,
p<0.001), 30-day mortality (OR 0.51, 95% CI 0.35 to 0.74, p<0.001), acute
kidney injury (OR 0.45, 95% CI 0.35 to 0.59, p<0.001), and bleeding (OR
0.35, 95% CI 0.27 to 0.46, p<0.001) were significantly lower in patients
undergoing TAVR compared to SAVR. In contrast, the odds of pacemaker
implantation (OR 2.60, 95% CI 0.36 to 18.90, p=0.34), post-procedural
stroke (OR 0.36, 95% CI 0.13 to 1.03, p=0.06) were similar between both
groups of patients. Length of hospital stay was significantly lower in
TAVR compared to SAVR patients (SMD -0.82, 95% CI -0.95 to -0.70,
p<0.001). CONCLUSION(S): In solid organ transplant patients, TAVR
appeared to be a safe procedure with fewer post-procedure complications,
shorter length of hospital stay, and lower in hospital mortality compared
with SAVR. Copyright © 2023 Elsevier Ltd. All rights reserved.

<93>
Accession Number
640753875
Title
Randomized Feasibility Trial of Prophylactic Radiofrequency Ablation to
Prevent Atrial Fibrillation after Cardiac Surgery.
Source
The Journal of thoracic and cardiovascular surgery. (no pagination),
2023. Date of Publication: 16 Mar 2023.
Author
Willekes C.L.; Fanning J.S.; Heiser J.C.; Sang S.L.W.; Timek T.A.; Parker
J.; Ragagni M.K.
Institution
(Willekes, Fanning, Heiser, Sang, Timek) Corewell Health Hospital
Department of Cardiothoracic Surgery, Grand Rapids, Michigan; College of
Human Medicine, Michigan State University, Grand Rapids, Michigan
(Parker) Corewell Health Office of Research and Education, Grand Rapids,
MI, United States
(Ragagni) Department of Cardiovascular Research, Grand Rapids, MI, United
States
Publisher
NLM (Medline)
Abstract
OBJECTIVE: Evaluate the feasibility of prophylactic radiofrequency
isolation of the pulmonary veins, with left atrial appendage amputation,
to reduce the incidence of postoperative atrial fibrillation (POAF) after
cardiac surgery in patients aged 70 and older. METHOD(S): The Federal
Food and Drug Administration granted an investigational device exemption
to utilize a bipolar radiofrequency clamp for prophylactic pulmonary vein
isolation in a limited, feasibility trial. Sixty-two patients without
prior dysrhythmias, were prospectively randomized to undergo either their
index cardiac surgical procedure, or bilateral pulmonary vein isolation
and left atrial appendage amputation during their cardiac operation. The
primary outcome was occurrence of in-hospital POAF. Subjects were on
24-hour telemetry until discharge. Dysrhythmias, any episode of atrial
fibrillation > 30 seconds, were confirmed by electrophysiologists blinded
to the study. RESULT(S): Sixty patients, mean age 75 years and mean
CHA2DS2-VASc score 4, were analyzed. Thirty-one patients randomized to
control and twenty-nine to the treatment group. Majority of cases in each
group were isolated CABG. No perioperative complications related to the
treatment procedure, need for permanent pacemaker, or mortality occurred.
The in-hospital incidence of POAF was 55% (17/31) in the control group and
7% (2/29) in the treatment group. (p<0.001) The control group had a
significantly higher requirement for antiarrhythmic medications at
discharge, 45% (14/31) vs 7% (2/29) in the treatment group (p<0.001).
 CONCLUSION(S): Prophylactic radiofrequency isolation of the pulmonary
veins with left atrial appendage amputation, during the primary cardiac
surgical operation, reduced the incidence of POAF in patients 70 years and
older with no history of atrial arrhythmias. Copyright © 2023.
Published by Elsevier Inc.

EPICORE Embase Updates

Saturday, April 1, 2023

EMBASE Cardiac Update AutoAlert: EPICORE Cardiac Surgery Blogger2

No comments:

Post a Comment

Followers

Blog Archive

About Me